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Abstract
The activation of 5-valerolactam with triflic anliydride is studied in detail. Triflic 
anliydride activation initially produces the 0-triflated lactam I, which rearranges, 
following the addition of base, to the N-tiiflated derivative II. Increasing temperatiues 
favoiu* tlris tiiflate gioup migiation, but only when a base is present.
NH Base NTf
On reaction with a suitable nucleophile, the lactam rmg is opened resulting in an acyclic 
product. The N-tiiflated derivatives have been reacted with a range of nucleophiles to 
produce esters and amides, which are formally dipeptides of cù-amino acids.
NTf NuH
hi addition, a synthetic pathway to 1,3,4-oxadiazole based dipeptide mimetics has been 
worked out staiting hom conmiercially available Boc-protected amino acids IV. This 
synthetic route improves on a published method for producing these types of compound, 
both in simplicity and yield of final compoimd. This route has been successfully used to 
synthesise novel hydrazide intermediates V and 1,3,4-oxadiazole products VI.
O R
H 
IV
OH
PyBOP
DIPEA
HgN' O'
O
DMF
/ O R  O
O \ r  O
THF
reflux
Burgess reagent
o
V I N-N
,0
o-
What we anticipate seldom occurs; what we least expect generally happens.
Benjamin Disraeli (1804-1881); British prime minister and novelist
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Introduction
Amino acids
Amino acids are used in every living organism. Moreover they are the constituent units 
which make up proteins (derived from the Greek proteios -  “of primary importance”), 
which occur as enzymes, catalysing and controlling biological reactions; as the fibroin of 
silk; in muscles and tendons, which allow animals to move; in bones to help provide 
support; and in antibodies to protect the body. Proteins are defined polymers of amino 
acids linlced by peptide (or amide bonds) into chains. There are 22 a-amino acids that are 
found in proteins of which 8 ai e essential to the adult human diet.^ ^^ ^
Amino acids are named a,p,y, etc. depending on where the amine group is in relation to 
the carboxylic acid frinction.
Figure 1 y amino acid
Amino acids are by convention drawn with the amino group on the left and the carbonyl 
group on the right, and because they contain both a basic amino gioup and an acidic 
carboxyl group they can exist as a dipolai' ion or zwitterion. hi the zwitterion form, the 
carboxyl group is present as a carboxylate ion (CO2”) and the amino group as an 
anmionium ion (NH3’*’).
Amino acids have a lai'ge dipole moment, aie generally water soluble and are more 
thermally stable tlian would be expected unless they exist primarily (in the solid state or 
neutral solution) as the zwitterions.^^^^ The amino acid zwitterion is neutral because the 
positive and negative charges cancel each other out. It is also amphoteric, which means it 
can react as both an acid (donatmg a proton to fomi the anion) and a base (accepting a 
proton to fonn the cation). The pKa of the carboxylate gioups of the amino acids is in the
range 1,82 -  2.83; the pKa of the ammonimn groups is 8.80 -  10.60.^ '^*^  An equilibrium 
exists in aqueous solution between the dipolar ion and the anionic and cationic forms, hi 
neutral solution, the dipolar ion is predominant and at a certain pH, the isoelectric point 
(pi), the concentration of the dipolar ion is at a maxiimuii and the concentrations of the 
amino acid anions and cations are equal. The isoelectric point of an amino acid depends 
on its structure so is characteristic for each individual amino acid.
H-N
H
R
OH -H'
O +H'
-H' R
+H+ H-NH
O
O
Cationic form 
(Low pH)
Dipolar ion 
Isoeiectric point Anionic form (High pH)
Scheme 1 Different forms of amino acids in solution
Neutral amino acids (see Figure 3) are slightly acidic in aqueous solution because the 
NHa^ gimip is more acidic than the CO2 gioup is basic. The isoelectric point is at pH 5.5 
-  6 because a small amount of acid is required to shift the acid-base equilibrium so that 
the overall charge is zero. The isoelectiic point of acidic amino acids is about pH 3 and 
that of basic amino acids is pH 9 -1 0 .^
Except for glycine, all amino acids are chiral and so can exist in two enantiomeric fomis. 
All amino acids which make up naturally occurring proteins, however, have the L 
configuration at the a  caibon. L  indicates that the amino acid in Fischer projection has the 
same relative configination as A-glyceraldehyde.
An alternative notational system is based on the Cahn-higold-Prelog rules, giving amino 
acids either an R or S  configuiation, fr om the Latin rectus, meaning right, and sinister, 
meaning left. Using this convention, all chiral amino acids derived from proteins are 
found in tlie S  configuration apart from cysteine, which is found in the R configuration.
HgN-
COOH 
■H
CH,
L-Alanine
HgN. . f COOHH3C
S-Alanine
Figure 2 5-Alanine shown 
as a Fischer projection and 
as a 3D stmcture
Of the 22 amino acids which exist in proteins, 2 ar e fonned in post-translational 
modifications. That is, they are fomied from reactions after the peptide chain is formed. 
These are cystine, which is foimed by the crosslinking of two cysteines; and 
hydroxyproline, which is fomied by the hydroxylation of proline. The 20 a-amino acids 
which are used by cells to make up proteins ai e shown in Figure 3. Each of the amino 
acids is connnonly abbreviated by a tlnee letter code, which is shown in Figure 3.
The first fifteen of the amino acids^ ^®^  shown have neutral side chains (Figure 3), but can 
be sub-grouped according to their varying properties as detennined by their sidechains. 
Glycine, alanine, valine, leucine, isoleucine and proline are aliphatic, though glycine and 
alanine are too small to have a hydmphobic effect in proteins. Valine, leucine and 
isoleucine ai e hydrophobic so prefer to be on the inside region of the protein, away fi'om 
water and like to gmup together, hi addition isoleucine contains two stereo genic centres 
centres. Proline is often in the bend section, (loop or (f-turn), of a peptide or protein and is 
confomiationally rigid because of its cyclic structure.
There are four amino acids which are aromatic, phenylalanine, tyrosine, tryptophan and 
histidine (which is covered later). This allows them to interact with other 7i-systenis and 
cations, and in the case of tyrosine, take part in electron transfer reactions. Phenylalanine 
and tryptophan are hydrophobic, but tyrosine's hydroxyl group makes it more water 
soluble and also more reactive.
Cysteine and methionine both contain a sulpliiu* atom in their side chains and are 
hydrophobic. Methionine is quite um eactive, but cysteine is reactive and can foiiii a 
disulfide bond with another cysteine to iiialce cystine, as mentioned earlier. These 
disulpliide bridges have an often substantial effect on the tluee dimensional stmcture of 
peptides/proteins because they can liiilc amino acids which are far apart in the primary 
sequence and so direct the folding o f the protein into a particular confomiation.
Figure 3 The 20 Amino Acids Common in Proteins 
* Amino acids essential for adult humans^(^)
Neutral amino acids 
Aliphatic:
HgN OH HgN OH HgN OH
O O
Glycine (Gly) Alanine (Ala) Valine(Val)
OH
O
OHH,' 2 ' o
Leucine (Leu) Isoleucine (lie)* Proline (Pro)
Aromatic:
OH
O
OH
OHKN
O
NH
OH
O
Phenylalanine (Phe)* 
Sulphur-containing:
Tyrosine (Tyr) Tryptophan (Trp) *
Hydroxyl-containing:
SH
HgN OH
O
OH
O
OH
H,N
OH
OH HgN OH
Cysteine (Cys) Methionine (Met) * 
Amide-containing:
o
Serine (Ser)
O
Threonine (Thr)
NH
NH.
OH OH
Asparagine (Asn) Glutamine (Gin)
Basic amino acids
NH.
OH
O
HN. MH.
Lysine (Lys) * Arginine (Arg)
NH
OHKN
O
Histidine (His)
Acidic amino acids
o O:^ ^OH
O O
Aspartic acid (Asp) Glutamic acid (Glu)
Serine and tlneonine contain hydi*oxyl groups in their side chains which allow them to 
hydi'ogen bond with water and other groups on neighboiuing peptides, and also makes 
them more hydrophilic. Also tlneonine contains two stereogenic centres.
Asparagine, glutamine, lysine, arginine, histidine, aspartic acid and glutamic acid are 
polar and are highly hydiophilic. Asparagine and glutamine can hydrogen bond and are 
amide derivatives of the acidic amino acids, aspartic acid and glutamic acid. Aspartic acid 
and glutamic acid possess a negative charge at neutral pH, and so can form ionic bonds 
from their side chains to positively charged species, for example, metal cations. The basic 
amino acids (Lysine, Aiginine, Histidine), possess a positive charge at neutral pH, which 
allows them to form ionic bonds fr om the side chains to negative ions.
Reactions of Amino Acids
Amino acids can react with both their amine and their carboxylic acid functional gi'oups. 
As mentioned earlier they are amphoteric, and so can react with acids or bases to form 
cations or anions, respectively. A typical reaction of the amino group is acylation, which 
can be readily achieved with an acid anliydride in the presence of NaOH (Scheme 2).^ 
When pyridine is used in place of NaOH, the amino group becomes acylated as before,
but additionally the carboxyl gioup is replaced by an acyl group in a reaction known as 
the Daldn-West reaction/
X o ^  +  —  X ^ \ o H  +  a c o h
o 130°C H II + NaOH
Scheme 2 Acylation of an amino acid by acetic anliydride in the presence 
of sodimn hydroxide
A typical reaction of the carboxylic acid gi*oup is estérification, which can be achieved by 
heating with an alcohol in the presence of a strong mineral acid, for example HCl^ or 
SOCI2/
R f
+  MaOH ^  +  H2O
O °
Scheme 3 Fischer estérification of an amino acid with methanol
The reaction of a-amino acids with innliydrin produces a deep blue/purple colour when 
the a-amino group is primary/° The formation of the product, known as Ruliemaim’s 
purple, can be used as a useful test for the presence of amino acids. Pro line reacts with 
ninliydrin to give a yellow colour because of the secondary a-amino gimip.^^
OH OH
O O Purple colourO
N inhydrin p
+ J  + CO2 + 4HgO
R
Scheme 4 Ninliydrin is a usefiil spot test for the presence of amino acids
Peptides/Proteins
a-Aniino acids can be polymerized by enzymes in the body to fonn a dipeptide and 
fiu'ther to a polypeptide. This reaction requires energy because the equilibrium favours 
hydi'olysis (Scheme
H-N
Peptide bond
H-N ' Y  +  H-Y
H o  H o
Scheme 5 Formation of a peptide
The peptide (or amide) bond is covalent and is formed between tire a-amino group of one 
amino acid and the carboxyl gr*oup of another. The amide nitrogens, imlike in amines, are 
not basic and are poor nucleophiles; and the carbonyl carbons in amides are not very 
electrophilic. Tlris is because the lone pair of electrons oir the sp^ hybridised airride 
iritrogeir, iirteracts with the carboiryl group to form resoirairce structures, as shown hr 
Scheirre 6 .
H Ô R'H q )  R'
Scheme 6 Resoirairce str uctur es of a peptide bond
This causes the amide bond to have partial double bond character, so it is shorter than 
would be expected for a C-N  bond (about 1.32 Â in amide compared to about 1.49 Â for 
a single C -N  bond). It also has greater kinetic stability, is planar and there is restricted 
rotation arormd this peptide bond, (the activation energy for rotation about the carboir- 
nitrogen bond in amides is typically 75 -  85 kJ/rrrol). The bond between the a  carbon and 
the amide carbonyl group, however, is a single bond, as is the bond on the other residue, 
between the a  carbon and the amide nitrogen. This allows relatively free rotation around 
these bonds so that proteins can fold in different ways.
The geometrically restricted peptide bond means that amide gr oups in peptides can exist 
as distinct cis and trajts isomers, though, almost all peptide bonds are trans due to the
steric pressure in the cis isomers. When the peptide bond involves proline as one of the 
amino acid residues however, the sterical differences between cis and ti'-ans are minimal, 
so both cis and trans isomers exist.^ ^^ ^
The amino acids in a peptide are often referred to as amino acid residues. Two amino acid 
residues fonn a dipeptide, tluee make up a tripeptide, 3-10 make up an oligopeptide and 
many (> 10) linlced amino acid residues is known as a polypeptide. Proteins are composed 
of 1 or more polypeptide chains.
Like amino acids, peptides ar e drawn, by convention, with the amino gioup on the left 
and the carbonyl group on the right. For example, in the dipeptide Ala-Val (Figiue 4), the 
free ammoniiun group, or N-temiinus, is on alanine and the ftee carboxylate group, or C- 
teiininus, is on valine. Val-Ala is not tire same as Ala-Val.
H O A
H3C CH3 H O
Ala-Val Val-Ala
Figure 4 Alanine-Valine and Valine-Alanine
Peptide Synthesis
Amino acids do not react together imaided to form peptides. As mentioned earlier, in 
natiue enzymes facilitate this process, which occius efficiently and selectively. Amides 
are often synthesised in good yield in the laboratory by converting the carboxyl group of a 
carboxylic acid, to an acid chloride or anliydride and then reacting it with an amine.
H^N-R- ^
R . .OH SOCIg Base
T  — ■  Ï  — -  Ï
Scheme 7 Synthesis of an amide by conversion of a carboxylic 
acid to an acyl chloride then its reaction with an amine
H„C .CM
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Amino acids, however, contain both an amino group and a carboxylic acid gr oup in the 
same molecule, so an amino acid, activated to an acyl chloride can react with another 
molecule of itself, as well as with a molecule of the amino acid it was intended to couple 
to. This can lead to a variety of products, which decreases the reaction yield considerably 
and causes a difficult separation problem because the dipeptides, tripeptides, etc. will be 
quite similar in polarities and other physico-chemical properties used in purification. The 
first problem in peptide synthesis is therefore selectivity, which also mcludes prevention 
of unwanted reactions to or between amino acid side-chains.
A second problem is prevention of épimérisation at the a-carbon, which if  produced at 
each step o f the peptide synthesis would lead to a gi owing proportion o f stereoisomeric 
impurities, which as well as reducing the overall yield of the tai get peptide, would also 
cause difficulties in sépar ation.
A third consideration is the requirement that each molecule of peptide imdergoes every 
coupling reaction to the next amino acid in the sequence. This is to keep a good yield of 
final product, but also because of the piuification difficulties it would cause, as in the first 
two considerations.
Fourthly many polypeptides are not very soluble in organic solvents.
Protecting Groups:
In order to form peptide bonds selectively, the fimctional groups, (including side-chains if 
applicable), need to be protected. The requirements of the protecting groups are: that they 
aie stable to the conditions under which the peptide bonds are formed; they can be readily 
removed without disturbing the rest of the peptide; the protecting group for the C- 
terminus and side-chains are not removed under the same conditions as that on the N- 
terminus (unless only a dipeptide is being synthesised), the protecting group for the side 
chains and C-temiinus can be removed under the same conditions as each other if 
building fi'om the N-terminus, (which is usually the preferred route).
Commonly used protecting gioups for the N-terminus are Boc (fg/Y-butoxycarbonyl), and 
Fmoc (9-fluorenyhnethoxycarbonyl). The Boc protecting group (Scheme 8) is widely 
used in both liquid and solid phase peptide synthesis and can be intioduced by reaction
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with di-^er^-butyl carbonate. It can be easily removed by treatment with cold, dilute 
trifluoroacetic acid (TFA) or 4 M hydro chloric acid, followed by evaporation, to give the 
product as a TFA or HCl salt (Scheme 8).^^’ This salt can be treated with an appropriate 
base to yield the fi-ee amine, or in the case of HCl salts, can often be used in the next 
step of a peptide synthesis with the addition of an extra equivalent of base.
O
OH 4M HCl
Dioxane
Scheme 8 Boc deprotection of a peptide
HOI ■ HgN
+  CO;
Evaporation in vacuo 
O
The Fmoc gioup (Figure 5) is widely used in solid phase peptide synthesis and can be 
introduced by reaction with Fnioc-Cl in the presence of sodimn carbonate. The 
protecting group can be removed by beatment with a mild base, such as piperidine, 
however, for long peptide chains incomplete deprotection can o ccu r,w h ich  can be 
solved by using a stronger base, such as l,8-diazabicyclo-[5.4.0]undec-7-ene (DBU).^^ 
Both Boc- and Fmoc-protected amino acids are commercially available, so the type used 
will depend on the circumstances of the peptide synthesis and also on personal preference.
^  1 - vy Q
Fmoc-Asp(OtBu)-OH Aspartic acid (Asp)
Figure 5 Aspartic acid, with amme functionality Fmoc- 
protected and acid side chain protected with a ^er^-butyl ester
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Other possible N-terminus protecting groups include benzyloxycarbonyl (Z or Cbz) and 
(trichloroethyl) carbamate (Troc). The Z group can be introduced by reaction with benzyl 
chloroformate in the presence of sodium hydi'oxide/^ and can be removed by 
hydrogenolysis over palladium^^ or by tieatment with HBr/AcOH.^^ Troc protection can 
be achieved by reaction with Troc-Cl in the presence of p y rid in e ,an d  can he removed 
by treatment with an excess of zinc dust in glacial acetic acid.^°
Commonly used protecting groups for the C-teiininus in liquid phase peptide synthesis 
are methyl or ethyl esters, which can be introduced by Fischer estérification as in Scheme 
3 (page 8), and deprotected by hydrolysis in b a s e . B e n z y l  esters are also commonly 
used and can be removed by catalytic hydrogenolysis under neutr al co n d itio n s .h i solid 
phase peptide synthesis the C-teiininus is usually attached to the resin and is protected in 
that way.
The protecting groups used for side chain functional groups will depend on the properties 
of the side chain, the C- and N-terrnmus protecting gr oups, and in the case of solid phase 
synthesis, on the type of linker attached to the resin.
Coupling Reagents:
Amine protected amino acids are normally coupled with acid protected amino acids using 
an in situ activating agent. A common type of activating agent used in liquid phase 
peptide synthesis is a carbodiimide, for example dicyclohexylcarbodiimide (DCC).^  ^The 
carbodiirnide activates the carbonyl gr oup of the unprotected acid, to give an 0 -acyl 
isourea. The amme can then react with this intermediate, to form the peptide bond with a 
water soluble urea as the by-product (Scheme 9).
1 -hydroxybenzotriazole (HOBT) and copper(II) chloride have been used as additives to 
carbodiirnides in peptide couplings. This was foiuid to increase yields as well as decrease 
racémisation.^^ A disadvantage of carbodiirnides in solid phase peptide synthesis is that 
the water soluble urea is not very soluble in organic solvents, which can cause difficulties 
in its removal from the resin.
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H,N
NH
NH
N, N'“Dicyclohexylurea 
(removed by aqueous work-up)
Scheme 9 Synthesis of BOC-Ala-Ile-OEt using DCC as a carbonyl group activating agent
Solid Phase Peptide Synthesis:
Solution phase peptide synthesis does not satisfactorily overcome the last two main 
problems of peptide synthesis mentioned on page 11. Solid phase peptide synthesis 
(SPPS) produces high yields (nearly quantitative) in each coupling step and ensures high 
reaction rates for othei*wise insoluble long peptide chains. SPPS was first introduced by 
R.B. Menifield using the Boc group for N-a-protection and chloromethylated polystyiene 
as the solid suppoi't. '^* An example of SPPS is illustrated in Scheme 10 on page 16, using 
the Fmoc gioup for N-a-protection, PyBop® as the coupling reagent and polystyiene- 
RINK-NH as the solid support (see Figure 6 on page 15 for structures of coupling reagent 
and resin). The main principles (shown in bold on scheme), are the same when following 
the Boc protection strategy, using different condensation reagents or using alternative 
resin.
An N-teiininiis-protected amino acid (or peptide) is attached to an inert solid support by a 
suitable linlcer usually at its C-teiininus. The protecting group is removed and the resin 
washed using organic solvents on a filter. This amino acid is then coupled to the next 
required C-protected amino acid in the sequence using a suitable coupling reagent (most 
of which are currently based on phosphoniiun or aminiiun salts).
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To ensure tliat the maximum possible proportion of attached amino acid/peptide is 
coupled to the C-protected amino acid, an excess of reagents are used. These can simply 
be removed after each coupling step, by the washing of the resin on a filter with suitable 
organic solvents. This ensures that basically each molecule of iimnobilised peptide 
imdergoes every coupling to the next amino acid.
After removal of mireacted reagents and by-products, the protecting group can be 
removed and the sequence continued following the same procedme as before. When 
synthesis of the peptide is complete the peptide is cleaved from the resin and if possible, 
its side-chains simultaneously de-protected.
Solvation of the growing peptide chain can be achieved by using polar solvents, such as 
DMF, which can be easily washed away with more volatile solvents at the end of the 
synthesis (or as required), but before cleavage fr om the resin.
MeO
OMe
Fmoc
O
O—P—N
Argonaut's Polystyrene-RINK-NH-Fmoc
PyBopG
Figure 6 RINK-NH-Fmoc resin and PyBop® coupling reagent used in solid phase 
synthesis example shown in Scheme 10
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2. Wash resin 1. Deprotect resin
3xDMF
HgN-RINK
3. Attach 1st 
amino acid 
to linker
Piperidine
DMF
Fmoc—N—RINK H
R
Fmoc. OH
OPyBop® (coupling reagent) 
DIPEA (tertiary base)
DMF
4. Wash resin SxDOMSxDMF
Fmocs 'RINK
5. Deprotect N-terminus 
6. Wash resin
Piperidine 3 x DMF R
O DMF
HgN RINK
O
R = amino acid side-chains, 
protected (if appropriate) 
orthagonai to N-terminus protecting 
group. Side-chain protecting 
groups are cleaved in step 12, if 
possible simultaneously with 
cleavage from resin
7. Couple to next 
N-protected 
amino acid
8. Wash resin
R'
Fmoc.
R"
Fmoc.
O
R 9. Repeat step s 5 - 8  n times
RINK
O
Fmoc'
PyBop®
DIPEA
DMF
3xDCM3xDMF
O R
OH
O
R'
RINK
0
10. Deprotect 
N-terminus
11. Wash resin
R"
H^N
O
O
R^
Piperidine
DMF
3 xDMF
3 X (1 X DOM, 1 X MeOH) 
1 X ether
12. Cleave
10% TFA in DOM, 
5% TFA in DOM,RINK 95% TFA in DOM + scavengers H^ N
R"
O O
O
R^
NH.
O
Scheme 10 Example of solid phase peptide synthesis using the Fmoc-protection strategy
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Protein Structure
The structure'*^ ®^  of a protein is described at four levels as set out below.
Quaternary Structure: This refers to the spatial positions of the individual polypeptide 
chains of a protein and the types of interactions connecting them.
Chain A
Figure 7 Human Embryonic Gower II 
Carbonmonoxy Haemoglobin (CO units hidden 
for simplicity) (“backbone” display). This 
protein is made up of 4 polypeptide chains.
Tertiary Structure: This is the three dimensional shape of the whole of each polypeptide. 
The hydrophobic amino acid residues avoid contact with any aqueous medium, so usually 
need to be on the interior. The hydrophilic residues, which are charged or able to 
hydrogen bond, are able to interact with water. These needs cause the polypeptide chain 
to fold in such a way as to minimise the repulsive interactions between hydrophilic and 
hydrophobic forces.
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a-Helix, an example of 
secondary structure
Figure 8 Chain A (“ribbon” display) of the 
haemoglobin shown in Figure 6. Dotted lines show 
presence of hydrogen bonds. Blue = hydrophobic 
residues. Red = hydrophilic residues?^
Secondary Structure: This refers to the local conformation of amino acids in a polypeptide 
chain. Three examples o f secondary structure are a-helices, ^-sheets and P-tums.
Primary Structure: The sequence of amino acids in a protein and the position of any other 
covalent bonds. This is mainly crosslinking disulphide bonds between cysteines, but also 
includes crosslinking between lysine and its aldehyde derivative allysine in collagen.
Ala-His-Leu-Asp-Ser-Leu-Ala-Ser-Leu-Ala-Asn-Pro-
Figure 9 The a-helix shown in Figure 8. “Ribbon” 
display on left, “sticks” display shown on right. Structures 
are colour coded according to amino acid residue.^^
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This primary structme’s sequence is very important because slight variations in individual 
amino acid residues can affect the function of the protein. The primary stmcture also 
specifies the tertiary structure because amino acids need to be in a specific order to fold 
into a certain tliree dimensional stmctiue.
Enzymes
Proteins/peptides are important biological substances that serve many functions as 
mentioned earlier. They can recognise and interact with many different molecules, but 
each binding site is often specific for a particular substrate. Enzymes^^^ '^ are bio­
catalysts that control reactions in the body and nearly all of them are proteins. They are 
normally specific for one substrate or gi'oup of similar substrates, and one reaction or set 
of analogous reactions.
Enzyme-catalysed reactions usually are highly selective and so are less wasteflil than 
many imcatalysed reactions. They ai'e also regulated, with the final product often acting as 
an inliibitor to the enzyme in a process called feedback inliibition, by regulatory proteins 
that can encourage or inliibit the reaction, and by covalent modification of the enzyme.
Enzymes increase tire rate of reaction dramatically, sometimes by factors of a million or 
more, if  compared to the imcatalysed reaction, hi fact, most reactions do not occur at 
perceptible rates in biological systems without the presence of enzymes. Enzymes lower 
the activation energy of a reaction usually by stabilising the transition state, but like all 
catalysts can not make a thermodynamically imfavoiuable reaction proceed. They can, 
however, get aioimd this in some cases, for example, by linldng the process to an 
energetically favoiuable reaction like the hydrolysis of ATP.
The enzyme reaction takes place in the active site of the enzyme, where the substrate 
binds to form a complex, then is converted to the product. The active site is a tliree 
dimensional structine that is relatively small compared to the rest of the enzyme. It is 
formed by amino acid residues which are often from different parts of the polypeptide 
chain. Only a few (on occasion a single) amino acid residues different in the active site 
can change the specificity and activity of the enzyme.
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The mam forces of athactioii between an active site and the substrates are van der Waals 
forces, hydrogen bonding, electrostatic bonds and hydrophobic interactions. These are all 
short range forces, so it is important for the substrate to have a matching shape and 
functionality to the active site of the enzyme in order for these interactions to take place. 
There are two main models used to explain the process of a substrate and enzyme binding 
together. The lock and key mechanism was expressed by Emil Fischer in 1890 and 
proposed that the substrate and enzyme’s active site fit together like a key in a lock. It is 
now known, however, that the active site of many enzymes is changed to fit the substrate 
on binding. This is called the induced-fit mechanism and was proposed by Daniel 
Koshland Jr. in 1958.'*''’
Enzyme Inhibitors
Errzymes can be inliibited by the binding of specific molecules. This is used by the body 
as a means of feedback control, where the product of a biosynthesis inliibits the enzymes’ 
synthesis of more products. Many drugs and toxins also act by inhibiting enzymes. 
Inliibitors can be reversible or irreversible. They are also classified as competitive, 
uncompetitive, non-competitive, mixed or allosteric,^^’
Reversible inliibitors bind to the enzyme using non-covalent interactions and so an 
equilibrium exists between the free enzyme + free inliibitor and the enzyme-inliibitor 
complex. The strength of the interactions will affect the position of the equilibrium, and 
so if  strong interactions exist, the equilibrium will be in favour of the fomiation of the 
enzyme-inliibitor complex. Reversible inliibitors can be removed by dialysis.
hrreversible inliibitors bind with covalent bonds to the enzyme. These bonds are not 
easily broken and so once inliibition has taken place the body often needs to breakdown 
the complex and synthesise a new enzyme, hi the case of competitive irreversible 
inhibitors, it can be an analogous structure to the substrate, but with a modified gioup 
which once reacted with the enzyme, remains bonded to it. Irreversible inliibitors can not 
be removed by dialysis.
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‘=U>w  substrate
enzyme-inhibitor
substrate
Figure 10(a)
Competitive Inliibition. The 
inliibitor blocks the substrate’s entry 
to the active site.
enzyme
v V
enzyme-substrate e nzy me-su bstrate-i n h i bi to r
Figure 10(bl Uncompetitive Inliibition. The inliibitor binds to tlie 
enzynie-substi'ate complex, but can not bind to the free enzyme.
+ substrate
- substrate
\ n j
enzyme
w
enzyme-substrate
inhibitor + inhibitor - inhibitor + inhibitor
enzyme-inhibitor
+ substrate
- substrate
enzyme-substrate-inhibitor
W
enzyme product
Figure 10(c) Simple Linear 
Non-competitive Inliibition. 
The inhibitor can bind either 
to the free enzyme or to the 
enzyme-substrate complex.
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Competitive inliibitors resemble the substrate and bind to the active site of the enzyme, 
thus preventing its interaction with the substrate (Figure 10(a)). The inliibitor may lack 
the appropriate reactive group or is held in an luisuitable position, when boimd to the 
enzyme, for reaction to occur. They compete with the natural substrate to bind to the 
active site of the enzyme, and so increasing their concentration increases the effectiveness 
of inliibition, whereas an increased concentration o f substiate reduces inliibition.
Uncompetitive inliibitors only bind to the enzyme when it has formed a complex with its 
substrate (Figure 10(b)). This can be due to a conformational change in the enzyme 
induced by substrate binding, which exposes a site which the inhibitor can bind to, or the 
inliibitor may directly bind to the enzyme-bound substrate. An increased substrate 
concentration can not reduce the level of inliibition because the inliibitor and substrate do 
not compete to bind at the same active site.
Non-competitive inliibitors bind to the enzyme at an alternative site to the substrate and 
can bind iirespective of whether an enzynie-substiate complex has formed or not (Figure 
10(c)). The inliibitor either binds at the catalytic site or induces a change in the 
confoimation of the catalytic site, whilst in either case not affecting substi ate binding. For 
simple linear non-competitive inhibition^ the substrate concentration has no effect on 
inliibition. This type of inliibition can only be reversible.
In cases when the characteristics of simple linear competitive inhibition, uncompetitive 
inhibition or simple linear non-competitive inliibition are not obseiwed, the inliibition is 
teimed mixed inhibition, regardless of the actual mechanism involved. In mixed 
inliibition, inliibitor binding is not completely independent of substrate binding.
Allosteric inliibitors bind at an alternative site of the enzyme, laiown as the allosteric site, 
which is used for the body’s feedback control mentioned earlier. On binding they alter the 
shape of the enzyme, (and hence the shape of its active site), so that it is not recognised by 
its substrate. The effect of allosteric inliibitors is usually greatest at low and moderate 
concenti'ations of substrate and negligible at high substrate concentrations, where the 
substrate does not need to be conserved. Allosteric inliibition generally occurs at the first 
step coimiiitted to synthesising the product whose concentration needs to be controlled. In 
the example shown in Scheme 11, the enzyme catalysing conversion of A ^  B, would be
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inliibited by E or its subsequent products. This allows the increased concentration of A 
made available by this inhibition, to be converted into different metabolites, thus ensining 
that concenti'ations of intermediates B — D do not become excessive.
B/ \
Scheme 11 Example metabolic sequence 
Peptidomimetics
Peptides perform a variety of important roles in the body, so are o f gieat medical interest 
and their use as dmgs in either their native or modified form, is constantly increasing.
The use of peptides as drugs, does though, often have several important disadvantages:
- Poor bioavailability caused by their relatively high molecular mass making it difficult 
to traverse biological membranes.
Short biological half-lives because of metabolism by proteolytic enzymes (especially 
during the process of digestion), and also due to their rapid excretion via the liver and 
kidneys.
- Undesired biological effects caused by interactions with receptors located outside of 
the target organ or cell, paiticularly when the peptides are confoimationally
flexible.“ W.29
To avoid these drawbacks of peptides, synthetic organic chemists often develop drugs 
Imown as peptidomimetics.
The term peptidomimetic (also known as peptide mimetic) has been defined in a variety 
of ways in the literatine. Some authors have favoured a fairly broad definition:
“A peptidomimetic is a compoimd that, as the ligand of a receptor, can imitate or block 
the biological effect of a peptide at the receptor level. As the ligand of an enzyme it can 
serve as substiate or inliibitor.” (Giaimis and Kolter).^ ^^ ®^
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“Peptidomimetic: a molecule with some or all peptide functional groups replaced by other 
groups, yet which exhibits properties analogous to a peptide.” (Fletcher and Campbell).^^
“Elements which mimic the structme of natiual peptide components.” (Kemp).^°
A more strict definition is given by Moore:
“A molecule that mimics the biological activity of a peptide but is no longer peptidic in 
chemical nature... A molecule that no longer contains any peptide bonds... and has a 
molecular weight of less than 700 Da.”^^
The definition prefeired in this report is that given by Fletcher and Campbell.
How peptidomimetics can overcome the shortfalls of peptides:
- Peptidomimetics can be made much smaller, in terms of their molecular weight, than 
the natural peptide because they only have to represent the pharmacophore instead of 
the entire peptide.
- The parts of the molecule susceptible to enzymatic degi adation can be modified to 
prevent proteolysis.
- Conformational restrictions can be introduced to limit the type o f peptide receptors 
that the drug can interact with (Scheme 11).
These required properties of peptidomimetics ai e relevant for both agonist and antagonist 
dings, and enzyme inliibitors.
Agonist dmgs bind to the receptor binding site and have the same effect as the natural 
peptide messenger in their action. Antagonists bind to the receptor, but do not activate it. 
Once boimd to the receptor, they can block it, thereby preventing its use by its natinal 
agonist. Antagonists can work by binding to the receptor binding site or by binding to a 
different part of the receptor and distorting both it and the binding site.^^
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A p ep tid e  in conform ationai equiiibrium
+ alternative
 ^ receptor + peptidase + receptor
alternative
receptor-peptide
complex
peptidase-peptlde
complex peptide-receptorcomplex
undesired  
biological effect desired biological effect
breakdown of peptide
Schem e 11 Peptides are in equilibrium between various conformations in the 
body. If a confomiational restriction (broken line) is introduced to the required 
conformation, the undesired fomis can not be foimed, and so only the desired 
biological effect is produced.^^C^)
Amide bond mimics
After administration to the body, many peptides are broken down or modified by cleavage 
at the amide bond by peptidases. Various strategies have been used by chemists to prevent 
tliis process, including the use of all D-isomers of the natural peptide and retro-inverso- 
isomers (peptides in which the sequence of amino acids is reversed and the chirality of 
each residue is inverted). Another solution is to use peptidomimetics with amide bond 
mimics.
The peptide bond siurogate can be positioned at the peptidase’s usual site of cleavage, but 
can also in some cases confer remote protection ftoin enzyme catalysed lysis.^^' 
Replacement of a peptide bond by an isostere can, however, alter the bio active 
conformation of the peptidomimetic. This can result in a decrease or change in activity, 
but can also be done to lock in the desired conformation of the peptidomimetic. The
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stiaictui’e of a peptidomimetic with an amide bond suiTogate is wiitten in the same way as 
the peptide it is based on, but with ^/(amide mimic’s stmcture) wiitten between the amino 
acid residues which have their peptide bond replaced. For example, -Gly-Ile-\|/(CH2NH)- 
Ai'g-Gly-, indicates that the peptide bond between isoleucine and arginine has been 
replaced by the reduced peptide, CH2NH.
Both cis and trans amide bond mimics have been prepared. Replacement of the amide 
bond by a ^rmM-caibon-caibon double bond at the preferred protease cleavage site 
improved the stability to proteolysis of an Enkephalin analogue (Figure 11). Furthermore 
the biological efficacy of the peptidomimetic was maintained compared with that of the 
natural substrate in the tests performed. This was attributed to the similar geometry of the 
/7^fl7w-olefinic group to a trans amide bond, and also that the bond in question is not 
involved directly in the secondary structui e nor does it interact with the binding site of the 
receptor. A cw-alkene is not so suitable, however, to mimic a cis amide bond because the 
cw-Py-imsaturated compound is prone to rearrange to the more stable tî^ans-isomer.^^
OH
Gly—P he—Leu—OH
OGly—P he—Leu—OH
The peptidomimetic. A fra/is-carbon-carbon The natural enkephalin
double bond replaces the peptide bond between 
the tyrosine and glycine residues.
Figure 11 An alkene as a trans-miidQ bond niimic^^
The incorporation of the reduced amide bond, \}/(CH2NH), in place o f the amide bonds at 
various sites of a histone hexapeptide, resulted in an increased resistance to the protease, 
try p s in .T h is  increase in stability to trypsin took place, not only with the analogues 
which had surrogates in the position where lysis occurs in the natural peptide, but also 
when the sunogates were at alternative positions.
The antigenic properties of these peptidomimetics were measined and it was found that 
their ability to bmd antibodies produced against their parent peptide differed depending 
on where the \|/(CH2NH) group was located. This was attributed to the conformational
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change caused by the differing location of the reduced amide bond in the peptide’s 
stnictine. (At physiological pH the reduced amide group is protonated and so can act as a 
strong proton donor, thereby stabilising a folded stmcture).
The inmumogenic properties of these peptidomimetics were tested and it was found that 
the analogues which had reacted poorly in most of the antigenic tests, generated 
antibodies that did not react with the parent peptide; whereas analogues which had reacted 
strongly in most of the antigenic tests, generated antibodies that did react with the parent 
peptide. This fur ther indicated that the intr oduction of the redirced amide bond in certain 
positions altered the conformation of the peptide.
hi a recent report, glutathione analogues with differing peptide bond isosteres were 
compared for their stability to protease and their activity as GST isoenzyme inhibitiors.^^ 
The amide bond mimics compared were tire reduced amide \}/(CH2NH), iV-methylarnide in 
place of the amine of an amide bond, methane and methylene linlcages. hr this study the 
reduced amide isostere (Figirre 12) showed the best resistance to the peptidase tested, 
whilst also having an activity close to the inliibitor the analogues were based on.
HO OH
NH,
"Reduced" isotere
OH
O
O
HO : OHNH, O
Figure 12 The use of a 
reduced amide as an amide 
bond isostere of a glutathione 
(GSH) conjirgate niirnic.^^
OH
O
Native GSH conjugate
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Sulphonamides \|/(CH2S02NH) have been used as amide bond siuTogates and this 
alteration in stmcture increased the stability of the peptidomimetic to proteolysis 
compared witli the parent peptide (Figure 13). Substitution of amide bonds by 
sulphonamide gioups close to the prefeiTed cleavage site for a peptidase, also gave an 
increased protection from protease catalysed degradation. '^^
o
H %
O
:
Figure 13 A sulphonamide as an amide bond mimic.^"^
A iu*ea linlcage (NFI-CO-NH) was used to replace the y-glutamyl amide bond of a potent 
glyoxalase inliibitor. The inliibition of glyoxalase enzyme can increase the levels of 
cellular methylglyoxal wliich is a powerful carcinostatic agent. The peptidomimetic was 
found to be completely resistant to proteolytic degradation by the enzymes tested, whilst 
retaining almost the same activity as the inliibitor it was based on.^^
Heterocycle-based peptidomimetics
Heterocycles have been used in the design of peptide mimetics because of their ability to 
mimic the electrostatic and steric properties of certain peptide bonds or peptide fragments. 
They can also be used to place a confomiational resti'aint on the part o f the peptide they 
ar e replacing.
Tetrazole dipeptide analogues have been developed as c/^^-amide bond mimics (Figure 
14). This was done in order to lock in the conformation of the cw-isonier, wliich was 
believed to be the bioactive fomi for certain peptides. A comparison of the crystal 
stmctmes for dilcetopiperazine and a tetrazole analogue, in which a tetrazole ring had 
replaced one of the cz.s'-aniide groups showed a similar geometiy.^^ Problems in the 
synthesis because the replacement of the amide bond with the teti azole ring made 
racémisation of the adjacent a-carbons more probable,^^ were later solved by the use of 
quinoline in the synthesis.'^^
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O H O
R, R' = amino acid side chains 
Figure 14 A tetrazole as a cw-amide bond mimic,
A more recent adaptation of the teti azole based dipeptide mimic has been developed 
which uses a non-hydrolysable a-keto tetrazole isostere \}/(C0 CN4) in place of an amide 
bond. This combines the confomiational restriction of the tetrazole ring with the non- 
hydrolysable a-keto amide ftinctionality \j/(COCONH). The synthesis of the a-keto 
tetrazole isostere ( 1,5-disubstituted) fomied a 2 ,5-disubstituted a-keto tetrazole as well, 
which may also be useful as a building block for peptidomimetics (Figure 15)/^
BccHN
OBn1,5-regicmer
BccHN
OBnO
2,5-regicmer
Figure 15 alpha-keto tetiazole-based dipeptide mimics.'^^
Pyrazole based peptidomimetics have been prepared as possible confoimationally 
constrained cw-amide bond mimics. These have a pyiazole ring where the tetiazole ring 
was in the tetrazole peptidomimetics.'*^
Thiazole and oxazole rings have been used to replace the peptide fi*agment, CONH-Leu, 
between Phe and Leu, in a library of peptidomimetics based on SFLLR, which were 
aimed at being used as tluombin receptor antagonists (Figure 16). The compounds were 
tested for inliibition of thiombin and SFLLRN-NH2 induced platelet aggiegation. Several 
analogues were found to have strong thrombin receptor affinity and to inhibit thionibin- 
induced platelet aggregation, with the oxazole-based analogue (1) (Figure 16), being an 
especially potent example.'*^
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Sen Leu-Arg-NH.
SFLLR
Leu-Arg-NH.:
X = 8  or O
Azole-based SFLLR mimic R = H or Me Sar = sarcosine
Safv
HN NH,
NH
Figure 16 The use of tliiazole and oxazole based peptidomimetics to inliibit 
tlnombin-induced platelet aggiegation.'^^
The use 1,2,4-oxadiazoles, 1,3,4-oxadiazoles and 1,2,4-triazoles in Phe-Gly mimetics in 
compoimds based on dermorpliin have been shown to be potent and selective 
peptidomimetics (Figure 17). The peptidomimetics had high affinity to rat p-opioid 
receptors, but not to 5-opioid receptors. As pai't of the same research 1,2,4-oxadiazole,
1,3,4-oxadiazole and 1,2,4-triazole based Phe-Gly mimetics were also incorporated into a 
peptidomimetic based on substance P (Aig-Pro-Lys-Pro-Ghi-Gln-Phe-Phe-Gly-Leu- 
MetNH2) (SP), but showed much lower activity than SP itself for the rat NKi receptor. It 
was speculated that the heterocycle moiety may affect the ability of the peptidomimetic to 
assume the bio active conformation, or perhaps to differences in electiostatic properties of 
the peptide and the peptide mimetic. Tins research indicates that the ability of a dipeptide 
mimetic to mimic the required properties of the fragment it is replacing, will vary between 
peptides.' '^^’
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H-Ty r-D - Ai Qi ^j
H O
Tyr-Pro-SerNH,
Dermorphin
H-Tyr-D-Ala'-.jyj' jj
H O—N
1,2,4-Oxadiazole
-Pro-SerNH,
O \ N
H-Tyr-D-Ala-^'^ ^  Tyr-Pro-SerNH, H -T yr-D -A la-^p^^^y V ^ T y r -P ro -S e rN H ,
H N -N   ^ H N -N  ^H
1,3,4-Oxadiazole -j ,2,4-T riazole
Figure 17 Oxadiazoles and triazoles as amide bond mimics' '^^
Transamidation
Transamidation is the reaction between an amide and compounds such as an amine, a 
carboxylic acid, an ester or a nitrile; which results in the breaking then reforming of an 
amide bond, with either the carbonyl component becoming bonded to a different nitrogen 
or the niti’ogen component becoming bonded to a different carbonyl. These reactions are 
“group transfer” reactions and can be intennolecular or intramolecular (Scheme 12).
H H ri__NH„ IntermoleculaH®
R R'iUo
NH,
Scheme 12 Types of transamidation
R'
R
O
NH Intramolecular'^^
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Intramolecular transamidation leading to ring expansion of lactam rings
There are many examples of intramolecular transamidation in the literature, and
intramolecular ti ansamidations to perfoiin ring expansion has been a topic of great 
interest. Hesse et al. determined in 1974 that this type of reaction could be perfomied in 
the presence of base on neooncinotine, which is a macrocyclic lactam ring with a tethered 
amine, to give isooncinotine (scheme 13). This allowed the isolation of oncinotine, which 
had previously been inseparable from neooncinotine.'^^^“^
Neooncinotine
K-t-butoxide
Isooncinotine
Scheme 13 Intramolecular transamidation 
leading to ring expansion.'^^(^)
A mechanism for this transformation is shown in scheme 14."^  ^This reaction has also been 
earned out with aminoethyl and aminobutyl units via 5- and 7-membered inteiinediates 
respectively. It was found that increasing the side chain length, decreases the rate of
reaction.48(b)
R'" "O
- H-*
R
R, R' = members of lactam ring
R'" "O
Scheme 14 Mechanism for lactam ring expansion.'^^
Intramolecular transamidative ring expansion has also been perfomied under acidic 
conditions (for example, p-TsOH, refluxed in xylenes).^®’
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By incorporation of successive aminopropyl components, polyaminolactams can be 
synthesised in good yield using the “zip” reaction, so named because of its resemblance 
with the use of a zip fastener (Scheme 15). The same product can also be synthesised m a 
stepwise transamidative ring expansion, with both methods using potassiiun-3- 
aminopropyl amide/1,3-diaminopropane for the hansamidation step."*^  This reaction has 
been used to synthesise a 53-membered polyaminolactani.^^
NH
NH
90% yield
Scheme 15 The "Zip" reaction."^^
In the case of transamidative ring expansion of p-lactam rings, the release of ring strain 
can favour ring expansion, so that in some cases reaction occur s without the need for 
additional reagents. Crombie et al. found that fimctional gi oup conversion of the bromide 
(2) to the primary amine (3), using liquid anmionia in a sealed tube at room temperature 
(8 days), leads to the formation of the diaminocyclooctane (4) (Scheme 16). If the 
reaction time was shortened, amine inteiinediate (3) could be isolated, but it converted to 
the 8-membered aminolactam, even when stored dry (>90% conversion after 40 days). 
Conversion was faster when in solution.^^’ ^
Ph Ph
H (4)
Scheme 16 Release of ring strain from 4-membered 
lactam favours ring expansion.^^» ^
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7- and 9-membered aniinolactanis have also been prepared from aminoethyl and 
aminobutyl units respectively, but the fomiation of the 9-membered aminolactam required 
elevated temperatuie (55 -  65°C) to obtain the product in good yield (67%). This is 
presimiably due to the requirement for formation of a 7-membered ti ansition state which 
would be less favoinable than a 5 or 6-membered intermediate, confinning the work of 
Hesse on larger aminolactams (see Scheme 14). It was not possible to isolate 13-, 15- or 
17-membered aminolactams from reaction of (3-lactams with appropriate length 
alkylamino chains (5), with the fomiation of acyclic amides (7) resulting instead. The 
authors suggest that the lai'ge aminolactams (6) are in fact fomied, but are then destroyed 
via annnonolysis of the lactam bond (Scheme 17).^ "^ ’^^
(5)
Ph 70°C Ph
CONK'2
Ph
n = 8, 10 or 12
(7)
Scheme 17 Inti amolecular transamidation of aminolactams, 
followed by intemiolecular transamidation by aninionia.^^, 55
Studies have also been cairied out to test the effect of geometiic constraint in the 
halogenoalkyl chain (Scheme 18). The cw-isonier (8) reacted to give the 9-membered 
aminolactam (9) (57% yield) when heated with liquid ammonia at 70°C for 10 days. After 
reaction of the /‘rrzw '^-isonier (10) imder the same conditions, however, only the acyclic 
amino amide (11) was isolated. The authors suggested that, like in the case of 13-, 15- or 
17-membered aminolactams, ring expansion does occin, but in the case of the trans- 
isomer there is sufficient ring stiain caused by the ^ra/i^-double bond, for transamidative 
ring opening by aimnonia to occiu (Scheme 18).^ "^ ’
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NHad)
70°C
CONHg
70"C Ph N
Scheme 18 Effect of geometric constraint in 
halogenoalkyl chain on transamidation.^'*»
Banfi et al. have reported that tlie natnie of substituents on the a  and p carbons of the 
p-lactams (12a -  d) affect the rate of the intramolecular transamidation to the 
dianiinocycloheptanes (13a -  d). Wlien the R gioup is OR, it has an activating effect on 
the lactam, with a phenoxy gioup being more activating than a methoxy. An unsaturated 
R’ group also causes an increase in the reactivity of the lactam (Scheme 19)."^ ’^
R' R'
No'
R , a: R = H, R' = OBOM
Y  NH b: R= OMe, R' = (E) CH=CHPh
)  c: R= OMe, R' = OBOM
\ — /  d: R= OPh, R' = OBOM
H(1 2a-d )  NHg (13a-d)
Scheme 19 Activating effect of substituents onN-(aminoethane)-p-lactams.'^^
hitramolecular tiansamidative ring expansion of N-(amino-alkyl)lactams (including “zip 
reactions”) has found use in many synthesises including that of natural products, for 
example, the macrocyclic spermidine alkaloids (±)-celacimiine^^’^^  and (+)- 
dihydroperiphyllme,^'^’ and the spermine alkaloids homaline^^ and (±)-verbascene,^^ as 
well as a range of other usehil compounds.'^^’
Other intramolecular transamidation reactions
hitramolecular transamidation of an acyclic amide by a nucleophilic secondary amine 
group leading to the formation of lactam rings on heating, was investigated by Stirling in 
1958 (Scheme 20). It was found that mcreased substitution a to the amine, reduced its 
nucleophilicity in this transamidation reaction. Cyclisation was complete in 1 hour at
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160°C when the amine was NHCH2PI1 (reaction 1, Scheme 20), whereas reaction was 
incomplete after 2 hours at 220°C with the cyclohexyl substituted amine (reaction 2 , 
Scheme 20).^^
1) O A
O
HgN
2)
A O
N HgN
Scheme 20 Ring formation by intramolecular transamidation.
Olsen et al. found that intramolecular tiansamidation can occur when the hydroxamates 
(14a -  b) are treated with sodiiun borohydiide in an attempt to synthesise the alcohol 
(15), causing reaiTangement of the hydroxamates via a cyclic iniide (16) to also produce 
the isomeric alcohol (17) (Scheme 21).^^
NaBH.
THF
NHBoc
NHOBn
NHBoc
NHOBn
(1 4 a -b )  \N a B H 4 
THF
14a, R = OCOCoH
14b, R
NHBoc
OBn
(16)
NHBoc 
OH
NHOBn
Scheme 21 hitramolecular transamidative rearrangement in hydroxamates.^^
hitramolecular transamidative rearrangement has been used in the synthesis of the marine 
bisindole alkaloids hamacanthin A and liamacantliin B. Boc deprotection of the primary 
amine group of (18) gives the amine (19), which can either yield the 3,5-bisindole (21), or
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rearrange, as a result of intramoleculai* tiansamidation, to give the 3,6-bisindole (22) 
(Scheme 22). Fiuther reaction gives hamacanthins A and B horn (22) and (21), 
respectively (R = Ac), This transamidation-cyclisation can be contiolled by changing the 
R substituent on (18), with a weaker electron-withdr awing group favouring 
transamidation to (22). Solvent choice could also affect regiocontr ol, with the level of 
transamidation being decreased in polar solvents.^"^
Ac
BocHN
(18)
Ac
H,N
Ac(21 )
(19)
Ac
HN R = H, Acetyl or TosylHO
AcAc
(22)
(20)
Scheme 22 Transamidation-cyclisation of 2-oxoethanarnides.^'^
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Intennolecular Transamidation
There appears to be much less research featiuing intennolecular tiansamidation in the 
literature, though a variety of methods for perfonning this transformation have been 
reported.
Enzymes have been used to catalyse intennolecular transamidation imder mild conditions, 
though reactions are slow and usually very substiate specific. Gotor et al. used the lipase 
Candida cylindracea to catalyse the transamidation of (±)-N-(2,2,2-trifluoroethyl)-2- 
chloropropionamide with various primaiy amines to obtain products with high to 
moderate enantiomeric excesses.^^
A more general method for enzyme catalysed transamidation has been reported using the 
lipase Candida antarctica. A-substituted and imsubstituted amides were reacted with 
amines in the presence of the lipase at 45 °C in anliydrous methyl feA-butyl ether 
(MTBE). Forty-five lipolytic and proteolytic enzymes were tested, but only Candida 
antarctica was found to be active for the catalysis of this type of reaction (Scheme 23).
O Candida
JJ p ,  antarctica W p .
+  H^N-R------------------  p J L .,.R '"  +  HN"
M TB E R M 
45°C
Scheme 23 Enzymatic intennolecular transamidation.^^
The reaction was not affected by vaiiation of the amides’ amine substituents: R' (Me or 
Pr) and R" (H or Me). The size of the R substituent, however, had a great effect on the 
reaction, with the best results obtained when R was stiaight-chained, consisting of 2 -  4 
units. Secondary and aromatic amines were not suitable for this reaction, but the reactivity 
of primary aliphatic amines was not affected by their side chain sti ucture (R'"). Higher 
yields of the desired amide could also be obtained by increasing the concentration of 
primary amine.^^
Gellman et al. have examined the metal-catalysed transamidation of secondary amides 
with primary amines using a variety of catalysts. Tlu ee classes of potential transamidation 
catalyst were investigated: Lewis acidic metal complexes, nucleophilic alkali-metal 
amides, and transition-metal and main-gioup metal amides.
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Ill the case of the theimodynamically favoured transamidation of A-phenyl heptanamide 
with benzylamine, several metal catalysts were active, with Ti(NMe2)4 and Sc(0 Tf)3 able 
to promote nearly quantitative reaction after 16 hom*s (Scheme 24). (Only 39% 
conversion is observed after 1 month at 90°C in tlie absence of catalyst). Similar results 
were obtained with most of the other alkylaniines tested.
O 5 mol % [cat.] O
90°C
Scheme 24 Catalysis of therniodynaniically favoured transamidation.'^^
Ti(NMe2)4 and Sc(0 Tf)3 catalysts were, however, ineffective at promoting the 
thermoneutral exchange reactions investigated between A-alkyl secondaiy amides and 
alkylaniines. In the absence of catalyst, these reactions do not proceed even after 1 month 
at 90°C, but the dimeric ahmiinium complex, Al2(NMe2)ô was able to promote about 50% 
conversion in each case, in either direction. (Scheme 25)."^ ^
j? 5 mol % [cat.] O
90°C
R R'
CHj—
IL J J
(b) CHg— CHg—
(c) Y  C H -  ^ C H -
Scheme 25 Catalytic tiaiisamidation 
of theiinoneutral equlibriimi.'^^
Microwaves have been used to promote the solvent-free transamidation of 1-benzoyl-3,3- 
diethylthioiuea to 1-benzoyl-3-alkylthioiueas on various solid supports. The best results 
using microwaves were obtained with potassimii fluoride impregnated alumina as the 
suppoif, obtaining, for example with R = H, R’ = Bn (Scheme 26), 81% yield after just 2 
minutes using a domestic microwave oven at 560W. Tliis compared to only 35% yield 
after 300 minutes, (15% yield after 60 minutes) using an oil bath at 95 -  100°C for the
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same reaction. Similar results were obtained using a selection of secondary and tertiary 
amines along the lines of Scheme 26.^^
p  KF/ALO3
HN" --------------- ^  4, HN'
Rt microwave |i J  ^
Scheme 26 Transamidation under microwave conditions in dry media.
Transamidation of five- and six-membered A^-Boc-lactams with various amines have 
resulted in acyclic products as set out in Scheme 27. 10 kbar pressure at usually about 
90°C was necessaiy to achieve the ti'ansfomiation, with no reaction occiming when 
simply refluxed under atmospheric pressure in acetonitrile. The lactams were Boc- 
protected for the reaction, to increase the reactivity of the amide bond following previous 
literature precedence for this effect (cited in paper). This reaction was selective to amine 
attack at the amide gi’oup, even when an ester group was present on the lactam. High 
yields of up to 97%, (reaction of 7/-Boc-pyiTolidin-2-one with benzylamine) have been 
obtained, though reaction with certain sterically hindered or less reactive amines did not 
proceed.^^
+  HNR’R" — °
Boo ^
(Reaction temperature = 25°C - reflux, 
depending on lactam and amines used)
Scheme 27 High pressiue intermolecular transaniidative 
ring opening of lactam to give acyclic product.^^
Intermolecular transamidation has been cairied out between an aliphatic secondary amide 
(iV-hexylhexanamide) and aromatic nitriles or dinitiiles (Scheme 28). The amide was 
reacted with various nitriles in the presence of 1% polyphosphoric acid (PPA) at 300°C to 
give an aromatic amide and an aliphatic nitrile. Good yields (up to 87%) were obtained in 
most cases, but were low (25%) for ortho substituted nitriles, which the authors attributed 
to steric hindrance. The mechanism proposed by the authors was deteiinined by additional 
experiments and NMR studies, and shows that water and PPA both act as catalysts in the 
reaction.^^
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ArCN PPA phosphorylatedintermediate
HgO RCONHR’
-PPA
ArCONH,
Scheme 28 Intemiolecular transamidation of 
an aromatic nitrile with a secondary amide.
RCONK +  ArCONHR'
-HgO PPA
RCN
An intermolecular transamidation imder mild conditions between the guanidine (23) and 
primary alkylaniines has recently been reported. The first step of the reaction is an 
intramolecular transamidation base catalysed by a primary or secondary allcylamine. Tliis 
is followed by an intermolecular transamidation with a primary alkylamine to yield the 
guanidine (25) (Scheme 29). The imidazolidinone intemiediate (24) is not isolated when a 
primary alkylamine is used for the first step, with the reaction proceeding stiaight away to 
the product (25), which is isolated in quantitative yields. A secondary alkylamine, 
however, does not react with the imidazolidinone (24) under the same conditions, even 
imder extended reaction times.^®
HgN ?N O NHgR or NHR,
HN.. ^  MeOH 
reflux
HN
?N. O NHgR HgN
MeOH
reflux
?N O
HN NHR
(23) (24) (25)
R = Me, Et, or Pr
Scheme 29 hitermolecular transamidation under mild conditions.^®
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Aims
Explore the reaction of a secondaiy amide with a nucleophile in the presence of triflic 
anlrydride because of its potential to be used in the synthesis of imidazole-based 
amide bond mimics.
hrvestigate the synthesis of heterocyclic amide bond mimics.
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A Study into the Effect of Triflic Anhydride Activation on a 
Secondary Amide, and its Subsequent Reaction with a Nucleophile
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Synthesis of Heterocycles from Secondary Amides Using Triflic 
Anhydride Activation
All aim of this project was to investigate the reaction of triflic anhydride with a secondary 
amide.
The group of de Charette has used triflic anhydride for amide activation to obtain imidate 
intemiediates that after nucleophilic attack with amino-tliiols yield thiazole heterocycles 
(Scheme 30).^*
O  T f 2 0  D T f
r , .  I s—
R" I :
R "
S
R-^ N
Scheme 30 0-Triflation of an amide, followed hy nucleophilic 
attack by an amino thiol to yield a thiazoline.'^^
Robl has also described the use of triflic anhydride to activate an amide bond to give 
imidate intermediates.^^ On the otlier hand Ghosez et al. reported that reaction of amides 
with triflic anliydride resulted in O- and N-triflation, though with the 0-triflated imidate 
products predominating by a ratio of 4:1 (Scheme 31).^^
^ -OT,
reflux R
Scheme 31 Activation of an amide bond by triflic anhydride can lead to both 
N- and 0-triflated products."^^
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Similai' amide activation using diazometliane in the presence of silica gel was reported to 
give the 0-activated hnidates/'^ but with TMS tiiflate gave an equilibriimi of O- and N- 
activated products^^. Talcing into accoimt these literatm e precedents it was decided to 
investigate the reaction between an amide and triflic anliydride in detail and exploit the 
activation to synthesise novel useful compounds for application in organic synthesis and 
medicinal chemistry.
As a model amide compound for our investigation ô-valerolactam (piperidin-2-one) was 
chosen. The choice of a cyclic amide was made to eiisiue that activation of the amide 
carbonyl by the electiophile would lead to either 0-triflated imidate or N-triflated iniide 
intennediates rather than to nitrile ylides as reported previously.^^
It was envisaged that this reaction would convert a secondary amide to an imidazole in a 
one-pot reaction following the sequence set out in Scheme 32.^  ^If this reaction did yield 
the expected product it could be used in developing a novel general route to imidazole- 
based peptidoniinietics with the peptide bond replaced by the imidazole. This could then 
have been used in the targeting of specific ailments and to make medical treatments for 
them, such as to synthesise an ACE inliibitor.
The secondary amide is activated by triflic anliydride to yield a liighly electrophilic 
intermediate (28),^*’ pyiidine is used to react with the triflic acid formed, thereby 
forcing the reaction to completion. An aminoacetal is reacted with (28) by nucleophilic 
addition, with pyiidine present as a buffer. Subsequent ring closure could give the stable 
intemiediate, 3-ethoxy-2,3,5,6,7,8-hexahydro-imidazo[l,2-a]pyiidine (29). Aqueous 
acidic work-up could remove the ethoxy-gioup to give the imidazole product (26) under 
ai'omatisation.
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o
NH
(27)
TfgO
Pyridine
DCM
OTf 
N
HgN OEt 
OEt
(28)
OEt
(29)
MCIn
(26)
Scheme 32 Conversion of a secondaiy amide into an imidazole
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Results/Discussion
Attempted Synthesis of 3-Ethoxy-2,3,5,6,7,8-hexahydro-imidazo[l,2-a]pyndine, (29)
OTfTfgO 
NH Pyddine
(27) 
Scheme 33
(28) (29)
Piperidin-2 -one was coupled with amino acetaldehyde diethyl acetal at -46°C, using triflic 
anliydride as an activating agent and pyiidine as a buffer. After work-up, TLC and 
NMR of the cmde reaction mixture showed a mixtiue of products. The crude mixture was 
piuified by cohmin clnomatogiaphy on SiO] to yield two significant products. These 
products were characterised.
1 -Trifluoromethanesulfonvl-piperidin-2-one (30)
o 0
p
- (V( 2 ) k ^
(3)
'>(4) F (2) L _ J ( 4 )
(3)
(30) (28)
The least polar of these fractions yielded a yellow liquid (51.2%) and was shown to be 
one of the tiiflate intemiediates of piperidiii-2-one shown above. The literature suggested 
that it could be the product with the tiiflate group bonded to the oxygen (28).^^’ The IR, 
however, suggested that there was a carbonyl moiety in the compound (band at 1739.19 
cin'^), and therefore, that the tiiflate group was bonded to Üie nitrogen, which would mean 
that the product was compound (30). The and NMR and mass spectra were 
inconclusive because they were consistent with either product.
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Figure 18 IR of l-Trifluorometliaiiesulfonyl-piperidin-2-one, (30) neat between 
KBr discs
The major absoiption frequencies of this compound in the IR (Figure 18) and their 
assignments were: Vmax (neat)/cm'^ 1739 (C= 0  stretch of 3° amide), 1402 (SO2 
asynunetiic stietch), 1226 (CF3), 1136 (SO2 symmetric stretch).
A NMR was recorded and the Ôn value obtained (150.3ppm), suggested that the 
triflate group was bonded to the nitrogen because it was more downfield than would be 
expected for the nitrogen in the 0-tiiflated product (Figure 19).
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Figure 19 NMR (50.7MHz) of l-Trifluoromethanesulfonyl-piperidin-2-one,
(30) in CDCI3
MS300102F #  1-3 RT: 0.10-0.26 AV: 3 NL: 2.26E8
T: + C [ 49.50-450.50]
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Figure 20 MS (El) of l-Trifluoromethanesulfonyl-piperidin-2-one, (30)
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The low resolution Mass Spectrum (El) (Figuie 20) was consistent with both the N- and 
the 0-ti*iflated derivatives. The major fragments and thefr possible assignments aie as 
follows (the suggested fragment for the N-triflated derivative is shown first in each case): 
MS (El) (m/z): 231 = M*‘ (both structures 28, 30), 175 = C3H4F3NO2S or C3H2F3O3S, 162 
= CH2NSO2CF3 + H or COSO2CF3 + H, 69 = CF3, 55 = CH2CH2CO -  H or 
CH2CH2CH2N - H .
An “accurate Mass Specti'um” (obtained fr om high resolution mass specti’ometry) o f the 
fr agment at m/z 175 was recorded because although both structures could form a fr agment 
of this mass, the ratio of the isotopes of oxygen and nitiogen are different so the mass will 
be slightly different (Scheme 34). This experiment showed the peak to be an accurate 
mass value of m/z 173.989, which would be consistent with the stiucture of (30) minus 1 
hydrogen. (C3H4F3NO2S for N-triflated intermediate (30) requires 173.984 and 
C3H2F3O3S for 0-triflated intermediate (28) would requhe 173.956).
O
El fragmentation
w  ------------^
(30)
C3H4F3NO2S 
requires 173.984
NTf Found:
173.989
C3H2F3O3S
requires 173.956
Scheme 34 Hypothetical fr agments produced on fr agmentation 
by El (blue zig-zag lines indicate proposed breakage of bonds)
It has to be noted that in the accurate mass experiment, migration of the triflate group 
from O to N in the gas phase can not be excluded; however, in summaiy all analytical 
data combined lead to assigmnent of the reaction product as the N-triflated derivative 
(30).
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With the stmctui'e of the triflate intermediate determined, the and NMR
assiginnents could be made from the *H, COSY and HSQC
experiments, as follows:
1. The quai’tet at 5c 119.86 in the spectium was assigned to C6 because it is the only 
carbon that can have its signal split by the 3 F atoms (spin (the experiment is
decoupled).
2. The signal at Ôc 170.62 in the spectium was assigned to C5 because it is 
deshielded as it is a carhonyl, and it is the only signal that does not couple to any in 
the HSQC, except that already assigned to C6 .
3. The C4 signal was assigned as ôc 49.33 because it is adjacent to N-Tf, which I would 
judge to be more deshielding than the carbonyl adjacent to C l. From this starting 
point, C4 correlates to the triplet, 5h 3.85, in the HSQC, which can, therefore be 
assigned to H-4.
4. H“4 couples to H-3 in the COSY, fr om which H-3 can be assigned as the more 
downfield of the signals at 5h 1.92. H-3 couples in the HSQC to the signal at 5c 23.10, 
which was therefore assigned as C3.
5. H-3 couples in the COSY to the other signal at 5h 1.92, providing the assigmnent of 
H-2. This can then be used to assign C2 as 5c 20.20, fiom it conelation in the HSQC.
6 . H-1 was assigned as 5h 2.60 from its conelation to H-2 in the COSY. H-1 correlates 
to the signal at 5c 34.56, which can therefore be assigned to Cl.
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Table 1 and *^CNMR assignments of l-Trifluorometlianesulfonyl-piperidin-2-one, (30) 
in CDCI3
‘H 13c
Assigned
groups
Sh
(ppm)
Multiplicity
(J/Hz)
Relative
Integial
Sc
(ppm)
Comment
C2, H-2 
C3, H-3
1.92 m 4H 20.20
23.10
The signals for H-2 and 
H-3 overlap in the 'H 
NMR.
C l, H-1 2.60 t
J=6.7
2H 34.56 Cl is deshielded by the 
carbonyl carbon C5 which 
is adjacent to a nitiogen. 
COSY shows H-1 couples 
to right hand side of the 
signal at 5h 1.92.
C4, H-4 3.85 t
J=6
2H 49.33 C4 is deshielded by the 
adjacent nitrogen which is 
adjacent to the triflate 
gi'oup and to the carbonyl 
carbon C5. COSY shows 
H-4 couples to left hand 
side of the signal at 5h 
1.92.
C6 119.86 Signal is a quartet split by 
the 3 F (spin 14).
C5 170.62 Signal is downfield 
because of stiong 
deshielding by the 
adjacent oxygen and 
nitiogen.
(30)
52
ppm
Figure 21 NMR (500MHz) of l-Trifluoromethanesulfonyl-piperidin-2-one, (30) in 
CDCI3
- 1 . 5
- 2 . 0
- 2 . 5
- 3 . 0
- 3 . 5
- 4 . 5
- 5 . 0
- 5 . 5
Figure 22 ^H-^ H COSY (500MHz) of 1 -Trifluoromethanesnlfbnyl-piperidm-2-
one, (30) in CDCI3
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F igure 23 NMR (125MHz) of l-Trifluorometliaiiesulfonyl-piperidin-2-one, (30) 
in CDCI3
pprr
20
4 0
6 0
8 0
- 1 0 0
- 1 2 0
- 1 4 0
ppm
Figure 24 HSQC (500MHz) of l-Trifluoromethanesulfonyl-piperidin-2-one,
(30) in CDCI3
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The Elemental Analysis of (30) for CnHnNn content was consistent with the proposed 
structure (Found: C, 30.5%; H, 3.45%; N, 5.8%. CeHgFsNOsS requires C, 31.2%; H, 
3.5%; N, 6.1%).
(5-Trifluoromethanesulfonvlamino-pentanoic acid t2.2-diethoxv-ethvl)-aniide) (31)
(3) (5) (12)
The more polar- fraction yielded a yellow oil (9.9%), which was identified as the title
compound (31) by ID NMR: 'H. "C  and DEPT-135 '^C; 2D NMR: 'H -‘H (COSY) and 
(HSQC) coiTelation experiments; Mass Spectrometry (El); IR; and Elemental
Analysis.
The and NMR assignments were made from the DEPT-135
COSY and HSQC experiments, as follows:
1. The signal at Ôh 4.49 in the ^H NMR can be used as a starting point because it is the 
only triplet with an integral of IH and it conelates to a carbon in the HSQC, so must 
be H-10. This correlates to ôc 100.35 in the HSQC, which was therefore assigned as 
CIO. This signal is shown to be a CH or CH3 in the DEPT-135, frirther confrnning the 
above assigmnent.
2. H-10 couples to H-9 wliich is found in the COSY to be the triplet at 5h 3.36. This 
allows the assignment of C9 as 5c 41.85 using the HSQC.
3. H-9 can be used to assign NH-8 as the broad singlet (integral IH) at Ôh 5.97 using the 
COSY. This is as far as can be advanced from this starting point.
4. NH-2 can be used as a re-start point and is assigned as the signal at Ôh 7.20 in the ^H 
NMR because it is the only other signal in the spectrimi with an integral of IH and it 
is a broad singlet which is often characteristic of NH signals.
5. The ^H and ^^ C peaks for the C3, C4, C5, and C6 were assigned using the COSY and 
HSQC in the same way as above. (The NH-2 couples to the H-3, which couples to C3 
and the H-4, and so on. The relationships are shown in Figure 25).
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HA ^Ha ^H. .H. aH y coupl i ng revealed in c o s y  are show n in blue
I 11 111 J11 I  ^J '•H-'*3C coupling revealed in HSQC are shown in red
^ 2  a9s ÂÇ4 ^Çs âÇb Both protons on a carbon wiil have the sam e U  ^H-^ ^C ^j |  I 11 1 1 i  I and iH-^H coup iing, assum ing they are magnetically
H H H equ ivalent (as in th is case). coupling show n at top and 
 ^J coup iing show n at bottom s ide o f m o iecule simpiy for 
convienance in this diagram.
Figure 25 Coupling between protons on adjacent 
atoms, and between carbons and then protons
6 . The H-12 methyls aie equivalent and so can be assigned to the triplet at Ôh 1.20 with 
an integral of 6 H. C12 is found at ôc 15.07 from it conelation with H-12 in the HSQC 
and is shown to be a CH or CH3 in the DEPT-135.
7. H-12 conelates to two signals at Ôh 3.53 and 3.69, which are from the 2 non­
equivalent ^Hs on each C ll. The H-11 signals are not equivalent because they are 
diastereotopic (see Scheme 35). The C ll can be found by its correlation on the HSQC 
spectnim with the 2 H-11 signals and is found at ôc 62.83,
H3C. "
H O. ^CHgNHR
H O^^^^^CH^NHR Replace each of the O
I H-2 hydrogens with X /
6 -----------------------------------------------^  ^  i  ^y  X cHgH^ C^ dD H3 C
CH3
Replacement of each of the H-11 6
hydrogens of (31) with X, gives H c md
compounds that are diasteroisomers  ^ \ CH3
Scheme 35 Diagram to show that H-11 hydrogens of (31) are diastereotopic
8 . The CF3 (Cl) could be assigned to ôc 119.74 in the ^^ C because the signal is split into 
a quai*tet by the 3 F atoms (spin 14).
9. C7 was assigned as ôc 173.30 in the ^^ C because it was the only remaining unassigned 
signal and is the most downfield, as would be expected as it is a carbonyl.
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Table 2 and NMR assiginnents of 5-Trifluoromethanesulfonylainino-pentanoic 
acid (2,2-diethoxy-ethyl)-aniide, (31) in CDCI3
^H ^'C
Assigned ÔH Multiplicity Relative ÔC Comment
groups (ppm) (J/Hz) Integral (ppm)
C12, H-12 1.20 t
J=7
6H 15.07
C4, H-4 1.64 m 2H 29.20 —
C5, H-5 1.72 111 2H 21.72 —
C6 , H-6 2.24 t
J=7
2H 35.22
C3,H-3 3.27 111 (maybe d 
oft)
2H 43.50 It looks like the signal has 
been split into a triplet by 
H-4 (CH2), then each line 
into a doublet by the NH.
C9, H-9 3.36 t
J=5.4
2H 41.85
C ll ,  H-11, 
H-11'
3.53,
3.69
111 2 x 2 H 62.83 H-11 signals are not 
equivalent because they 
are diastereotopic.
CIO, H-10 4.49 t
J=5.0
IH 100.35 CIO (and so H-10) is 
deshielded by the 2 
adjacent oxygen atoms.
NH-8 5.97 bs IH NH signals change 
chemical shifts depending 
on sample concentiation.
NH-2 7.20 bs IH NH-2 is more downfield 
than NH-8 because the 
adjacent tiiflate group is 
strongly deshielding.
Cl 119.74 Signal is a quartet split by 
the 3 F (spin */4).
C l 173.30 C7 is downfield because 
of deshielding by adjacent 
oxygen and nitiogen.
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Figure 26 NMR (500MHz) of 5-Trifluoromethanesulfonylamino-pentanoic 
acid (2,2-diethoxy-ethyl)-aiuide, (31) in CDCI3
Figure 27 COSY (500MHz) of 5-Trifluoromethanesulfonylamino-pentanoic
acid (2,2-diethoxy-ethyl)-amide, (31) in CDCI3
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Figure 28 NMR (125MHz) of 5-Trifluoromethanesiilfonylamino-pentanoic 
acid (2,2-dietlioxy-ethyl)-amide, (31) in CDCI3
180 160 140 120 100 80 60 40 20 pp m
Figure 29 DEPT-135 NMR (125MHz) of 5-Tnfluoromethanesulfonylaniino- 
pentanoic acid (2,2-dietlioxy-ethyl)-aniide, (31) in CDCI3
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Figure 30 HSQC (500MHz) of 5-TrifluoroniethanesulfonylaiTiino-
pentanoic acid (2,2-dietlioxy-etliyl)-amide, (31) in CDCI3
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Figure 31 IR of 5-Trifluorometlianesulfoiiylamino-pentanoic acid (2,2-diethoxy- 
ethyl)-amide, (31) neat between KBr discs
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The major absorption frequencies of this compound in the IR (Figuie 31) and their 
assignments were: Vmax (neat)/cm’* 3313 and 3099 (NH stretch of 2® amide), 2887 (C-H 
stretch in ether), 1652 (C=0 stretch of 2° amide), 1541 (NH bend of 2° amide), 1447 (CH2 
scissoring bend), 1375 and 1149 (-SO2NH-), 1230 and 1190 (CF3), 1074 (CF3 and C -0 
stretch in ether).
MS250402G # 2-3  RT; 0.32-0.43
I :  + c [ 59.50-700,50]
AV: 2 NL: 2.68E6
100
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m/z
Figure 32 MS (Cl) of 5-Trifluoromethanesulfonylamino-pentanoic acid (2,2- 
diethoxy-ethyl)-amide, (31)
The major fragments of this compound in the MS (Figiu e 32) and their assiginnents are as 
follows MS (Cl) (m/z): 365 = M* + H, 364 = IvT, 319 = M" -  OEt, 250 = M + -O E t -  
CF3, 231 = M + -T f.
The elemental analysis o f (31) for C„H„N„ content was consistent with the proposed 
structure (Found: C, 39.7%; H, 6 .8%; N, 7.3%. C12H23F3N2O5S requfres C, 39.6%; H, 
6.4%; N, 7.7%,).
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All explanation for the foiination of this product, as opposed to the intended product (29), 
is shown in Scheme 36. It appears that the amine has coupled to the triflate intemiediate 
as expected, but instead of the amino acetal undergoing cyclisation, the C-N  bond in the 
lactam ring has broken. The likely cause of this is that the intennediate has the tiiflate 
group bonded to the nitrogen instead of the oxygen, as supported by the characterisation 
of the intermediate (30).
NH,
EtO (31)(30)
OEt
OTf HNHN
:OEt
NH.
EtO (28)
OEt
OEt
OEt
(29)
Scheme 36 Suggested mechanism for the formation of acyclic amide (31) from 
N-tiiflated intermediate (30), and theoretical foiination of imidazo (29) from 
O-triflated intemiediate (28)
Attempted Synthesis of trifluoro-methanesulfonic acid 3,4,5,6-tetrahydro-pyridin-2- 
yl ester, (28)
It was decided to attempt the imidazole synthesis in two sepai'ate steps. First isolating the 
triflate intemiediate, and then using it in the second step to react with the aminoacetal. 
This could detemiine in which part of the synthesis the N-triflated iniide is formed and 
also allows for a purer final product, with optimisation of each step possible.
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Piperidin-2-one was acylated with triflic anliydride in the presence of pyiidine at -46°C to 
give the N-tiiflated imide (30) as a yellow liquid (64.1%). This product was identified by
H NMR and IR.
As it had not been possible to isolate the desired O-triflated imidate, a series of NMR 
experiments were performed to establish, firstly if  this product is actually foimed (as is 
predicted in theory), and secondly if  it is fomied, what factors influence its conversion to 
the N-triflated derivative.
NMR variable tem perature experiments
Piperidin-2-one was reacted with hiflic anliydiide and the reaction followed at various 
temperatures by NMR and COSY experiments. The spectra show the presence 
of two products formed in different ratios, depending on temperatiu e (Table 3). These 
were assigned as protonated O-triflated lactam (32) and O-protonated piperidin-2-one 
(33) (Scheme 37). hiterestingly, the N-triflated intermediate (30), which has been 
previously foimed in these types of reactions, was not formed.
OTf
NH NH
CDCI
(27) 
Scheme 37
(32) (33)
Table 3 Ratio of compoimds (33) to (32) at vaiious temperatures 
(deteimined by integiation in ^H-NMR spectroscopy, 500 MHz; peak
Temperature/K Relative amount of 32 Relative amount o f 33
213 1 3.6
228 1 3.1
243 1 3.0
298 1 4.2
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The sti'uctiu'e of (33) was confirmed in a separate control experiment, in which triflic acid 
was added to (27) in CDCI3 and the resulting solution, containing protonated derivative 
(33), added to the reaction mixture of tire previous experiment. This compound 
presumably arises fiom tiaces o f moistiue contaminating the reaction mixture during the 
set up of that experiment.
Addition of a base (pyiidine) at various temperatures in the NMR experiment resulted in 
foiination of the N-tiiflated imide (30) as the major product in the spectrum (Scheme 38). 
The proportion of (30), relative to products (32) and (33), increased with temperature to 
gieater than 90% at 298K. Wlien the primary amine, amino acetaldehyde diethylacetal, 
was added instead of pyiidine, this led to foiination of the acyclic product (31), in 
addition to the N-triflated imide (30). Compound (30) could be isolated by column 
clnomatography in an analytically pure form, however, it was not possible to isolate the 
O-triflated imidates (28) or (32). After addition of an amine base, the O-triflated 
derivative (32) could not be used in a synthetically usefiil way imder the conditions 
studied.
OTf
NH NH Pyridine NTfNH
CDCI
(32) (33) (30)(27) 
Scheme 38
This work suggests that the lactam is triflated initially at the oxygen, but this is followed 
by fast triflate migration under basic reaction conditions. Furtheiinore, increasing 
temperature results in a shift of chemical equilibrium towards the N-triflated imide (30), 
reminiscent of the Chapman reaiTangement.^^’
It is interesting if formation of an O-triflated intermediate has been achieved and it has 
remained in solution for a day even at (relatively high) room temperatiu e. If these 
conditions can be replicated in a reaction vessel long enough for reaction to occur with a 
suitable nucleophile, then foimation of the bicyclic heterocyclic (eg. imidazole) product 
may be possible. In other words if the rate constant for nucleophilic attack exceeds the
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rate constant for O to N migration, then it should be possible to synthesise a bicyclic 
heterocycle using this reaction. The nucleopliile that has been used, amino acetaldehyde 
diethylacetal (or amino acetaldehyde dimethylacetal), is basic so may have been 
promoting foiination of the N-triflated intermediate more rapidly than it can react as a 
nucleophile with the O-triflated intemiediate.
Strategies attempted to synthesise heterocycles from piperidin-2-one (27) under mild 
conditions
This reaction was attempted using 2-amino-ethanethiol hydrochloride because it is a 
stronger nucleophile than those previously used. Pyiidine was added slowly after addition 
of the aminotliiol to diive the reaction to completion. This gave a brown/orange oil. 
Analysis of this crude product by and COSY NMR experiments showed a 
19:8:1 mixture of the N-tiiflated imide (30), piperidin-2-one (27), and the acyclic product 
(34).
NHHS ^  
NH Pyridine NTf NH,
DCM
-40“C (34)(27) (30)
Scheme
To hmder the formation of the N-triflated intermediate, 1 -rnethylpiperidin-2-one was used 
as the amide, instead of piperidin-2-one, because the amide nitrogen is protected by a 
methyl group (Scheme 40). 1 -Methylpiperidin-2-one was reacted with amino 
acetaldehyde dimethyl acetal at -46®C, using triflic anhydride as an activating agent and 
pyridirre as a buffer. This reaction did not proceed at all and only starting reagents could 
be recovered.
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DCM
-46°C
HgN
O.
TfgO Pyridine
Scheme 40 Attempted synthesis of 
(2,2-Diniethoxy-ethyl)-(l-methyl-piperidin-2-ylidene)-amine
It was reasoned that the bases used (either pyridine, a primary amine or amino mercaptan) 
may have been favouring formation of the N-triflated imide by acting as a nucleophilic 
catalyst facilitating tiiflate migr ation horn O to N. We decided to attempt reactions using 
l,8-diazabicyclo[5.4.0]imdec-7-erre (DBU) in place of pyridine because it is non- 
nucleophilic. The primary arnirre would still need to be present because the products we 
were interested hr syrrthesisirrg necessitated its use.
A series of reactions were performed irr which piperidirr-2-one (27) was reacted with 
various activating agerrts, followed by the nucleophile, amino acetaldehyde diethyl acetal, 
in the presence of DBU, as set out irr Scheme 41. The results are siunmarised in Table 4.
1. n(DBU)
2. (a) (TfgO or TMSOTf or Tosyl Chloride)
3. H^ N
(DBU)
DCM
Stirred at -42°C for 10 minutes after 
addition of (a), then at -42°C for further 
2 hours after addition of 3rd reagents, 
then at room temperature overnight.
Scheme 41
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Table 4 Results and details of the experiments that are illustrated in Scheme 41 
('^undesired reaction specifies no evidence for the formation of target molecule 
(29))
Experiment (a) Activating 
agent
n equivalents of 
DBU as reagent 1
Result
1 Triflic Anliydiide 
(0.168ml, 0.282g, 
Immol)
0 brown oil (0.299g) —^ 
some compound of type 
(31) and other undesired 
reactions*
2 Triflic Anliydride 
(0.168ml, 0.282g, 
Inunol)
1 clear, yellow/orange oil 
(0.535g) imdesired 
reactions
3 TMS tiiflate 
(0.181ml, 0 .222g, 
Immol)
0 clear pale yellow liquid 
(0.052g) —> undesired 
reactions
4 TMS tiiflate 
(0.181ml, 0 .222g, 
Immol)
1 clear yellow oil (0.1 lOg) 
—> undesired reactions
5 Tosyl chloride 
(0.191g, Immol)
0 red/brown oil (0.273g) 
undesired reactions
6 Tosyl chloride 
(0.191g, Immol)
1 cloudy very pale yellow 
oil (0.355g) —> 
undesired reactions
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Peptidomimetic Synthesis Using Triflic Anhydride Activation of a 
Secondary Amide Followed By Nucleophilic Addition
111 contrast to what had been originally anticipated, on reaction with triflic anliydride, 
triflation occms at the nitrogen of the piperidin-2 -one, instead of the oxygen, leading to 
the opening of the lactam ring on coupling to a nucleophile (Scheme 42).
NHg
(30)EtO
OEt
Scheme 42 Coupling of an amine to a secondaiy amide
This type of reaction can be considered fomially to be an internioleculai* transamidation 
and occms imder extremely mild conditions. A thorough search of the literatine using 
SciFinder Scholar® did not reveal any other examples of this synthetic process. It, 
therefore, seemed interesting to hu tlier investigate the N-triflated imide's (30) reactivity 
towards a nmnber of other nucleophiles.
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Results/Discussion 
One-pot syntheses
S-Trifluoromethanesulfonylamino-pentanoic acid (2,2-diinethoxy-ethyl)-amide, (38)
TfaO o
Pyridine J-L
NH r  NTf
(38)DCM(27) 
Scheme 43
(30)
Piperidin-2-one was reacted with triflic anliydride (1 eq.) in the presence of pyiidine (1 
eq.) at -46°C. The resulting imide (30) was coupled (without prior isolation) with amino 
acetaldehyde dimethyl acetal at -46°C, and a further 1 eq. pyridine added. The crude 
product was piuified by cohmm cluomatography on SiOi to yield two significant 
products. These products were chaiacterised.
The least polar fraction yielded a yellow oil (6.0%). Tliis was identified as 1- 
trifluoromethanesulfonyl-piperidin-2-one (30) by NMR and IR.
The more polai* fraction yielded a colourless oil (34.5%). It was identified as the title 
compound (38) by ID NMR: *H, ‘^C and DEPT-135 "C ; 2D NMR: 'H -'H  (COSY) and 
(HMQC) coiTelation experiments; Mass Spectrometry (Cl); IR; and Elemental 
Analysis. All NMR signals could be assigned unambiguously and are given in the 
experimental.
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5-Trifliiorometliauesiilfoiiylamiiio-peutanetliioic acid S-(2-ammo-etliyl) ester, (34)
TfgO 
NH Pyidine NHHS NHNTf
(34)DCM
(27) 
Scheme 44
(30)
This experiment had been performed as part of the research covered in the previous 
section, but without pyiidine present for the first part of the reaction. The product of 
interest to this research had not been isolated on that occasion because it had been formed 
in too small a quantity,
Piperidin-2-one was reacted with triflic anliydiide (1 eq.) in the presence of pyiidine (1 
eq.) at -40°C. The resulting imide (30) was coupled (without prior isolation) with 2- 
amino-ethanethiol hydiochloride at -40°C, and a further 2 eq. pyiidine added. After work­
up, TLC showed a mixtiue of 6 products. NMR of this crude product showed 3 main 
products. These were pyiidine, the N-tiiflated imide (30) and the title compound (34). The 
crude mixture was purified by coluimi chromatography on S1O2 to yield two significant 
products. These products were characterised.
The least polar of these fractions yielded a yellow liquid (5.0%). This was identified as 1- 
trifluoromethanesulfonyl-piperidin-2-one (30) by NMR and IR.
The more polar haction yielded a pale yellow oil (5.6%). It was identified as the title 
compound (34) by ID NMR: 'H  and "C ; 2D NMR: 'H-'H  (COSY) conelation 
experhnent; and GCMS. All product NMR signals could be assigned imambiguously and 
are given in the experimental. This product was slightly impure, so purification by column 
cliromatogiaphy on alumina was attempted, but it was not stable on aliunina. A review of 
the spectra for the crude product and the product isolated fiom the more polar fraction of 
the coluimi chiomatogi aphy on Si02 , suggest that it was also slightly unstable on silica.
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Two step sequence
Since the yields obtained for the preceding reactions were quite low, it was decided to use 
N-triflated imide (30) that had been isolated, rather than (30) generated ft'om the one pot 
sequence. (30) could be isolated in acceptable purity directly after work-up in 64.1% 
yield, as established as part of the research covered in the first half of the chapter.
A limited optimisation study foimd that (30) could be coupled with amino acetaldehyde 
diethylacetal in the presence of pyiidine (4eq.) at -46°C to give the acyclic amide (31) in 
the vastly improved yield of 89.8% (compared to 9.9% in the one-pot sequence). (31) was 
isolated analytically pure directly after a basic aqueous work-up, without the need for 
further piuification.
5-TrifliioromethanesulfonylaminO“pentanoie acid benzylamide, (39)
NTf
(39)DCM(30)
Scheme 45
The coupling reaction with the N-tiiflated intermediate was further explored. The N- 
triflated inteimediate (30) was coupled with benzylamine at room temperature to give a 
yellow/orange oil (38.0%). It was identified as the title compoimd (39) by ID NMR: ^H, 
and 2D NMR: (COSY) and (HMQC) conelation experiments; Mass
Spectrometry (Cl); and IR. All NMR signals could be assigned unambiguously and are 
given in the experimental.
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5-Trifluoromethanesulfonylamino-pentaiioic acid ethyl ester, (40)
HO ^ 
Na,CO,
(40)DCM(30) 
Scheme 46
The reactivity of the N-tiiflated imide (30) towards an alcohol nucleophile was 
investigated. The triflate intermediate was coupled with ethanol at room temperature 
using sodium carbonate to neutialise any triflic acid formed. This gave the expected 
product (40) in good yield as a yellow/brown oil (76.9%). This was characterised by ID 
NMR: 'H, "C  and DEPT-135 "C ; 2D NMR: 'H -'H  (COSY) and 'H-'^C (HSQC) 
conelation experiments; Mass Spectiometiy (Cl); IR; and Elemental Analysis. All NMR 
signals could be assigned unambiguously and are given in the experimental.
(*S)“2-(5-TrifluoroinethanesuIfonylamiiio-peiitaiioylamiiio)-propioiiic acid tert-hxdyX 
ester, (41)
H,N
NTf
(41)(30)
Scheme 47
It seemed interesting to react the N-triflated imide (30) with C-protected amino acids in 
order to synthèse a range of dipeptides, composed of an co- and an a-amino acid. (30) was 
coupled with Z-alanine t-butyl ester hydrochloride (leq.) at -40”C, using pyridine (leq.) 
as a buffer. After work-up, TLC showed a mixtiue of 4 products. NMR of this crude 
product showed 2 main products. These were (30) and the title compoimd (41). The crude
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mixture was pmifîed by column cliromatogi'aphy on S1O2 to yield two significant 
products. These products were characterised.
The least polar of these fractions yielded a yellow oil (12.6%). This was identified as 1- 
trifluoromethanesulfonyl-piperidin-2-one (30) by ‘H NMR and IR.
The more polar haction yielded a clear, colourless oil (71.7%). It was identified as the 
title compound (41) by ID NMR: 'H  and "C ; 2D NMR: 'H-'H  (COSY) and 'H -"C  
(HMQC) correlation experiments; Mass Spectrometry (Cl); IR; Elemental Analysis; and 
Polarimetiy. All NMR signals could be assigned unambiguously and are given in the 
experimental.
(iS)-2-(5-Trifluoromethaiiesulfoiiylamiiio-pentaiioylamiiio)-pentanedioic acid 
dimethyl ester, (42)
•jITf pyridine
(15)
DCM (42)(30)
Scheme 48
(30) was coupled with Z-glutamic acid dhnethyl ester hydrochloride (leq.) at -40°C, using 
pyiidine (leq.) as a buffer. After work-up, TLC showed a mixtuie of 4 products. The 
cmde mixture was puiified by cohmm cliromatography on Si02  to yield two significant 
products. These products were characterised.
The least polar of these fractions yielded a yellow/orange oil (20.4%). This was identified 
as l-trifluoromethanesulfonyl-piperidin-2-one (30) by NMR and IR.
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The more polai* fraction yielded a clear, colomiess oil (42.2%). It was identifred as the 
title compound (42) by ID NMR: ‘H and "C; 2D NMR: 'H -'H  (COSY) and 'H-'^C 
(HMQC) correlation experiments; Mass Spectrometry (Cl); IR; Elemental Analysis; and 
Polarimetry.
As a representative example of the dipeptides, the spectioscopic assignments for (42) are 
discussed in detail below. The ^H and ^^ C NMR assigmnents were made from the ^H, '^C, 
^H-^H COSY and ^H-^^C HMQC experiments, as follows:
1. The two most downfield signals in the ^H NMR (except for that of residual CHCI3 
from the CDCI3), are a broad singlet at 5h 6.72 and a doublet at Ôh 6.55. Both have 
integrals of IH and do not coiTelate to any '^C signal in the HMQC, so can be 
attiibuted to the two NH ^Hs, NH-2 and NH-8 . The more downfield signal was 
assigned as NH-2 because it couples in the COSY to the triplet at Ôh 3.30 with an 
integial of 2H, whereas the signal at ôh 6.55 couples to the multiplet at ôh 4.59, which 
has an integral of IH. Also I would judge the adjacent triflate group on NH-2 to be 
more deshielding than NH-8 ’s adjacent carbonyl group.
2. NH-2 couples in the COSY to the triplet at ôh 3.30 with an integial o f 2H (as 
mentioned above), which can be assigned at H-3. This conelates to the signal at 5c 
43.80 in the HMQC, which can be assigned as C3.
3. H-3 couples in the COSY to the multiplet at ôh 1.65 with an integial o f 2H, which was 
assigned as H-4. The signals for C4, H-5, C5, H-6 and C6 were assigned using the 
COSY and HMQC in the same manner as above and using the same principles as in 
Figure 25.
4. The doublet at 5h 6.55 in the ^H NMR, assigned to NH-8, can be used as a re-start 
point. Tliis signal conelates to the multiplet at Ôh 4.59 in the COSY. This multiplet 
has an integral of IH and can be assigned as H-9. H-9 can be used to assign the signal 
at 6c 52.02 as C9 from its correlation in the HMQC.
5. H-9 couples to the diastereotopic H-10 ^Hs which were found to be the multiplets, 
each with an integral of IH, at 6h 2.02 and 6h 2.19 using the COSY. The H-10 signals 
conelate to the signal at 6c 27.04 in the HMQC, which was therefore assigned as CIO.
6 . The H-10 signals correlate to the multiplet at 6h 2.41 in the COSY, which has an 
integral of IH and so was assigned as H-11. H-11 couples to C l 1 which can be 
assigned as the signal at 6c 30.28 using the HMQC.
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7. The two singlets, each with an integral of 3H, at Ôh 3.69 and Ôh 3.76 do not couple to 
any other signal in the COSY and were assigned as the methyls, H-13 and H-15. It 
was not possible to distinguish between these methyls using the experiments 
performed.
8 . The CF3 (C l) could be assigned to 6c 120.04 in the ^^ C because the signal is split into 
a quai'tet by the 3 F atoms (spin %).
9. The signals at 6c 172.65, 6c 173.40 and 6c 173.81 in the ^^ C were assigned to the 
tluee caibonyls: C7, C12 and C l4. It was not possible to distinguish between these 
carbonyls using the experiments perfomied.
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Table 5 and NMR assignments of (6)-2-(5-Trifluorometlianesulfonylamino- 
pentanoylamiiio)-pentanedioic acid dimethyl ester, (42) in CDCI3
'H ^'C
Assigned
groups
ÔH
(ppm)
Multiplicity
(J/Hz)
Relative
Integral
ÔC
(ppm)
Comment
C4, H-4 1.65 m 2H 29.32 —
C5, H-5 1.75 m 2H 21.82 —
CIO, H-10, 
H-10’
2 .02 ,
2.19
m 2 x  IH 27.04 The 2 ‘ n  on CIO are not 
equivalent so produce 
separate signals in 
NMR and both interact 
individually with H-11.
C6 , H-6 2.31 t
J=6.9
2H 35.22
C11,H-11 2.41 m 2H 30.28 —
C3, H-3 3.30 t
J=6.4
2H 43.80
C13, C15, 3.69, s 3H 52.19, These methyls can not be
H-13,H-15 3.76 s 3H 52.83 differentiated from the 
experiments performed.
C9, H-9 4.59 m IH 52.02 —
NH-8 6.55 d
1=7.6
IH
NH-2 6.72 bs IH Does not correlate to H-3 
signal in COSY.
Cl 120.04 Signal is a quartet split by 
the 3 F (spin !4).
C7, C12, 
C14
172.65,
173.40,
173.81
These carbonyls can not 
be differentiated from the 
experiments perfonned.
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Figure 33 NMR (500MHz) of (jS)-2-(5“Trifluoromethanesulfonylamino- 
pentanoylaiîiino)-pentaiiedioic acid dimethyl ester, (42) in CDCI3
ppm
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p p m
Figure 34 COSY (500MHz) of (iS)-2-(5-TrifIuorometlianesiilfonylamino-
pentanoylamino)-pentanedioic acid dimethyl ester, (42) in CDCI3
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F igure 35 NMR (125MHz) of (i5Ç)-2-(5--TrifluoromethanesulfonylammO" 
pentanoylamino)-pentanedioic acid dimethyl ester, (42) in CDCI3
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Figure 36 HMQCNMR(500MHz) of (5)-2-(5-
Trifluoromethanesulfonylamino-pentanoylamino)-pentanedioic acid dimethyl ester, 
(42) in CDCI3
78
87.5 >
80-
70-
50-
% T
40-
30-
2 0 -
10 -6.5-1-----
4000.0 3000 2000 1500 1000 500.0
cra-1
Figure 37 IR of (5)-2-(5-Trifluoromethaiiesiilfonylamino-pentaiioylamino)- 
pentanedioic acid dimethyl ester, (42) neat between KBr discs
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Figure 38 MS (Cl) of (jS)-2-(5-TrifliioromethanesulfonyIamino-pentanoyIamino)- 
pentanedioic acid dimethyl ester, (42)
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The major absorption frequencies of this compound in the IR (Figure 37) and their 
assignments were: Vmax (neat)/cm'^ 3278 and 3089 (NH stretch of 2° amide), 2957 (CH2 
asynnnetric stretch), 2868 (CH2 symmetiic stretch), 1741 (C=0 stretch of ester), 1653 
(C=0 stretch of 2° amide), 1538 (NH bend of acyclic 2° amide), 1440 (CH2 scissoring 
bend), 1374 and 1150 (-SO2NH-), 1230, 1188 and 1080 (CF3).
The major h agments of this compound in the MS (Figure 38) and their assigmnents are as 
follows MS (Cl) (iWz): 408 (M+ + 2H), 407 (M+ + H), 375 (M* -  OMe).
The elemental analysis of (42) for CnHuNn content was consistent with the proposed 
structure (Found C, 38.7%; H, 5.45%; N, 6.4%. C13H21F3N2O7S requires C, 38.4%; H, 
5.2%; N, 6.9%).
(iS)-l-(5-Trifluoromethanesulfonylammo-pentanoyl)-pyrrolidine-2-carboxylic acid 
benzyl ester, (43)
NTf Pyridine (43)
DCM(30) NH
i - S r °
Scheme 49
(30) was coupled with 7,-proline benzyl ester hydrochloride at -40°C, using pyridine as a 
buffer. The crude product was purified by cohmm chromatography on SiOi to yield a 
clear, colomiess oil, which was crystallised horn DCM, then washed with hexane to give 
a fine white powder (54.0%). It was identified as the title compound (43) by ID NMR: ^H 
and "C ; 2D NMR: 'H-'H  (COSY) and 'H-'^C (HMQC) conelation experiments; Mass 
Spectrometry (Cl); Accurate Mass Spectrometi y (Cl) of parent ion; IR; and Polarimetry.
80
At room temperature two sets of signals can be observed in a ratio of 4:1 in the NMR 
spectra, which we assign to the two rotamers of the proline amide (43). The product can 
exist as two rotamers around the amide bond, so a variable temperature experiment of a 
sample was performed in d^-DMSO (variable temperature spectra are shown in Figures 39 
and 40 including assignments of signals). At higher temperatures, the two sets of signals 
coalesce into one set of signals indicating rapid rotation on the NMR time scale around 
the C-N bond. On cooling the signals separate out, demonstrating the reversibility of the 
process. Similar rotamers have been observed with other proline derived amides.*®’ *^
It is worth noting that addition of chiral shift reagents and CD spectra of (43) indicate that 
no racémisation has occurred, as can be expected when using a relatively weak base (such 
as pyridine). All NMR signals could be assigned unambiguously and are given in the 
experimental section.
Ph
(12 )
H-14
(43)
H-12
NH-2
448 K
423 K
373 K
HNj
298 K
7 .0
Figure 39 Expanded variable temperature NMR of compound (43) in d®-DMSO
(4-lOppm)
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DMSO
H-4 + H-5
Æ oJ O
•JW 
NH
p‘5 : °
(43)
(10)
I t  V JL
----------------- ' 298 K
(9)
O
HN^ (3)
F^F
Figure 40 Expanded variable temperature NMR of compound (43) in d^-DMSO
(0-4ppm)
(5)-3-Phenyl-2-(5-trifluoromethanesulfonylamino-pentanoylamino)-l-propioiiic acid 
methyl ester, (44)
Pyridine
^ 5DCM(30) (44)
Scheme 50
(30) was coupled with Z-phenylalanine methyl ester hydrochloride (l.leq .) at -42°C, 
using pyridine (leq.) as a buffer. After work-up and drying, the title compound (44) was 
isolated in good purity and excellent yield as a yellow oil (98.6%). This product was 
characterised by ID NMR: 'H and ”C ; 2D NMR: 'H-'H (COSY) and 'H-'^C (HSQC) 
correlation experiments; LC-MS (ESI); Mass Spectrometry (Cl); Accurate Mass
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spectrometiy (CI) of parent ion; IR; Elemental Analysis; and Polarimetiy. The liquid 
clnomatogiaphy of the LC-MS gave the purity of this compoimd as 100%. All NMR 
signals could be assigned unambiguously and are given in the experimental.
(S) 4-Methyl-2-(5-trifluoromethanesulfoiiyIammo-pentauoylammo)-l-pentanoic acid 
methyl ester, (45)
NTf pyridine
DCM (45)(30)
Scheme 51
(30) was coupled with L-leucine methyl ester hydrochloride (l.leq .) at -42°C, using 
pyridine (leq.) as a buffer. After work-up and diying, the title compound (45) was 
isolated in good purity and excellent yield as a yellow oil (91.6%). This product was 
characterised by ID  NMR: ‘H and ; 2D NMR; 'H -'H  (COSY) and ‘H-'^C (HMQC) 
coiTelation experiments; LC-MS (ESI); Mass Spectrometry (Cl); Accinate Mass 
Spectrometry (Cl) of parent ion; IR; and Polarimetry. The liquid clu omatogi aphy of the 
LC-MS gave the purity of this compound as 100%. All NMR signals could be assigned 
unambiguously and are given in the experimental.
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(iS) 3--Methyl-2-(5-trifliioromethanesiilfonylamiiio-peiitanoylamino)-l-butyric acid
methyl ester, (46)
H,N
DCM (46)(30)
Scheme 52
(30) was coupled witliZ-valine methyl ester hydiochloride (l.leq .) at -42°C, using 
pyiidine (leq.) as a buffer. After work-up and drying, the title compoimd (46) was 
isolated in good piuity and excellent yield as a yellow oil (77.9%). This product was 
chaiacterised by ID NMR: ‘H aiid "C ; 2D NMR: 'H-'H (COSY) aiid 'H-"C (HMQC) 
correlation experiments; LC-MS (ESI); Mass Spectrometry (Cl); Accmate Mass 
Specti'ometry (Cl) of parent ion; IR; and Polaimietry. The liquid clu omatography of the 
LC-MS gave the puiity of this compound as 100%. All NMR signals could be assigned 
unambiguously and are given in the experimental.
5-TrifluoromethanesuIfoiiylammo-peiitanoic acid ((»S)-l-hydroxymethyI“3-methyI- 
butyl)-amide, (47)
OH
NTf pyridine OH
DCM(30) (47)
Scheme 53
To determine whether an amine or an alcohol acts preferentially as the nucleophile in 
reacting with the N-triflated species (30), (30) was coupled with Z-leucinol (leq.) at
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-42°C, using pyridine (leq.) as a buffer. After a basic aqueous work-up, this yielded a 
clear very pale yellow liquid (49.7%). It was identified as the title compoimd (47) by ID 
NMR: 'H  and "C ; 2D NMR: ‘H-'H  (COSY) and (HMQC) coiTelation
experiments; Mass Spectrometiy (Cl); Accurate Mass Spectrometry (Cl) of parent ion; 
IR; and Polarimetiy. All ISIMR signals could be assigned imambiguously and are given in 
the experimental.
It was expected, in tliis type of reaction, that the N-triflated imide would react 
preferentially with the more nucleophilic amine group than with the less nucleopliilic 
alcohol group, hi this reaction the N-triflated imide reacted exclusively with the amine 
fimctionality, with no other products detected after the work-up.
This reaction was repeated using the same procedure, but with 1.1 equivalents of L- 
leucinol to see the effect on the yield and if any by-products would be foimed. This 
resulted in an improved yield of 54.6% compared to 49.7% using 1 equivalent of the 
amino alcohol. The product was again foimed pine after basic work-up and drying under 
high vacuum.
5-TrifluorometUanesulfonylamiiio-peiitanoic acid ((*S)-l-beiizyl-2-liydroxy-ethyl)- 
amide, (48)
OH
NTf Pyridine OH
DCM(30) (48)
(49)Scheme 54
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(30) was coupled with Z-phenylalaninol (leq.) at -42°C, using pyridine (leq.) as a buffer. 
After a basic aqueous work-up, TLC showed a mixture of 2 products. The crude mixture 
was purified by preparative TLC on SiOz to give 2 bands of products. These products 
were characterised.
The least polar of these products was isolated as a clear, colomiess oil (21.2%). It was 
identified as the title compound (48) by ID NMR: and ^^C; 2D NMR: (COSY)
and (HMQC) correlation experiments; Mass Spectrometry (Cl); Accurate Mass
Specti'ometi y (Cl) of parent ion; IR; and Polarimetry. All NMR signals could be assigned 
unambiguously and are given in the experimental.
The more polar of these products was isolated as a clear, colourless oil (6.4%). It was 
identified as 5-Trifluoromethanesulfonylamino-pentanoic acid (6)-3-phenyl-2-(5- 
trifluoromethanesulfonylamino-l-pentanoylamino)-propyl ester, (49), by ID NMR: 
and ^^C; 2D NMR: ^H-^H (COSY) and ^H-^^C (HMQC) correlation experiments; Mass 
Spectrometry (Cl); Accurate Mass Spectrometiy (Cl) of parent ion; and IR. All NMR 
signals could be assigned imambiguously and are given in the experimental.
This minor product was imexpected considering the result Rom the synthesis of (47). It 
appears that in this case, though the N-ti'iflated imide reacts preferentially with the more 
nucleophilic amine fimctionality, the less nucleophilic alcohol functionality can also act 
as a nucleophile in the reaction.
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Summary of Results
-  It has not been possible to synthesise a beterocycle as originally planned, by reaction 
of a cyclic secondary amide with an appropriate nucleophile, using tiiflic anliydride as 
an activating agent. The reaction should take place via an O-triflated intermediate.
-  The main reaction talcing place has been to couple the nucleophile to the secondary 
amide, via an N-triflated intermediate, resulting in the opening of the lactam ring to 
form an acyclic compound (Scheme 55). This process of triflate gioup migi ation is 
base catalysed and is also favoured by higher temperatuies.
TfgO
NH Base
DCM
Base
DCM
Only the N-triflated intermediate is left 
after the 1st stage of the reaction. This 
is either produced directly, or more 
likely via the O-triflated intermediate 
(28), with fast migration of the triflate 
group to the nitrogen.
A NTf NuH
O H Nu
(30)
Scheme 55 Activation of piperidine-2-one with tiiflic anliydiide, followed by 
reaction with a nucleophile.
The N-triflated imide can be used as a highly reactive carbonyl derivative and has 
been coupled to various nucleophiles, including C-terniinal protected amino acids.
These reactions are perfonned under extremely mild conditions and products can be 
foimed in good to excellent yield (Table 6).
This reaction represents a formal transamidation (in some cases tianspeptidation) and 
proceeds (to oui" laiowledge) under the mildest conditions Imown for such a 
transformation.
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-  The novel compoimds obtained using this reaction are dipeptides with an umiatural co­
amino acid.
Table 6 Yields of compounds synthesised
Compound Yield/% Method'*' Compound Yield/% Method*
30 51.2 N.A. 42 42.2 B
31 9.9 A 43 54.0 B
34 5.6 A 44 98.6 B
38 34.5 A 45 91.6 B
31 89.8 B 46 77.9 B
39 38.0 B 47 54.6 B
40 76.9 B 48 21.2 B
41 71.7 B 49 6.4 B
'’'Method A uses a one pot synthesis starting from (27) without isolation and puiifrcation 
of (30); method B starts from isolated (30).
Synthesis of Oxadiazole-Based Peptidomimetics
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Background
Peptidomimetics containing 1,2,4- and 1,3,4-oxadiazoles have been shown by Lutliman et 
al., to be effective Phe-Gly mimetics when incorporated into compounds based on 
dermorphin (see section entitled “Heterocycle based peptidomimetics,” page 30 of this 
thesis).' '^^’ The authors synthesised the oxadiazole-based dipeptide mimetics 
individually. These compounds could then be used as building blocks for soHd phase 
peptide synthesis of peptidomimetics using the Boc-chemistry shategy.
The yields obtained for the published syntheses of the 1,3,4-oxadiazole-based derivatives 
were, however, quite modest (Table 7),^  ^which prompted om" reseai'ch into an alternative 
synthetic route to 1,3,4-oxadiazole-based dipeptide mimetics.
Table 7 Yields and enantiomeric excesses of 1,3,4-oxadiazole based dipeptides 
published by Luthman et al.^^
Boc-protected amino acid 
(50)
Oxadiazole Yield 
(starting from Boc-amino acid)
ee%
Boc-Phe-OH 30 >95
Boc-Gly-OH 17 N.A.
Boc-Ala-OH 17 >95
Boc-Cys(Bn)-OH 6 Not determined
Boc-Ser(Bn)-OH 20 Not determined
Boc-Pro-OH 6 >95
The oxadiazole derivatives were synthesised from their corresponding Boc-protected 
amino acids as set out in Scheme 56. The moderate yields obtained could be attributed to 
the harsh dehydrating conditions employed. Thionyl chloride is not compatible with all 
functional groups, and the liberation of HCl, (even with the presence of pyridine as a 
scavenger), may result in some Boc de-protection.
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O H 
(50)
DCC
DMAP
R
EtOH/EtgO
NHgNHg- HgO
EtOH
rt (51)
ClCOCOOEt
EtaN
THF
rt
1 ,
R O
SOCI2 
Toluene Pyridine
H N N qoq
(53)
R = various amino acid side-chains
(52)
Scheme 56 Method used by Lutlmian et al. for the synthesis of 1,3,4-oxadiazole-based 
dipeptide mimetics.^^
There are various approaches to synthesising 1,3,4-oxadiazoles in the literatme. One of 
the most coimnonly used is to effect the cyclisation of diacylhydrazides using a 
dehydrating agent, as in the synthesis shown in Scheme 56. Coimnonly used reagents, like 
SOCh,^^ POClg^^ or sulphmic acid,^ "^  are harsh and so have compatibility problems with 
the amino acids/peptides to be used.
Clemens et al. have reported an interesting mild solid phase approach to producing this 
transfomiation, employing the coupling reagent, diisopropylcarbodiimide in DMF. They 
obtained the 1,3,4-oxadiazole analogues in good yields and pmities from a range of
subsfrates 85
A particularly promising mild liquid phase method was reported by Brain et al., which 
uses Burgess reagent in refluxing THF or polymer-supported Burgess reagent imder 
microwave conditions. The reported yields when employing the latter method are 
impressive (70 -  99% on a range of substrates), but aie not given for the more 
conventional liquid phase route.
It was preferred to attempt the cyclisation using the liquid phase route with Burgess 
reagent, as it seemed accessible to a wider range of reseaidiers who may not have access
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to solid phase materials. Also for simplicity, it was decided to first attempt the cyclisation 
using conventional heating, rather than under microwave conditions.
Retrosynthesis hom  the 1,3,4-oxadiazole derivative, therefore, gives the diacylhydiazide
(52) (Scheme 57), as in the synthesis reported by the Lutliman g ro u p .I t  seemed more 
pmdent in the next step, however, to disconnect to the Boc-amino acid (50) + ethyl oxalyl 
hydrazide (54) because the Boc amino acid is the site of variation in the syntheses. The 
ethyl oxalyl chloride could be made in laige batches, then coupled to various Boc-amino 
acids using parallel synthesis.
O R 0 R .. O
n- n o - - \  Ô "  6
(53) (52)
\ IV
O R  H U
OH + HjN" ' A ' C '
H M O
(50) (54)
Scheme 57 Retrosynthetic analysis of 1,3,4-oxadiazole derivatives
Compounds (50) and (54) can be coupled using standard peptide coupling protocols, hi 
om- case we used PyBOP® as the condensation reagent in the presence o f DIPEA (Scheme 
58). PyBOP® was chosen due to its availability in our laboratory, as well as, om previous 
experience in its use for peptide synthesis. DIPEA was chosen as the base because it is a 
liindered tertiary base so does not cause racémisation of amino acids, wliich can be a 
problem when they are exposed to some bases (due to épimérisation at the a-carbon). 
Cyclisation of the diacylhydi azide (52) can be achieved using Burgess reagent in THF 
under reflux conditions (Scheme 58).^^
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DIPEA
O R HgN'
O
O(50)
G
O (54)
DMF
THF
reflux
O 
(52)
\  -oo
N - S - N  II O
(Burgess reagent)
O R
o
(53)
.0
o-
Scheme 58 Planned synthesis of 1,3,4-oxadiazole derivatives starting from 
various Boc-protected amino acids, (50)
The ethyl oxalyl hydrazide (54) can be synthesised by a two step reaction starting hom 
commercially available compounds (Scheme 59). Acylation of ^ ^r/-butyl carbazate (55) 
with ethyl oxalyl chloride in the presence of triethylamine yields Boc-ethyl oxalyl 
hydrazide (56), which can be de-protected with 5/6M hydr ochloric acid to give the 
hydrochloride salt of (54). This HCl salt could then be used directly in the next reaction, 
(Scheme 58), with an extr a equivalent of DIPEA.
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Results/Discussion
Hydrazino ethyloxalate hydrochloride, (57)
1. NEt.
2. Cl
NH.
o  (56)
5/6M HCl In 
propan-2 -ol
DOM
(55)
HCl H,N
(57)Scheme 59
tert-BwXy\ carbazate was acylated with ethyl oxalyl chloride (L2eq.) in the presence of 
triethylamine (2eq.), with the reaction flask cooled in an ice-water bath. After an acidic 
aqueous, then basic aqueous workup, the product was dried luider liigh vacuum with an 
oil pump. The Boc gi’oiip was removed by reaction with 5 to 6M hydrochloric acid in 
propan-2-ol to give a pale yellow powder. Washmg with diethyl ether on a sintered fumiel 
and drying at 40°C with an oil pmnp, gave a white powder (59.5%). It was identified as 
the title compound (57) by ID NMR: ‘H; 2D NMR: 'H-'H  (COSY) and 'H -"C  (HMQC) 
conelation experiments; Mass Spectrometry (Cl); and IR. All NMR signals could be 
assigned imambiguously and are given in the experimental.
The product was only sparingly soluble in d-chlorofoim, so the NMR experiments were 
performed in d-methanol. Exchange between the product’s ethyl group and the methyl 
group of methanol was obseiwed to occur when the product was left to stand in solution 
for just 30 minutes.
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(25) (N'“Ethyloxyoxalyl)-2-(N“to*^-butyloxycarbonyl)pyrrolidine-2-acetic acid 
hydrazide, (59)
PyBOP®
DIPEA
OH
(57)
DMF
(59)(58)
Scheme 60
Boc-Pro-OH was coupled to hydi'azino ethyloxalate hydi'ochloride (57) (1.2eq.) using 
PyBOP® (1.1 eq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then 
basic aqueous work-up, TLC showed a mixture of 3 products. The crude product was 
piuified using “CombiFlash®” colimni chromatography,^^ to give a clear, coloiuless oil 
(14.0%). It was identified as the title compound (59) by ID NMR: ^H, and DEPT-135 
2D NMR: ^H-^H (COSY) and (HMQC) correlation experiments; Mass
Spectrometiy (Cl and ESI); Accurate Mass Spectrometry (Cl) of two main fragments; and 
IR. All NMR signals could be assigned imambiguously and are given in the experimental.
The parent ion could not be obseiwed in the MS under Cl conditions, but M"^  + Na could 
be observed under ESI conditions using a different mass spectiometer. The two main 
h agments obseived in the Cl at m/z 230 and m/z 274 are caused respectively by the loss 
of a rer^-butyl group, or the loss of the entire Boc group.
This compound had been synthesised by the Lutliman group, but it had not been purified 
and the yield had not been published.^^ The yield of the Proline-based oxadiazole ûom 
Boc-Pro-OH was reported as 6%, but it is not clear what stage in the synthesis caused the 
low yield.
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(2iS) (N’-Ethyloxyoxalyl)-2-(ter/-butyloxycarbonyl)ainino-3-plienylpropaiioic acid 
hydrazide, (61)
PyBOP®
DIPEA
OH (57)
DMF(60)
Scheme 61 (61)
The yield of the reaction using Boc-Pro-OH (58) was disappointing, so the reaction was 
attempted using Boc-Phe-OH (60) because the reagent (60) and the product (61) would 
both have good cluomophores maldng monitoring of the reaction by TLC more 
straightforward. The synthesis of the hydr azide (61) and its oxadiazole product had been
published. 82
Boc-Phe-OH was coupled to hydr azino ethyloxalate hydrochloride (57) (1.1 eq.) using 
PyBOP® (leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, therr 
basic aqueous work-up, TLC showed a rnixtrue of 3 products. The crirde product was 
purified using colunm chromatography on SiOz to yield a pale white wax (18.6%). It was 
identified as the title compoimd (61) by ID NMR; ^H arrd *^ C; 2D NMR: ^H-^H (COSY) 
arrd ^H-^^C (HMQC) correlation experhnerrts; Mass Spectr*ometry (Cl); Accurate Mass 
Spectrometry (Cl) of parent ion; and IR. All NMR signals could be assigned 
unambiguously and are given in the experimental.
The yield of (61) was very disappoirrting (18.6%), as the published yield of this product
was 49.5%. 82
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Hydrazino ethyloxalate, (54)
1.N E t
2. Cl
NH
DCM (56)(55)
20% TFA in 
DCM1. SCX-2 column 
in CH3CN
2. 2M TEA 
in CH-CN
(54) (62)
Scheme 62
It was decided to use the free hydrazino ethyloxalate (54), as perhaps the HCl was 
interfering with the synthesis of the amino acid-hydrazides. (It is Imown that it is usually 
preferable not to use TFA salts directly in peptide coupling reactions, but we are not 
aware o f any previous cases where using the HCl salt created problems in a synthesis).
We chose to de-protect the Boc group this time with tiifluoroacetic acid (TFA) rather than 
HCl because of previous successfril experience using TFA de-protection in peptide 
synthesis. By liberating the TFA using an Isolute® SCX-2 column (see Scheme 63),^^ it 
was also possible to remove any (N'-Ethoxyoxalyl-hydrazino)-oxo-acetic acid ethyl ester 
(63) (Figure 41) (observed as a second peak in the LCMS of (56)), which could have 
formed by reaction of hydrazine (present as a small impm ity in tert-hwtyX caibazate) with 
ethyl oxalyl chloride.
Figure 41 hnpurity present in crude product (62) (Scheme 62)
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1. s e x  can separate a reaction mixture 
containing compounds with basic 
components and compounds without 
basic components.
SCX-2
' <
\  1 WS l - O - S i - (C H ,)fSq 1 0
S i-O H/
R'"
CH3CN (or MeOH)
\
q  I  0  R '  | ^ „ R
2 .
2 X  CH3CN 
(or MeOH)
R"
S i-O H
R"
R" 3 -
T E A /C H 3C N
(or NH3 / MeOH)
3. Compound with basic group can R V -  ^R
now be removed from column by N
treatment with a sufficiently strong r " 
base.
2. Sulphonic acid groups on SOX 
form ion pair with lone pair of 
nitrogen containing compound 
so it stays on the column. 
Other organic compounds 
without basic functional groups 
are removed by washing with 
CH3CN or MeOH.
Scheme 63 Brief explanation as to the use of SCX-2 columns to separate a mixtuie of 
basic and non-basic compounds
ter^Butyl carbazate was acylated with ethyl oxalyl chloride (1.2eq.) in the presence of 
triethylamine (2eq.), with the reaction flask cooled in an ice-water bath. After an acidic 
aqueous, then basic aqueous workup, the evaporation of the solvent yielded a yellow oil. 
The Boc gi'oup was de-protected by reaction with 20% TFA in DCM, then evaporation of 
the solvent, to give the TFA salt as a white solid. This product was dissolved in 
acetonitrile, then purified and the TFA removed by passing the solution tlirough an 
Isolute® SCX-2 coluimi. The fi'ee hydrazino ethyloxalate (54), was liberated from the 
column by treatment with 2M triethylamine in acetonitrile. Evaporation of the solvent 
yielded a yellow oil (88.0%). It was identified as the title compound (54) by ID NMR:
'H; 2D NMR: 'H -‘H (COSY) conelation experiments; and LC-MS (ESI). All NMR 
signals could be assigned unambiguously and are given in the experimental.
The puiity was measured to be 91.7% by the liquid chiomatography on the LC-MS. This 
seemed sufficiently pure to continue with the next stage of the synthesis. Column 
cliromatography would be necessary anyway for pmification of the amino acid hydrazides 
of type (52), to remove the PyBOP® and its derivatives.
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( 2 aS )  (N’“Ethyloxyoxalyl)-2-(^er^-butyloxycarbonyl)amino-3-phenylpropanoic acid 
hydrazide, (61)
PyBOP®
DIPEA
OH (54)
DMF(60)
Scheme 64 (61)
Boc-Phe-OH was coupled to hydrazino ethyloxalate (54) (l.leq .) using PyBOP® (leq.) in 
the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic aqueous work­
up, TLC showed a mixtiue of 3 products. The cmde product was purified using column 
cln omatography on SiOito yield a wliite solid (61.1%). It was identified as the title
compound (61) by ID NMR: ‘H and "C ; 2D NMR: 'H-'H  (COSY) and (HMQC)
conelation experiments; Mass Spectrometry (Cl); Accurate Mass Spectrometry (Cl) of 
paient ion; and IR. All NMR signals could be assigned unambiguously and are given in 
the experimental.
The yield was gi'eatly improved compared with tlie reaction using the hydrazino 
ethyloxalate as an HCl salt (57) (61,1% compared 18.6%), which therefore suggests that 
the HCl was in fact interfering in some way with the reaction. It was decided to perfomi 
fiuther reactions using the fi'ee fonn of the hydi azide (54) and this effect presumably 
caused by the HCl, was not further investigated because of time constraints.
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Ethyl-5-[(5)-l-[(terr-butyloxycarboïiyl)ammo]-2-phenylethyl]-l,3,4-oxadiazole-2‘
carboxylate, (64)
Burgess
reagent
THF
reflux N—N
(61) (64)
Scheme 65
Dehydi'ation of the diacylliydrazide (61) was achieved by reaction with Burgess reagent in 
refluxing anliydrous THF. The reaction was monitored by FIA and several additional 
equivalents of Bui'gess reagent needed to be added to drive the reaction to completion 
(7.2eq. Burgess reagent used in total). The solvent was evaporated to give a yellow oil. 
This was re-dissolved in DCM and after aqueous work-up the solvent was evaporated to 
give a yellow/red oil. TLC showed a mixtuie of 3 products. The cmde product was 
purified using “CombiFlash®” column cliromatography, to give white crystals (64.4%). It 
was identified as the title compound (64) by ID NMR: ^H, ^^ C and DEPT-135 ^^ C; 2D 
NMR: ^H-^H (COSY), (HSQC) and multiple bond ^H-^^C (HMBC) çoirelation
experiments; LC-MS (ESI); Accmate Mass Spectrometry (Cl) of paient ion; and IR. The 
liquid chromatography of the LC-MS gave the purity of this compoimd as 100%. All 
NMR signals could be assigned imambiguously and are given in the experimental.
The yield of the oxadiazole (64) from Boc-Phe-OH was 39.3%, which is only a slight 
improvement on the published yield of 30%.^^ The disappointing yield of the reaction can 
be attributed to contamination by atmospheric moistiue as it was performed open to the 
air. This also accounts for the requirement to use several equivalents of Burgess reagent.
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(26  ^(N’-Ethyloxyoxalyl)-2-(ter^butyloxycarbonyl)aminopropaiioic acid hydrazide, 
(66)
PyBOP®
DIPEA
H,N
OH (54)
DMF(65)
Scheme 6 6 (66)
The Alanine-based hydi'azide (66), had also been synthesised by the Luthman group, 
which would allow another comparison of our different synthetic m e th o d s .Its  methyl 
side-chain should presumably not be problematic because it is neutral and non-reactive, so 
this seemed a good choice to synthesise next.
Boc-Ala-OH (65) was coupled to hydiazino ethyloxalate (54) (l.leq .) using PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixture of 4 products. The crude product was purified 
using “CombiFlash®” cohunn clnomatography, to give a cleai', colouidess oil (95.7%). It 
was identified as the title compound (66) by ID NMR: and 2D NMR: ^H-^H
(COSY), ^H-^^C (HMQC) and multiple bond ^H-^^C (HMBC) correlation experiments; 
LC-MS (ESI); Mass Spectrometry (Cl); Accui ate Mass Spectrometry (Cl) of parent ion; 
and IR. The liquid chromatography of the LC-MS gave the purity of this compoimd as 
100%. All NMR signals could be assigned unambiguously and are given in the 
experimental.
The yield was very encouragmg, but can not be compaied at this stage as it was not 
reported in the published synthesis.
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EthyI-5-[(5)-l-[(ter/-butyloxycarbonyl)amino]ethyll--l,3,4-oxadiazole-2-carboxylate,
(67)
Burgess
reagent
THF
reflux
(67)(66)
Scheme 67
Dehydration of the diacylliydrazide (66) was achieved by reaction with Burgess reagent in 
refluxing anliydrous THF, imder a flow of dry N2(g). The reaction was monitored by FIA 
and additional equivalents of Burgess reagent needed to be added to diive the reaction to 
completion (4eq. Burgess reagent used in total). The solvent was evaporated to give a 
yellow/brown oil. This was re-dissolved in DCM and after aqueous work-up the solvent 
was evaporated to give a yellow oil. TLC of this crude product showed a mixture of 4 
products. The crude product was puiified using colmmi clnomatography on SiOi to yield 
one significant product, made up of the 3 least polar products fi om the TLC of the cmde 
product. This product was separated using preparative TLC on SiOi to give 3 bands of 
products.
The least polar product was isolated as a white solid (61.3%). It was identified as the title 
compound (67) by ID NMR; *H and "C ; 2D NMR: 'H -'H  (COSY) and 'H-'^C (HMQC) 
coirelation experiments; Mass Specti'ometry (Cl); Accurate Mass Spectrometry (Cl) of 
paient ion; and IR. All NMR signals could be assigned unambiguously and are given in 
the experimental.
The yield of the oxadiazole (67) from Boc-Ala-OH (65) was calculated to be 58.7%. This 
compares very favouiably to tlie published yield of 17%.^^ By rumiing the condensation 
reaction under a flow of N2(g), we were able to reduce contamination by atmospheric 
water, allowing less equivalents of Burgess reagent^^ to be used than in our synthesis of 
the Phenylalanine-based oxadiazole (4eq. compared to 7eq.).
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[N’"((iS)-3-Benzyloxy-2-rer^-butoxycarbonylammo-propioiiyl)-hydrazmo]-oxo-acetic 
acid ethyl ester, (69)
PyBOP®
DIPEA
o  {U)H,N
OH (54)
DMF (69)(68)
Scheme 68
Boc-Ser(Bn)-OH (68) was coupled to hydrazino ethyloxalate (54) (l.leq .) using PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixtine of 3 products. The crude product was pmified 
using cohunn clnomatography on Si02  to yield a clear, colourless oil (64.3%). It was 
identified as the title compoimd (69) by ID NMR: and 2D NMR: (COSY),
(HMQC) and multiple bond (HMBCLP) correlation experiments; Mass
Spectrometry (Cl); Accurate Mass Spectrometi y (HI) of parent ion; and IR. All NMR 
signals could be assigned unambiguously and are given in the experhnental.
The and ^^ C NMR assigmnents were made fiom the ^H, ^^C, 'H-^H COSY,
HMQC and *H-^^C HMBCLP experiments, as follows:
1. The signal at Ôh 1.45 hi the ^H NMR was assigned as H-1 because it is the only singlet 
with an integml of 9H in the spectimn. This correlates to the signal at 8c 28.45 in the 
HMQC, which is therefore assigned as C l.
2. H-1 couples to C2 (via coupling), which was found to be the signal at 5c 81.07 
using the HMBCLP.
3. The signals at 8h 3.63 and 5h 3.91 both conelate to the same ^^ C signal at 8c 69.27 in 
the HMQC, suggesting that they are diastereotopic H-6 ^Hs and that the ^^ C signal is 
C6 . hi the COSY they coixelate to each other and to the broad singlet at 8h 4.46 which 
has an integial of IH so must be H-5. There are only two methylene units in (69) that 
are expected to have diastereotopic ^Hs (the other being at C7), and only the H-6 ^Hs
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should be able to couple to other ^Hs in the COSY, which confirms our assigmnent of 
5h 3.63 and 5h 3.91 as H-6 and H-6 ’.
4. H-5 couples to C5, wliich was found to be the signal at 8c 53.32 using the HMQC.
The signal for H-5 conelates in the COSY to the broad singlet at 8h 5.43 with an 
integral of IH, which does not correlate to any ^^ C signal in the HMQC and so was 
assigned as NH-4.
5. The signals at 8h 7.28-7.36 with an integral of 5H were assigned to the phenyl ring 
due to their chemical shift being suggestive of a phenyl ring and it is the only signal 
with an integral of 5H in the ^H NMR spectrum. The Ph ^H signals correlate to four 
^^ C signals in the HMQC (8c 128.15, 128.28, 128.76 and 137.22) which were 
assigned to the Ph carbons.
6 . The signal at about 8h 4.56 is an AB quartet and is actually made up of the signals for 
the two diastereotopic H-7 ^Hs at 8h 4.56 and 8h 4.57, each with an integi*al of IH. 
These signals correlate to the Ph signals at 8c 128.28, 8c 128,76 and 8c 137.22 in the 
HMBCLP (via and coupling). The H-7 signals also correlate to the signal at 8c 
73.86 in the HMQC, which was assigned as C7.
7. The quai'tet at 8h 4.38 has an integi*al of 2H and can be assigned to H-13 as it is the 
only true quartet expected in the spectrmn. H-13 couples to C l3 which can be 
assigned as the signal at 8c 63.81 using the HMQC,
8 . The signal for H-13 conelates in the COSY to the tiiplet at 8h 1.39 that has an integral 
of 3H, so was assigned as H-14. This signal correlates in the HMQC to the signal at 8c 
14.15, which was assigned as C14.
9. The remaining unassigned signal in the ^H NMR is the very broad singlet at 8h 9.31 
that has an integial of 2H. This signal does not couple to any other ^H signals in the 
COSY and does not couple to any ^^ C signals in the HMQC, so was assigned as the 
combined signals for NH-9 and NH-10.
10. The signal at 8c 167.80 in the ^^ C NMR can be assigned as C8 because it correlates in 
the HMBCLP to the signal for NH-4 and the two H-6 signals (all via coupling).
11. The signal at 8c 158.82 in the ^^ C NMR can be assigned as C12 because it conelates 
in the HMBCLP to the signal for H-13 (via coupling).
12. The signals at 8c 152.75 and 8c 155.76 in the ^^ C NMR were assigned as the 
carbonyls C3 and Cl 1 because they were the only unassigned peaks left in the 
spectrmn and are at a suitable chemical shift for a carbonyl. It was not possible to 
conclusively distinguish between these ^^ C signals, but there is a faint cross-peak in
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the HMBCLP at about 6c 153 and 6h 1.45. We considered this, however, to possibly 
be coincidental and be ti-noise from H-1, as it would requhe a coupling for such an 
interaction to occur with C3 and there is other ti-noise in the HMBCLP from this ^H 
signal.
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Table 8 and NMR assignments of [N'-((5)-3-Benzyloxy-2- 
butoxycarbonylamino-propionyl)-hydrazino]-oxo-acetic acid ethyl
■tert~
ester, (69) in CDCI3
'H 13c
Assigned 8h Multiplicity Relative Sc Conmient
groups (ppm) (J/Hz) Integial (ppm)
C14, H-14 1.39 t
1=6.9
3H 14.15
C l, H-1 1.45 s 9H 28.45 —
C6, H-6, 
H-6 ’
3.63
3.91
m
bs
2 x l H 69.27 The 2 H-6 ^Hs are not 
equivalent so produce 
separate *H NMR signals.
C13,H-13 4.38 q
J=6.9
2H 63.81
C5, H-5 4.46 bs IH 53.32 —
C7, H-7, 
H-7’
4.56
4.57
dJ=11.9
d J= 12.1
2 x  IH 73.86 The 2 H-7 ‘Hs are not 
equivalent so produce 
separate signals in ‘H 
NMR, but have very 
similar chemical shift, so 
appear as an AB quartet.
NH-4 5.43 d
J=6.0
IH
Ph 7.28-7.36 m 5H 128.15,
128.28,
128.76,
137.22
NH-9,
NH-10
9.31 bs 2H These NH signals 
completely overlap.
C2 — — — 81.07 —
C3, C ll 152.75,
155.76
These carbonyls can not 
be differentiated from the 
experiments performed.
C12 — — — 158.82 —
C8 — — — 167.80
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Figure 42 *H NMR (500MHz) of [N'-((S)-3-Benzyloxy-2-fert- 
butoxycarbonylamino~propionyl)-hydrazino]-oxo-acetic acid ethyl ester, (69) in 
CDCI3
p p m
^10
10 ppm
Figure 43 COSY (500MHz) of [N'-((jS)“3“Benzyloxy-2-^er^
butoxycarbonylamino-propionyl)-hydrazino]-oxo-acetic acid ethyl ester, (69) in
CDCI3
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F igure 44 NMR (125MHz) of [N-((6)-3 -Benzyloxy-2-^er^-
butoxycaibonylamino-propionyl)-hydrazino]“Oxo-acetic acid ethyl ester, (69) in 
CDCI3
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Figure 45 HMQC (500MHz) of [N'-((6)-3-Benzyloxy-2-/gr^-
butoxycarbonylamino-propionyl)-hydrazino]-oxO“acetic acid ethyl ester, (69) in
CDCI3
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Figure 46 HMBCLP (500MHz) of pSf'-((5)-3-Benzyloxy-2-terr-
butoxycarbonylamino-propionyl)-hydrazino]“Oxo-acetic acid ethyl ester, (69) in 
CDCI3
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Figure 47 IR of [N'-((5)-3-Benzyloxy-2-^er/-butoxycarbonylamino-propionyl)-
hydrazino]-oxo-acetic acid ethyl ester, (69) as CH2CI2 film between KBr discs
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The major absorption frequencies of this compound in the IR (Figiue 47) and their 
assigmnents were: Vmax (CDCI3 film)/cm'^ 3275 (NH stretch of 2° amide), 2980 (CH3 
asynnnetric stretch), 2937 (CH2 asymmetiic and symmetric stretch), 2871 (CH3 
synnnetiic stietch), 1720 and 1691 (C~0 stretch in ester), 1497 (NH bend), 1455 (CH3 
asymmetric bend), 1368 (CH3 synnnetric bend), 1251 and 1165 (asymmetric C-C(=0)-0 
stretch of ester).
ms071204g #  18 RT: 1.15 AV: 1 NL: 1.80E6
T: + c El Full ms [ 79.50-600.50]
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Figure 48 MS (Cl) of [N'-((*S)-3-Benzyloxy-2-te7'/:“butoxycarbonylamino- 
propionyl)-hydi'azino]-oxo-acetic acid ethyl ester, (69)
The major fr agments of tliis compound in the MS and their assignments are as follows 
MS (Cl) (m/z): 410 (MF + H), 366 (M+ -  OEt + 2H), 354 (M+ -  «-butyl + 2H), 338 (M* -  
0C(CH3)3 + 2H), 310 (M* -  BOC + 2H).
An "accurate Mass Spectrmn” (El) (obtained from high resolution mass spectrometry) of 
the pealc at m/z 409 was recorded. This experiment found the peak to be m/z 409.1805; 
C19H27N3O7 requires 409.1844.
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(2iÜ) (N’-Ethyloxyoxalyl)-2-(ter^-butyloxycarbonyl)amino-3-beiizylsulfanylpropanoic
acid hydrazide, (71)
PyBOP®
DIPEA
(54)
OH
DWIF
(70) (71)Scheme 69
Boc- Gys(Bn)-OH (70) was coupled to hydrazino ethyloxalate (54) (l.leq .) using 
PyBOP® (leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then 
basic aqueous work-up, TLC showed a mixture of 5 products. The crude product was 
pmified using “CombiFiash®” colmnn cliromatography, to give a white solid. This 
product was slightly impure so was pmified by passing tluough a pad of Si02  to give a 
clear, colomiess oil (46.1%). It was identified as the title compoimd (71) by ID NMR: 
and 2D NMR: (COSY), and (HMQC) conelation experiments; Mass
Spectrometry (Cl); Accurate Mass Spectrometry (El) of parent ion; and IR. All NMR 
signals could be assigned unambiguously and are given in the experimental.
This compound had been previously synthesised in a yield of 49.2% by the Lutlmian 
g r o u p .O u r  yield of 46.1% is slightly lower, wliich we would attribute to solubility 
problems with the eluant used for the “ConibiFlash®” column cluomato graphy.
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(25) [N'-Ethyloxyoxalyl)-2-(terr-butyloxycarbonyl)amino-4-methylpentanoic acid
hydrazide, (73)
PyBOP®
DIPEA
H,N
OH (54)
DMF(72)
Scheme 70 (73)
Boc-Leu~OH (72) was coupled to hydrazino ethyloxalate (54) (l.leq .) using PyBOP * 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixture of 3 products. The crude product was purified 
using column chi'omatography on Si02  to yield a white solid (74.5%). It was identified as 
the title compotmd (73) by ID NMR; 'H  and "C ; 2D NMR: 'H -'H  (COSY) and 'H-'^C 
(HMQC) correlation experiments; Mass Spectrometry (Cl); Accuiate Mass Spectrometry 
(Cl) of parent ion; and IR. All NMR signals could be assigned imambiguously and are 
given in the experimental.
This compoimd was not novel as it had been previously published in a Patent application 
(yield not reported), but was synthesised to show the reproducibility of our method.^^
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(25) (N'-Ethyloxyoxalyl)-2-(^e/*/-butyIoxycarbonyl)amino-6-
(benzyloxycarbonyl)aminohexanoic acid hydrazide, (75)
PyBOP®
DIPEA HNHN
(54)
OH
DMF
(74) (75)
Scheme 71
Boc-Lys(Z)-OH (74) was coupled to hydrazino ethyloxalate (54) (l.leq .) using PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixture of 3 products. The crude product was purified 
using “CombiFlash®” column cinematography, to give a clear*, colourless oil/solid 
(66.1%). It was identified as the title compound (75) by ID NMR: and 2D NMR:
(COSY), and (HMQC) correlation experiments; LC-MS (ESI); Mass
Spectr ornehy (Cl); Accm ate Mass Spectrometr y (Cl) of parent ion; and IR. The liquid 
cluomato graphy of the LC-MS gave the pmity of this compoimd as 100%. All NMR 
signals could be assigned miambiguously and are given in the experimental.
A thorough search of the literatme usmg SciFinder Scholar® did not reveal any instances 
of this compomid being previously reported.
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(2S) (N’-Ethyloxyoxalyl)-2-(ter^butyloxycarbonyl)ammo-5-
(benzyloxycarbonyl)ammopentaiioic acid hydrazide, (77)
PyBOP®
DIPEA NHNH
OH (54)
DMF
(77)(76)
Scheme 72
Boc-Oiii(Z)-OH (76) was coupled to hydrazino ethyloxalate (54) (l.leq .) using PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixture of 3 products. The cmde product was purified 
using “CombiFlash®” column cliromatography, to give a clear, colomiess oil/solid 
(72.5%). It was identified as the title compound (77) by ID NMR: and 2D NMR:
(COSY), and (HMQC) coiTclation experiments; LC-MS (ESI); Mass
Specti'ometi y (Cl); Accurate Mass Spectrometry (Cl) of pai ent ion; and IR. The liquid 
cliromatography of the LC-MS gave the pmity of this compoimd as 100%. All NMR 
signals could be assigned unambiguously and are given in the experimental.
A Üiorough search of the literatme using SciFinder Scholar® did not reveal any instances 
of this compomid being previously reported.
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(25) [N'-Ethyloxyoxalyl)-2-(ter^-butyloxycarbonyI)amino-4-methyIsulfanyl-butanoic
acid hydrazide, (79)
PyBOP®
DIPEA
OH (54)
DMF (79)(78)
Scheme 73
Boc-Met-OH (78) was coupled to hydiaziuo ethyloxalate (54) (l.leq .) using PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixtiue of 3 products. The cmde product was piuified 
using “CombiFlash®” column cluomatogiaphy, to give a clear', colourless oil (44.9%). It 
was identified as the title compomid (79) by ID NMR: and 2D NMR:
(COSY), and (HMQC) correlation experiments; Mass Spectrometry (Cl);
Acciuate Mass Spectrometry (El) of par'ent ion; and IR. All NMR signals could be 
assigned unambiguously and are given in the experimental.
A thorough search of the literature using SciFinder Scholar® did not reveal any instances 
of this compound being previously reported.
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(2*S) (N*-Ethyloxyoxalyl“2-(ter^butyloxycarbonyl)amino-4-(benzyloxycarbonyl)
butaiioic acid hydrazide, (81)
PyBOP®
DIPEA
H,N
(54)
OH DMF
(81)(80)
Scheme 74
Boc-Glu(OBn)-OH (80) was coupled to hydiaziuo ethyloxalate (54) (l.leq .) using 
PyBOP® (leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then 
basic aqueous work-up, TLC showed a mixture of 3 products. The crude product was 
purified using “CombiFlash®” column cliromatography, to give a clear, colourless oil 
(64.3%). It was identified as the title compoimd (81) by ID NMR: and 2D NMR:
(COSY), and (HMQC) conelation experiments; Mass Spectrometry (Cl);
Accurate Mass Spectrometry (Cl) of parent ion; and IR. All NMR signals could be 
assigned unambiguously and are given in the experimental.
A thorough search of the literature using SciFinder Scholar® did not reveal any instances 
of this compound being previously reported.
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(25) (N'“Ethyloxyoxalyl)-2-(teft-butyloxycarbonyl)amino-3-
(benzyloxycarbonyl)propanoic acid hydrazide, (83)
PyBOP®
DIPEA
(54)
OH DMF
(82) (83)
Scheme 75
Boc-Asp(OBn)-OH (82) was coupled to hydrazino ethyloxalate (54) (l.leq .) using 
PyBOP® (leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then 
basic aqueous work-up, TLC showed a mixture of 3 products. The crude product was 
purified using “CombiFlash®” colmmi cluomatography, to give a clear, colourless oil. 
This product was slightly impme so was purified by passing through a pad of SiOi to give 
a clear, colourless oil (36.5%). It was identified as the title compoimd (83) by ID NMR: 
*H and "C ; 2D NMR: ‘H-'H (COSY), and (HMQC) conelation experiments;
Mass Spectrometry (Cl); Accur ate Mass Spectrometry (El) of parlent ion; and IR. All 
NMR signals could be assigned unambiguously and are given in the experimental.
A thorough search of the literature using SciFinder Scholar® did not reveal any instances 
of this compoimd behig previously reported.
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(2iS) [N’“Ethyloxyoxalyl)“2-(^er^butyloxycarbonyl)amîno-3-methyl-butanoic acid 
hydrazide with diisopropylethylamine, (85)
PyBOP®
DIPEA O (15)
OH (54) (16](85) X17)DMF(84)
(18)Scheme 76 (19)
Boc-Val-OH (84) was coupled to hydiaziuo ethyloxalate (54) (l.leq .) usmg PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixtiue of 3 products. The cmde product was purified 
using column chi'omatography on SiOi to yield a clear, colourless oil/solid. It was 
identified as the title compoimd (85) + DIPEA by ID NMR: and 2D NMR:
(COSY), (HMQC) and thraugh space ^H-^H NOESY correlation experiments;
Mass Spectrometry (Cl and ESI); and IR. All NMR signals could he assigned 
unambiguously and are given m the experimental.
The DIPEA appears to interact with the hydrazide (85) in some way so that it can not be 
removed even after repeated diying of the product in a vacuimi oven at 45°C for several 
horns. The signals for the DIPEA in the NMR are shifted downfield in compaiison to 
the spectrum of pme DIPEA in CDCI3, suggesting that (85) could be a DIPEA salt. The 
NMR signals associated with DIPEA do not correlate to the hydrazide’s signals in the 
COSY. The NOESY shows possible conelations between the signal for H-18 (DIPEA) 
and that of H-14 (hydi azide).
The parent ion of the hydrazide + H (ni/z 332) could be obseiwed in the MS under Cl 
conditions, but there was also a pealc at m/z 461, which coiTesponds to M"*" + DIPEA + H. 
There was also a ft agment at m/z 130, which is compatible with DIPEA + H.
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In the MS under ESI conditions (+ve), there was a peak at ni/z 460, which corresponds to 
4- DIPEA. When this peak was subjected to ftirther fragmentation in the ion tiap (MS^ 
m/z 460), the peaks produced were m/z 360 (M^ + C tl2=NH) and m/z 404 (M’*' + 
CH2='^ 1SIHC(CH3)2). Fragmentation of 404 (MS^ m/z 460 404) led to a peak at m/z
360. Further fragmentation (MS"^  m/z 460 —> 404 —> 360) resulted in the following main 
fiagments, m/z\ 360 (M"*" + CH2=NH), 332 (M”^ + H) and 286 (M"^  -  OEt). These MS 
experiments flirther support the hypothesis that the DIPEA is interacting in some way 
with the hydrazide (85).
A thorough search of the literatur e using SciFinder Scholar® did not reveal any instances 
of this compound (with or without association with DIPEA) being previously reported.
(25) [N’-Ethyloxyoxalyl)-2“(^er^butyloxycarbonyl)aminO“3-methyI-pentaiioie acid 
hydrazide with diisopropylethylamine, (87)
PyBOP®
DIPEA
(54)OH
DMF (87)
(86)
Scheme 77
Boc-Ile-OH (86) was coupled to hydrazino ethyloxalate (54) (l.leq .) using PyBOP® 
(leq.) in the presence of DIPEA (3eq.) in DMF. After an acidic aqueous, then basic 
aqueous work-up, TLC showed a mixture of 3 products. The crude product was purified 
using column cluomatogiaphy on Si02 to yield a clear, colour less oiFsolid. It was 
identified as the title compoimd (87) + DIPEA by ID NMR: and 2D NMR:
(COSY), (HMQC) and tluough space ^H-^H NOESY coiTelation experiments;
Mass Spectrometry (Cl); and IR. All NMR signals could be assigned unambiguously and 
are given in the experimental.
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The DIPEA appears to interact with Üie hydr azide (87) in some way so that it can not be 
removed even after repeated drying of the product in a vacuum oven at 45 °C for several 
hours.
The signals for the DIPEA in the NMR are shifted downfield in comparison to the 
spectrum of pure DIPEA in CDCI3, suggesting that (87) could be a DIPEA salt. The 
NMR signals associated with DIPEA do not correlate to the hydrazide's signals in the 
COSY. There was no evidence in the NOESY of any interactions between DIPEA and the 
hydrazide (87).
The parent ion of the hydrazide + H (m/z 346) could be observed in the MS under Cl 
conditions, but there was also a peak at m/z 475, which coiTesponds to M^ + DIPEA + H. 
There was also a fragment at m/z 130, which is compatible with DIPEA + H.
A thorough search of the literature using SciFinder Scholar® did not reveal any instances 
of this compound (with or without association with DIPEA) being previously reported.
Ethyl-5-[(*S)-l-[(^e/*^butyloxycarboiiyI)amino]-3'-(benzyIoxycarbonyl)propyI]-l,3,4- 
oxadiazole-2 -carboxylate, (8 8 )
Burgess
reagent
THF
reflux (15)
({2 ) 0 N—N 
(1 1 ) (1 2 ) (16)(81) (88)Scheme 78
Dehydration of the diacylhydrazide (81) was achieved by reaction with Burgess reagent in 
refluxing anliydrous THF, imder a flow of dry Nz(g). The reaction was monitored by FIA 
and additional equivalents of Burgess reagent needed to be added to drive the reaction to
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completion (4eq. Burgess reagent used in total). The solvent was evaporated to give a 
yellow/brown oil. This was re-dissolved in DCM and after aqueous work-up the solvent 
was evaporated to give a pale yellow oil. TLC of this crude product showed a mixture of 
4 products. The cmde product was purified using column chi'omatography on SiOzto 
yield a clear, colourless oil (50.3%). It was identified as the title compound (88) by ID 
NMR: 'H  and "C ; 2D NMR: 'H -'H  (COSY), 'H-'^C (HMQC) and multiple bond 'H-'^C 
(HMBC) coiTelation experiments; Mass Spectrometry (Cl); Accurate Mass Spectiometry 
(Cl) of parent ion; and IR. All NMR signals could be assigned unambiguously and are 
given below and in the experimental.
The yield of the oxadiazole (88) fiom Boc-Glu(OBn)-OH (80) was calculated to be 
32.3%. A thorough search of the literature using SciFinder Scholar® did not reveal any 
instances of this compound being previously reported. The yield was disappointing when 
compared to that of the Alanine-based oxadiazole (67), which could be because of the 
additional functionality in the side-chain causing some sort of difficulties in the synthesis.
The and ^^ C NMR assignments were made from the ^H, '^C, COSY, ^H-^^C 
HMQC and ^H-^^C HMBC experiments, as follows:
1. The signal at Ôh 1.44 in the ^H NMR could be unequivocally assigned to H-1 because 
it is the only singlet with an integral of 9H. This couples to C l which could be 
assigned as the signal at 6c 28.44 using the HMQC.
2. There are 4 signals with an integial of IH  in the ^H NMR. The two at 6h 2.21 and 5h 
2.36 are multiplets which conelate in the HMQC to the same ^^C signal (6c 28.81) 
and to each other in the COSY. This suggests that they are the diastereotopic H-6 ^Hs 
and that the ^^ C signal is C6 . They conelate to the multiplet at 6h 2.55 in the COSY, 
which does not correlate to any other signals in the COSY and has an integral of 2H 
so must be H-7. This confimis our assignment of H-6 because H-7 is the only other 
signal that could show as diastereotopic in the ^H NMR (if H-9 does show as 
diastereotopic it is more likely to be an AB quartet). H-7 couples to C7 which can be 
assigned as the signal at 6c 30.23 using the HMQC.
3. H-6 also correlates to the broad singlet at 6h 5.15, which has an integral of IH and so 
can be assigned to H-5. C5 can be assigned to the signal at 6c 47.22 using the HMQC.
4. H-5 correlates to the broad singlet at 6h 5.26, which has an integial of IH and does not 
couple to any signals in the HMQC, so was therefore assigned as NH-4.
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5. The quartet at 5h 4.51 has an integral of 2H and can be assigned to H-15 as it is the 
only true quaitet expected in the spectium. H-15 couples to C l5 which can be 
assigned as the signal at 6c 63.85 using the HMQC.
6. H-15 correlates in the COSY to the triplet at 6h 1.45, partially obscured by the large 
H-1 singlet, which has an integial of 3H and can therefore be assigned to H-16. C16 
can be assigned as the signal at 6c 14.27 using the HMQC.
7. The signals at 6h 7.33-7.37 with an integral of 5H were assigned to the phenyl ring 
due to their chemical shift being suggestive of a phenyl ring and it is the only signal 
with an integral of 5H in the ^H NMR spectrum. The Ph ^H signals conelate to four 
^^ C signals in the HMQC (6c 128.54, 128.61, 128.84 and 135.75) which were 
assigned to the Ph carbons.
8. The Ph signal correlates in the COSY to the singlet at 6h 5.12 with an integral of 2H, 
which was therefore assigned as H-9 (via long range coupling). This signal (OCTi^Ph) 
would have been expected to appear as an AB quartet in theory, but in practice we 
have consistently found it to be a singlet for the oxadiazole (88) and its corresponding 
hydrazide (81). H-9 couples to C9 which can be assigned as the signal at 6c 66.98 
using the HMQC.
9. The signal at 6h 1.59 in the ^H NMR was assigned as residue water in the d- 
chloroform, which was confirmed by nmning a ^H NMR of a blank sample using d- 
chloroform fiom the same bottle.
10. The five most downfield signals, 6c 154.31,155.12,157.24,168.61,172.30, can be 
assigned to the three ester signals (C3, C8 and C l4), and the 2 oxadiazole signals 
(CIO and C l3), as they are the most de-shielded carbon nuclei in the molecule. They 
can be distinguished by reference to the HMBC (Figure 40) (performed at restricted 
range 5h 2 -  5.5 and 6c 150 -  175), which shows (predominately) and ^H-^^C 
coupling. There are several processing artifacts m the HMBC (circled in red in Figure 
40), which can be distinguished from genuine con elations because they appear at 
chemical sliifts where there are no ^^ C signals in the ^^ C spectrum. These artefacts are 
likely caused by residual t%-noise caused by the parent ^H-^^C signals, which can 
occur when conventional HMBC spectra ar e recorded using phase cycling for signal 
selection.^^
11. The signal at 6c 172.30 can be assigned as C8 because it coiTelates to the signals for 
H-9 (^J), H-7 (^J) and H-6 (^J) in the HMBC.
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12. The signal at 6c 168.61 can be assigned as CIO because it correlates to the signal for 
H-6 (^J) in the HMBC.
13. The signal at 6c 155.12 can be assigned as C3 because its chemical shift coiTesponds 
to that found for this carbonyl in the Boc group of the hydi azides synthesised 
(determined by HMBCLP experiments). It possibly also correlates to the signal for 
H-6 ("^ J) in the HMBC, but this would be from a interaction, wliich are rarely 
detected in an HMBC.
14. The signal at 6c 154.31 can be assigned as C14 because it correlates to tlie signal for 
H-15 (’j)  in the HMBC.
15. The signal at 6c 157.24 can be assigned as C13 because it is the only xmassigned of 
these five most downfield signals in the ^^C. It does not appear as a projection in the 
HMBC because it is four bonds away fiom the nearest ^H and such interactions are 
usually too faint to detect in a HMBC experiment.
16. The signal at 6c 81.12 in the ^^ C NMR was assigned to C2 because it was the only 
unassigned signal and was found to be at a siniilai* chemical shift for all of the Boc- 
oxadiazoles and Boc-hydrazides synthesised, and has been confirmed by HMBCLP 
for selected Boc-hydrazides. (It was not confirmed by the HMBC for this compound, 
which was performed over a reduced chemical shift range that did not include this 
signal).
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Table 9 and NMR assignments of 5-((*S)“3-Benzyloxycarbonyl-l-^e7"^ - 
biitoxycai'bonylamino-propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88) in CDCI3
'H ........
Assigned ÔH Multiplicity Relative 8 c Comment
groups (ppm) (J/Hz) Integial (ppm)
C l, H-1 1.44 s 9H 28.44 —
C16, H-16 1.45 t
J=7.1
3H 14.27 The H-16 signal partially 
overlaps with the H-1 
signal in the ‘H NMR.
C6, H-6, 
H-6’
2.21
2.36
m 2 x  IH 28.81 The 2 H-6 ^Hs are not 
equivalent so produce 
separate signals in H^ 
NMR and separately 
interact with H-5 and H-7.
C7, H-7 2.55 m 2H 30.23 —
C15,H-15 4.51 q
J=7.1
2H 63.85
C9, H-9 5.12 s 2H 66.98 —
C5, H-5 5.15 bs IH 47.22 —
NH-4 5.26 bs IH — —
Ph 7.33-7.37 m 5H 128.54,
128.61,
128.84,
135.75
C2 — — — 81.12 —
C14 — — — 154.31 —
C3 — — — 155.12 —
C13 -—- -—- — 157.24 —
CIO — — — 168.61 —
C8 — — — 172.30 —
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Figure 49 NMR (500MHz) of 5-((*S)-3-Benzyloxycai'bonyl-l-fer^- 
butoxycarbonylamino-propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88) 
in CDCI3
ppm
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r 3
- 4
r5
r7
p p m
Figure 50 ^H-^HCOSY (500MHz) of 5-((6)-3-Benzyloxycaibonyl-l-^e;i- 
biitoxycarbonylainino-propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88) 
in CDCI3
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Figure 51 NMR (125MHz) of 5-((6)-3-Beiizyloxycarbonyl“l-ter?- 
butoxycarbonylamiiio-propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88) 
in CDCI3
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Figure 52 HMQC (500MHz) of 5-((iS)-3-Benzyloxycai’bonyl-l-^er^-
biitoxycai'bonylammo-propyl)"[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88) 
in CDCI3
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Figure 53 Expanded HMBC (500MHz) of 5-((iS)-3-Benzyloxycarbonyl-l-
ter/-butoxycarbonylammo-propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, 
(88) in CDCI3 (Ôh 2-5.5ppm, ôc 150-175ppm). (Artifacts present at chemical shifts 
where there is no signal in the have been circled in red).
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Figure 54 IR of 5-((S)-3-Benzyloxycarbonyl-1-fer/-butoxycarbonylamino- 
propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88) as CDCI3 film 
between KBr discs
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The major absoiption frequencies of this compound in the IR (Figure 54) and their 
assignments were: Vmax (CDCI3 fihn)/cnT^ 3353 (NH stretch of 2° amide), 2980 (CH3 
asyimnetric stretch), 2937 (CH2 asymmetric and symmetiic stretch), 1746 and 1716 (C=0 
stretch in ester), 1514 (NHbend), 1368 (CH3 symmetric bend), 1252 and 1166 
(asyimnetric C-C(=0)-0 stretch of ester).
ms260105e #15-17 RT: 0,95-1,07
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Figure 55 MS (Cl) of 5-((6)-3-Benzyloxycarbonyl-l-^er^-butoxycarbonylamino- 
propyl)-[l,3,4]oxadiazole-2-carboxylic acid ethyl ester, (88)
The major h  agments of this compoimd in the MS and their assigmnents are as follows 
MS (Cl) (m/z): 434 (M+ + H), 378 (M* -  t-butyl + 2H),
An “acciuate Mass Spectrum” (Cl) (obtained hom high resolution mass spectrometry) of 
the peak at m/z 434 was recorded. Tliis experiment foimd the pealc to be m/z 434.1943; 
C21H27N3O7 + H requhes 434.1922.
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Ethyl-5-[(*S)-l-[(^er^-butyloxycarbonyl)amiiio]-5-(benzyloxycarbonyl)ammopeiityll-
l,3,4-oxadiazole-2-carboxylate, (89)
HN HN
Burgess
reagent
THF
reflux
N—N
(75) (89)Scheme 79
Dehydi'ation of the diacylhydrazide (75) was achieved by reaction with Burgess reagent in 
refluxing anhydrous THF, under a flow of dry N2(g). The reaction was monitored by FIA 
and additional equivalents of Burgess reagent needed to be added to diive the reaction to 
completion (4eq. Burgess reagent used in total). The solvent was evaporated to give a 
yellow/brown oil. This was re-dissolved in DCM and after aqueous work-up the solvent 
was evaporated to give a clear yellow oil. TLC of tliis crude product showed a mixtine of 
4 products. The cmde product was purified using column chromatography on Si02 to 
yield a clear, colouiless oil (42.8%). It was identified as the title compound (89) by ID 
NMR: *H and ‘^ C; 2D NMR; *H-'H (COSY), (HMQC) and multiple bond 'H -‘^ C
(HMBCLP) coiTelation experiments; Mass Spectiometry (Cl); Accurate Mass 
Spectrometiy (Cl) of parent ion; and IR. All NMR signals could he assigned 
imambiguously and are given in the experimental.
The yield of the oxadiazole (89) from Boc-Lys(Z)-OH (74) was calculated to be 28.3%. A 
thorough search of the literature using SciFinder Scholar® did not reveal any instances of 
this compound being previously reported.
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Summary of NMR data for synthesised hydrazides of general structure 
(52) and synthesised oxadiazoles of general structure (53)
(7) (8)
Scheme 80
The and NMR assignments for the main pai*t of the molecule (excluding the 
differing amino acid side-chains) appear at similar positions for all o f the hydrazides and 
oxadiazoles synthesised (Tables 10 and 11).
Table 10 and NMR assignments of synthesised hydrazides o f general structure 
(52) in CDCI3
^H 13c
Assigned gi'oups Ôh Multiplicity Relative ÔC
(ppm) (J/Hz) Integral (ppm)
C12, H-12 1.31-1.39 t
J=6.9-7.2
3H 13.94-14.17
C l, H-1 1.39-1.45 s 9H 28.40-28.50
C11,H-11 4.31-4.38 q
J=6.9-7.2
2H 63.68-63.88
C5, H-5 4.27-4.67 bs IH 48.91-54.59
NH-4 4.95-5.72 bs/d
J=6.0-7.7
IH
NH-7, NH-8 8.6-9.66 1 X bs/2 X bs 2 X 1H/2H —
C2 — — — 80.63-81.44
C3, C9 152.71-154.38,
155.76-156.21
CIO — — — 158.79-158.98
C6 — — — 167.80-170.92
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Table 11 and NMR assigmnents of synthesised oxadiazoles of general 
structure (53) in CDCI3
'H " c
Assigned groups ÔH Multiplicity Relative Sc
(ppm) (J/Hz) Integral (ppm)
C l, H-1 1.43-1.45 s 9H 28.44-28.56
C12, H-12 1.43-1.45 t
J=7.1
3H 14.26-14.40
C11,H-11 4.51-4.52 q
J=7.1
2H 63.81-63.95
C5, H-5 5.09-5.15 bs IH 43.58-48.98
NH-4 5.15-5.27 bs IH —
C2 — — — 80.95-81.12
CIO — — — 154.31-154.50
C3 — — — 154.85-155,26
C9 — — — 157.12-157.24
C6 — — — 168.61-169.86
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Summary of Results 2
-  A route to 1,3,4-oxadiazole based dipeptide mimetics has been developed (Scheme 
81).
-  This route is simpler than the previously reported method and results in improved 
yields of oxadiazole product starting from various Boc-protected amino acids.^^
-  The synthesis begins with the coupling of a Boc-amino acid (50) with hydrazino 
ethyloxalate (54), using PyBOP® as the coupling reagent. The hydrazide product (52), 
then imdergoes dehydration by reaction with Burgess reagent, to form the oxadiazole 
product (53).
PyBOP®
DIPEA
O R
H 
(50)
HgN
OH
O
O (54)
O DMF
THF
reflux
O 
(52)
.0
O -U JN - S - N  II O
(Burgess reagent)
O R
9
o-
Scheme 81 Synthesis of 1,3,4-oxadiazole derivatives starting from various 
Boc-protected amino acids, (50)
The synthesis is compatible with a wide variety of functionalised side-chains.
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Chiroptical properties of compounds synthesised
Many of the compounds synthesised within this thesis are cliiral and all were obtamed 
from enantiomerically pure starting materials. Hence it can be anticipated that all chiral 
products obtained are either enantiomerically pure or enantiomerically emiched (relative 
to a racemate), depending on the degree of racémisation dui ing the synthesis and work­
up. For that reason it seemed important to gather infoimation ahout the chiroptical 
properties of a selection of compoimds synthesised.
As the technique of choice Circular Dichroism (CD) spectroscopy was used to 
characterise the compounds. In CD spectroscopy the absoiption o f left and right linear 
polarised light is measmed. Any enantiomerically emiched compoimd is expected to 
display a CD curve due to the difference in absoiption of left and right lineai* polarised 
light. From the sign of the CD ciuwe the absolute confrgin ation of the compoimd imder 
investigation can be determined or confinned. Furtheiinore, if  the absolute configuration 
o f the compound is Imown, infoimation about the conformation of the compoimd in 
solution can be obtained. The physical basis of the CD effect is based on the fact that 
enantiomerically enriched compoimds have electiic and magnetic ti ansition dipole 
moments whose angle towards one another is different from 90°. All compounds 
synthesised show characteristic CD spectra and indicate that little or no racémisation has 
occimed during their synthesis by compaimg molai' ellipticity values obtained with those 
reported in the literature.
In order to imderstand and interpret the CD data obtained fr om the compounds 
synthesised it appears useful to stai't with the benzene cliromophore present in most 
derivatives. Application of the rules proposed by Schellman makes it possible to 
deteimine the number of sectors into which the space surrounding the clnomophore must 
be divided. In a mono-substituted benzene derivative the Dgh symmeti y o f benzene is 
reduced to C2V symmetry requiring fom* sectors (quadrant mle).
hi coimection with CD specti a of benzene derivatives it should be noted that the UV 
spectra of mono-substituted benzene derivatives are rather complex with thi ee principal 
transitions that are usually observed at 260-280 mn (^Ly transition), 210-230 nm (^La
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transition) and 190-200 nm (^E2u transition). The established qnadiant rule focuses on the 
L^b tiansition. Since the absolute configuration of all products is known, an analysis of the 
observed Cotton effects should allow the classification of the dominant pertuiber in each 
individual compound. Since this thesis contains a selection of derivatives with various 
functional groups an empirical mle for flirther substituents can be derived from the 
measmed CD spectra.
As a first example the CD spectmm of NTf ester 44 was obtained and analysed using the 
quadi'ant mle. The CD spectnun shown in Figure 57 shows clearly a positive Cotton 
effect with a maximum at 220 mn. In Figure 56 below the stereostructme and Brewster- 
Buta-Smith-Fontana sector mle for the ^Lb tiansition is shown. (Note although the CE 
maximum at 220 nm corresponds to the ^La transition, the L^b transition is as well 
characterised by a positive Cotton effect).
( S ) - ( 4 4 )
MeOOC NHR
 X ......MeOOC NHR 
+ MeOOC NHR 
Figure 56 Analysis of (5)-(44) using the quadrant rule
From the positive Cotton effect obseiwed in 6"-configmed (44) it becomes obvious that the 
amide frmctionality is the dominant perturber if  compared to the ester group. This is 
consistent with a larger effective tiansition moment for an amide function as compared to 
an ester fimction. As reported for the positive Cotton effect observed in (6)-NBoc- 
PheOMe and (5)-Gly-PheOMe.”
It is worth noting that for iS-phenylalanine itself a negative Cotton effect for the 'L t
transition was reported consistent with CO2' being a dominant perturber if  compared to 
NH3*.“
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More recent analysis of CD spectra of phenylalanine derivatives have shown a strong 
solvent effect on the sign of the Cotton effect. This observation was rationalised in terms 
of two conformers in equilibrium in solution. The major conformer determines the sign of 
the CD Cotton effect for the 'Lb transition. The two conformers are shown below (Scheme 
82).
FaCO^S.^
NHCOR
MeO,C NHCOR
(S)-(44) A (-)-conformer B (+)-conformer
Scheme 82 The equilibrium of two conformers of (S)-(44) when in solution.
From the CD data it appears that conformer B is the major conformer in methanol 
contributing to the positive Cotton effect observed.
g1
phe-NTf (44)
25
20
(S)-(44)15
10
5
0
200 220 240 260 280 300
[nm]
Figure 57 CD spectrum of (5)-(44) 0.1 mM in MeOH.
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Using analogous arguments the CD spectra of the (5)-Phe derived hydrazide and 
oxadiazole can be analysed. (S)-Phenyl-hydrazide 61 shows a negative Cotton effect for 
the *Lb transition at 250 nm. Using the quadrant rule (Figure 59) the hydrazide 
functionality can thus be identified as the dominant perturber if compared to the NHBoc 
functionality. Furthermore a positive Cotton effect for the L^a transition at 230 nm and a 
negative Cotton effect for the 210 nm 'E2u transition can be identified.
Phe-Hydrazide (61)
260 280 300
-10
(S )-(6 1 )-15
[nm]
Figure 58 CD spectrum of (5)-(61) 0.1 mM in MeOH.
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(S)-(61)
RHNHNOC NHBoc
Ir h n h n o c T nhbog
RHNHNOC NHBoc
F igure 59 Analysis of (6)-(61) using the quadrant rule
Plie-oxadiazole (64) shows a negative Cotton effect for the ^Lb transition at 250 mn. 
Using the quadrant mle (Figure 60) the oxadiazole flmctionality can thus be identified as 
the dominant perturber if  compaied to the NHBoc flmctionality. Furthermore a positive 
Cotton effect for the ^La transition at 220 mn and a negative Cotton effect for the mn *E2u 
transition can be identified. The quadi'ant mle for the oxadiazole is shown below (Figure 
60).
O
O V
O x ^ N H B o c
(S)-(64)
IO x ^ 'NHBoc 
+ O x  N H B oc
Figure 60 Analysis of (6)-(64) using the quadrant rule
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Phe-Oxadiazole (64)
O)•S 200
_
220 !40 260 280 300
(S)-(64)
[nm]
Figure 61 CD spectrum of (S)-(64) 0.1 mM in MeOH.
An alternative approach towards the interpretation of the Phe-oxadiazole CD spectra uses 
the Exciton chirality approach.^  ^When two chromophores are in close spatial proximity 
to one another dynamic coupling between the two chromophores results in distinctive CE 
couplets, often referred to as exciton coupling. The term exciton, termed by Davidov, 
applies to a non-degenerate excited state in a polychromophoric system. Such a 
polychromophoric system is present with the benzene and oxadiazole chromophore in 
(64). The CD spectrum of (64) can thus be viewed as an exciton couplet with positive 
chirality and a maximum at 2 2 0  nm.
In order to assign the sign of the CE couplet the dihedral angle between the individual 
electric dipole transition moments of the two chromophores must be established. For this
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reason semi-empirical methods (CNDO) were used to calculate the signs and orbital 
coefficients of the HOMO and LUMO of a model oxadiazole. Figure 62 shows the result. 
From the signs of the orbital coefficients the electric dipole transition moment can be 
determined.
•
è
Figure 62 HOMO (top) and 
LUMO (bottom) of model 
oxadiazole
NHBoc
NHBoc H
N-N
(-)-conformer (+)-conformer
Scheme 83 The equilibrium of two conformers of (5)-(64) when in solution.
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Figure 63 Minimised conformation (MM-2) 
level of (64) with dihedral angle of + 69
All CD spectra obtained for other hydrazide and oxadiazole derivatives with a benzyl 
protecting group synthesised follow the arguments above. They all show in a consistent 
fashion Cotton effects with identical signs for all the transitions mentioned above and 
allow the generalisation of the above findings.
Finally it is worth commenting on the CD spectra of the (5)-Ala derived hydrazide (66) 
and oxadiazole (67). The spectra are shown below (Figure 65 and 66). The hydrazide 
displays a negative Cotton effect at 230 nm. Similarly the oxadiazole displays bisignate 
curve with a negative Cotton effect at 230 nm accompanied by a maximum at 212 nm. 
Applying the benzene quadrant rule to (5)-Ala-oxadiazole (67) identifies NHBoc as the 
stronger perturber if compared to Me (Figure 64).
"  1^'
(S)-(67)
b
CH,
EtOOC bogHN
BocHNXCH l “o ' f CH,EtOOC BocHN
Figure 64 Analysis of (5)-(67) using the benzene quadrant rule
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Ala-Hydrazide (66)
20
200 220 240 280 3Ô0
w -10Q>
15  -20
-30
" 5 " B
(S )-(6 6 )
-40
-50
[nm]
Figure 65 CD spectrum of (5)-(66) 0.1 mM in MeOH.
Ala-Oxadiazole (67)
200 220 240 260 280 3Ô0
O)Q)
" OE
(S )-(6 7 )
[nm]
Figure 66 CD spectrum of (S)-(67) 0.1 mM in MeOH.
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Experimental
General Experimental
All procedui'es were earned out under N2(g) except those indicated with 
All NMR experiments were canied out on a Brulcer DRX 500 or a Bruker DPX 300 
spectrometer, using CDCI3 as the solvent (except where stated otherwise). 5 values are 
quoted relative to tetrainethylsilane (5h 0.00 ppm), chloroform (Ôh 7.26 ppm), 
dimethylsulfoxide (5h 2.50) or methanol (Ôh 3.31) for NMR and relative to chlorofoim 
(Ôc 77.23 ppm) for NMR.^"  ^Coupling constants / are m Hz. All signal assignments are 
based on ^H-^H COSY and HSQC spectra, and also where appropriate on
HMBC spectra.
All Cl and El MS (with the exception of GCMS) analyses were canied out on a Theimo 
Fimiigan MAT95XL double focusing spectrometer.
All GCMS analyses were carried out using a Hewlett Packard G1800 A GCD, which 
consists of a GC capillaiy colunni (25m, 0.22mm internal diameter and 0.25pm film 
thiclmess, BPx5 bonded phase fused silica), coupled to a quadruple El mass spectrometer. 
All LCMS and ESI MS (except (85) and (87)) were canied out using an Agilent 1100s, 
which consists of an LC column (Supelco Discovery, Cl 8 silica, diameter 3mm, length 
5cm, 5 micron packing) (Coluimi conditions; 7 minutes nm time 4minutes gradient and 3 
minutes hold. Solvents water and acetonitiile both containing 0.04% fonnic acid.
Gradient 95% water to 95% Acetonitiile. Flow rate 0.8 ml / minute), coupled to an ESI 
(+ve or -ve) mass spectrometer.
ESI MS for (85) and (87) were recorded using a Theimofimiigan DECAQPlus 
spectrometer.
All IR analyses were canied out on a Perkin-Elmer 2000 FT-IR spectrometer, with the 
product pure between KBr plates (except where stated otherwise).
Thin layer chromatography (TEC) was canied out on commercially available pre-coated 
plates (Merck Kieselgel 60 F254 silica) using the solvent system stated: Flash column 
chromatogiaphy at a pressure of 1 bar was carried out on Merck Kieselgel 60 (230-400 
mesh) silica.
CD spectra were recorded using an Applied Photophysics Chirascan spectrometer using 
10mm quartz cuvettes.
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Elemental analyses were carried out using a Leeman CE 440 automatic elemental 
analyser.
Melting points were detemiined on a Kofler hotstage appamtus and are imcoiTected. 
Optical rotations were determined on a Bellingham and Stanley ADO 220 polaiimeter. 
Optical rotations are given in 10'  ^ deg cm^ g'  ^ and were detemiined at two concentiations. 
Pet. Ether refers to petrolemn ether (bp. 40-60 C).
5-Trifluoromethanesulfonylamino-peiitaiioic acid (2,2-diethoxy-ethyl)-amide, (31)
Pyiidine (0.4ml, 0.396g, 5mmol) was added to a solution of piperidin-2-one (0.496g, 
5mmol) in DCM (100ml) in a 3-necked flask and the mixtme was cooled to -46°C. Triflic 
anliydride (0.85ml, 1.411g, 5mmol) was added and the mixtuie stirred for 2 houis at 
-46°C, then for 30 minutes at room temperature. The solution was cooled to -46°C and 
amino acetaldehyde diethylacetal (0.75ml, 0.665g, 5.02mmol), pyridine (0.4ml, 0.396g, 
5mmol) and DCM (100ml) were added and the solution stmed for 30 minutes at -46°C, 
then overnight at room temperatuie. A satmated solution of NaHCOa (aq) (220ml) was 
added and the organic phase separated, then the product extiacted fi'om the aqueous phase 
with DCM (3 X 100ml). The combined organic phase was washed with water (100ml) and 
the organic phase separated, then the product extracted from the aqueous phase with 
DCM (3 X 100ml). The combined organic phase was diied (MgSO#), filtered through 
Celite and the solvent evaporated in vacuo to give a red/orange liquid (1.39g). This 
product contained pyridine by TEC so was dried under high vacuum at 30°C for 2 houis. 
Tills removed all the pyiidine (new mass=E09g). TEC and NMR of this cmde product 
showed a mixtui e of products, but the NMR showed peaks that appeared indicative of the 
desired product. The cmde product was absorbed on 4g silica, then separated by column 
chi'omatography (16.35g silica, first 255ml = Pet. Ether:AcOEt 60:40, second 170ml = 
Pet. Ether:AcOEt 55:45, third 102ml = Pet. Ether:AcOEt 30:70, fourth 425ml = AcOEt, 
fifth 755ml = AcOEt:MeOH 97:3), to give two main products. The solvent was
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evaporated in vacuo firom the least polar product to give 1-Trifluoromethanesulfonyl- 
piperidin-2-oiie, (30) as a yellow liquid (0.592g, 51.2%).
( 3 0 )
One spot by TLC, Rf 0.6 (Pet ether:AcOEt 55:45); (Found: C, 30.5%; H, 3.45%; N, 5.8%. 
CeHsFsNOaS requires C, 31.2%; H, 3.5%; N, 6.1%); Vmax (neat)/cm'^ 1739 (C=0 stretch 
of 3° amide), 1402 (SO2 asymmetric stietch), 1226 (CF3), 1136 (SO2 symmetric stretch); 
ÔH (500MHz, CDCI3): 3.85 (2H, t, J 6 .0 , CH2N), 2.60 (2H, t, J6 .7 , CH2CO), 1.92 (4H, m, 
C7Z2CH2N, % C H 2CO); Sc (125MHz, CDCI3): 170.62 (CO), 119.86 (q, J324 , CF3),
49.33 (CH2N), 34.56 (CH2CO), 23.10 (CH2CH2N), 20.20 (CH2CH2CO); Sn (50.7MHz, 
CDCI3): 150.3; m/z (El) 231 (M ^, 175 (C3H4F3NO2S), 162 (CH2NSO2CF3 + H), 69 
(CF3).
The solvent was evaporated in vacuo from the more polar product to give the title 
compound (31) as a yellow oil (0.18g, 9.9%). One spot by TLC, Rf 0.6 (AcOEt); (Found: 
C, 39.7%; H, 6 .8%; N, 7.3%. C12H2 3F3N2 O5S requires C, 39.6%; H, 6.4%; N, 7.7%,); v^ax 
(neat)/cm'^ 3313 and 3099 (NH stretch of 2° amide), 2887 (C-H stretch in ether), 1652 
(C=0 stretch of 2° amide), 1541 (NH bend of 2° amide), 1447 (CH2 scissoring bend),
1375 and 1149 (-SO2NH-), 1230 and 1190 (CF3), 1074 (CF3 and C-O stretch in ether); Sh 
(500MHz, CDCI3): 7.20 (IH, bs, NHTf), 5.97 (IH, bs, NHCO), 4.49 (IH, t, J5 .0 , CH), 
3.69 (2H, m, CH3CFZ2), 3.53 (2H, m, CHgCH^'), 3.36 (2H, t, J5 .4 , CHCT^NH), 3.27 (2H, 
m, CTTzNHTf), 2.24 (2H, t, J7.0, COCH2), 1.72 (2H, m, COCH2CB2), 1.64 (2H, m, 
CÆ2CH2N), 1.20 (6H, t, J7 .0 , CH3); Sc (125MHz, CDCI3): 173.30 (CO), 119.74 (q, J  
321, CF3), 100.35 (CH), 62.83 (CH3CH2), 43.50 (CHzNHTf), 41.85 (CHCH2NH), 35.20 
(COCH2), 29.20 (CH2CH2N), 21.72 (COCH2CH2), 15.07 (CH3); m/z (Cl): 365 =M ^ + H, 
364 = M% 319 = M'"-  OEt, 250 = M"" -  O E t-  CF3, 2 3 1 = M "-T f.
l-TrifluoromethanesuIfoiiyl-piperidiii-2-one, (30)
Pyiidine (0.32ml, 0.316g, 4mmol) was added to piperidin-2-one (0.397g, 4mmol) and 
DCM (20ml) in a 3-necked flask and the mixture was cooled to -40°C. Triflic anhydride
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(0.67ml, 1.129g, 4mmol) was added aiid the mixtme stirred for 2 horns at -40°C. A 
satmated solution of NaHCOs (aq) (80ml) was added and the organic phase sepaiated, 
then the product extiacted from the aqueous phase with DCM (3 x 20ml). The combined 
organic phase was washed with water (40ml), and the organic phase separated, then the 
product extracted from the aqueous phase with DCM (3 x 20ml). The combined organic 
phase was dried (MgS04), filtered tlirougli Celite and the solvent evaporated in vacuo to 
give a yellow liquid. Tills contained pyiidine by TLC and so was put under high vacuum 
at 50°C for 2 hours to give the title compound (30) as a yellow liquid (0.593g, 64.1%). 
One spot + small hnpurity by TLC, Rf 0.6 (Pet ether:AcOEt 55:45); vmax (neat)/cm‘^  
1739 (C=0 stretch of 3° amide), 1402 (SO2 asymmetric stietch), 1226 (CF3), 1136 (SO2 
symmetric stretch); 8» (500MHz, CDCI3): 3.80 (2H, t, J6 .0 , CH2N), 2.55 (2H, t, J6 .7 , 
CH2CO), 1.87 (4H, m, CTTzCHzN, C ^ C H 2C0 ).
NMR variable tem perature experiment 1
NH NH
(32) (33)
Piperidin-2-one (0.018g, 0.186imiiol) dissolved in CDCI3 (1ml) in an NMR tube was 
cooled to about -70°C. Triflic anliydride (0.031ml, 0.052g, 0.186mmol) was added, the 
tube was shaken and NMR experiments were perfoiined at -60°C, -45°C, -30°C and at 
room temperature. The sample was then stored in a refrigerator overnight at +4°C. A 
NMR of the sample was recorded at room temperatme. 2 products were shown in each 
NMR experiment, but these ai e reported separately in this section for ease of reading.
(32): NMR 5h (500MHz, CDCI3): 12.70 (bs, IH, NH^, 3.93 (2H, bs, CH2N), 3.17 (2H, 
bs, CH2CO), 2.13 (2H, bs, C7/2CH2CO), 2.05 (2H, bs, C7Z2CH2N).
(33): NMR 8h (500MHz, CDCI3): 13.25 (IH, bs, OH), 9.95 (IH, bs, NH), 3.58 (2H, bs, 
CHzN), 2.76 (2H, bs, CH2CO), 1.94 (4H, bs, CT^CHgCO, CH2CH2N).
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NMR variable temperature experiment 2
Piperidin-2-one (0.018g, 0.186mniol) dissolved in CDCI3 (1ml) in an NMR tube was 
cooled to about -70°C. Triflic anliydiide (0.031ml, 0.052g, 0.186mmol) was added, the 
tube was shaken and the NMR of the sample was recorded at room temperature. 
Pyiidine (0.015ml, 0.015g, 0.186nmiol) was added, the tube was shaken and a NMR 
experiment was performed at -40°C. The spectrum showed little change from before the 
pyiidine addition and showed very little free pyiidine, so the tube was shaken vigorously 
to get full mixing of reagents. A NMR experiment was performed at -20°C straight 
away (without shhnming sample), then 15 minutes later (after shmmiing). The sample 
was stored overnight at room temperature, then the NMR was recorded at room 
temperature.
Attempted Synthesis of 2-(3,4,5,6-Tetrahydro-pyridin-2-ylsulfanyl)-ethylamine
Piperidin-2-one (0.129g, 1.3mmol) was dissolved in DCM (7ml) in a 3-necked flask and 
the mixture was cooled to -40°C. Triflic anhydride (0.219ml, 0.366g, 1.3mmol) was 
added and the mixture stirred for 1 hoiu 45 minutes at -40°C. 2-amino-ethanethiol 
hydi'ochloiide (0.148g, l.Smmol) and DCM (7ml) were added, then pyridine (0.105ml, 
0.103g, 1.3mmol) was added slowly over 10 minutes. The reaction was stirred for 1 hour 
at -40°C, then overnight at room temperatme. A saturated solution of NaHCOs (aq) 
(30ml) was added and the organic phase sepaiated, the product extracted from die 
aqueous phase with DCM (3 x 10ml). The combined organic phase was extracted with a 
satmated solution of NaHCOs (aq) (30ml) and the organic phase sepaiated, then the 
product extiacted from the aqueous phase with DCM (3 x 10ml). The combined organic 
phase was washed with water (20ml) and the organic phase separated, then the product 
exhacted fi'om the aqueous phase with DCM (3 x 10ml). The combined organic phase 
was dried (MgS04), filtered tluough Celite and the solvent evaporated in vacuo to give a 
yellow/orange oil (0.072g). This contained pyridine by NMR so was put imder high 
vacuum at 40°C for 1 horn* 50 minutes to give a brown/orange oil (0.017g). This was 
found to be a 19:8:1 mixtme of the N-tiiflated imide (30), piperidin-2-one and a very 
small quantity of 5-Trifluoroniethanesulfonylamino-pentanethioic acid S-(2-amino-ethyl) 
ester (34), by NMR, so was not purified ftirther.
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General procedure for attempted synthesis of 3-Ethoxy-2,3,5,6,7,8-hexahydro 
imidazo[1,2-a]pyridine, (29), using DBU as an alternative base to pyridine and with 
various activating agents
(Number of equivalents of DBU and type of activation agents used are shown in Table 4). 
n equivalents o f DBU (n eg. for Immol: 0.149ml, 0.152g, Immol) were added to 
piperidin-2-one (0.099g, Immol) and DCM (5ml) m a reaction vessel and the mixture was 
cooled to -42°C. Activating agent was added (according to Table 4, page 67) and the 
mixtuie stiixed for 10 minutes at -42°C. DBU (0.149ml, 0.152g, Immol), amino 
acetaldehyde diethylacetal (0.145ml, 0.133g, Immol), and DCM (5ml) were added and 
the solution stirred for 2 hours at -42°C, then overnight at room temperature. A satur ated 
solution of NaHCOa (aq) (20ml) was added, the organic layer separated and the product 
extracted with DCM (3 x 5ml). The organic layers were mixed and washed with water 
(10ml), the organic layer separated and the product extracted with DCM (3 x 5ml). The 
organic layers were mixed and dried (MgS04), filtered thr ough Celite and the solvent 
evaporated in vacuo. (Refer to Table 4, page 67, for results).
5-TnfluoromethanesulfonyIammo-pentanoic acid (2,2-dimethoxy-ethyl)-amide, (38)
- y
Pyiidine (0.105ml, 0.103g, 1.3mmol) was added to a solution of piperidin-2-one (0.129g, 
1.3mmol) in DCM (7ml) m a 3-necked flask and the mixture was cooled to -46°C. Triflic 
anhydride (0.219ml, 0,366g, 1.3nmiol) was added and the mixture stirred for 2 horns at 
-46°C. Pyridine (0.105ml, 0.103g, 1.3mmol), amino acetaldehyde dimethylacetal 
(0.143ml, 0.137g, 1.3mmol), and DCM (7ml) were added and the solution sthred for 1.5 
hours at -46°C, then overnight at room temperatme. A saturated solution of NaHCOa (aq) 
(30ml) was added, the organic phase separated, then the product extracted from the 
aqueous layer with DCM (3 x 10ml). The combined organic phase was extracted with a 
saturated solution of NaHCOs (aq) (30ml), the organic phase separated and the product 
extiacted fi'om the aqueous phase with DCM (3 x 10ml). The combined organic phase
147
was washed with water (20ml), the organic phase separated and the product extiacted 
from the aqueous layer with DCM (3 x 10ml). The combined organic phase was diied 
(MgS04 ), filtered through Celite and the solvent evaporated in vacuo to give a 
brown/orange oil. This contained pyiidine by TLC and NMR so was put under high 
vacuum at 40°C for 1 horn to give a brown/orange oil (0.206g). TLC and NMR of this 
crude product showed a mixtme of 3 products. The cmde product was absorbed on 2.3g 
silica, then separated by column chromatography (9.2g silica, first 187ml = Pet.
Ether;AcOEt 40:60, second 220ml = AcOEt, third 555ml = AcOEt:MeOH 97:3, fourth 
400ml = AcOEt:MeOH 95:5), to give two main products. The solvent was evaporated in 
vacuo fiom the least polar product to give (30) as a yellow oil (0.018g, 6.0%). Vmax 
(neat)/cm‘^  1737 (C=0 stretch of 3° amide), 1403 (SO2 asymmetric stretch), 1225 (CF3), 
1134 (SO2 symmetric stretch); Ôh (500MHz, CDCI3): 3.89 (2H, t, J6 .0 , CH2N), 2.65 (2H, 
t, J6 .7 , CH2CO), 1.95 (4H, m, CH2CH2K  CH2CE.2CO).
The solvent was evaporated in vacuo from the more polar product to give the title 
compomid (38) as a clear, colourless oil (0.15 Ig, 34.5%). (Found: C, 34.9%; H, 5.6%; N, 
8.35%. C10H19F3N2O5S requires C, 35.7%; H, 5.7%; N, 8.3%); Vmax (neat)/cm'^ 3432,
3318 and 3091 (NH stretch of 2° amide), 2946 (C-H stretch in ether), 1651 (C=0 stietch 
of 2° amide), 1547 (NH bend of 2° amide), 1461 (CH2 scissoring bend), 1373 and 1150 
(-SO2NH-), 1231 and 1192 (CF3), 1077 (CF3 and C-O stretch in ether); Ôh (500MHz, 
CDCI3): 7.45 (IH, bs, NHTQ, 6.14 (IH, bs, NHCO), 4.38 (IH, t, J5 .0 , CH), 3.38 (8H, m, 
CHCH2, CH(OCi73)2), 3.28 (2H, m, C%NHTf), 2.26 (2H, t, 77.1, NCOCH2), 1.72 (2H, 
m, NCOCH2C7Ï2), 1.64 (2H, m, CT^CHgN); Ôc (125MHz, CDCI3): 173.70 (CO), 120.01 
(q, 7322, CF3), 102.64 (CH), 54.53 (CH3), 43.74 (CHzNHTf), 41.09 (CHCH2), 35.42 
(NCOCH2), 29.42 (NCOCH2CH2), 22.07 (CH2CH2N); m/z (Cl): 337 (M" + H), 306 (M^ -  
OEt +H ),305 (M ^-O E t).
5-Trifluorometliaiiesulfoiiylamino-pentanethioic acid S“(2-amiiio-ethyl) ester, (34)
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Piperidin-2-one (0.397g, 4mmol) in DCM (20ml) was cooled to -40°C in a 3-necked 
flask. Triflic anhydride (0.673ml, 1.129g, 4mmol) and pyiidine (0.323ml, 0.316g, 4mmol) 
were added and the mixtme stiiTed for 2 horns 15 minutes at -40°C. A solution of 2- 
amino-ethanethiol hydrochloride (0.454g, 4mmol) and pyiidine (0.646ml, 0.632g,
Simnol) in DCM (20ml) was added to the reaction which was then stirred for 1 hour at 
-40°C, then overnight at room temperatm e. A satmated solution of NaHCOs (aq) (60ml) 
was added, the organic phase separated and the product extracted hom the aqueous phase 
with DCM (3 X 20ml). The combined organic phase was washed with water (40ml), the 
organic phase separated and the product extracted fiom the aqueous phase with DCM (3 x 
20ml). The combined organic phase was dried (MgS04), filtered thi'ough Celite and the 
solvent evaporated in vacuo to give a yellow/orange liquid. Tliis contained pyridine by 
TLC as well as 5 other products. NMR showed 3 major products, 1 o f which was 
pyiidine. This crude product was absorbed on 1.79g silica, then separated by column 
clnomatogiaphy (10.22g silica, first 544ml = DCM, second 417ml = DCMiMeOH 98:2, 
third 400ml = DCM:MeOH 95:5), to give two main products. The solvent was evaporated 
in vacuo from the least polar product to give (30) as a yellow liquid (0.046g, 5.0%).
Vmax (neat)/cm‘* 1739 (C= 0  stietch of 3° amide), 1402 (SO2 asymmetric stretch), 1236 
(CF3), 1139 (SO2 symmetiic stretch); 6h (500MHz, CDCI3): 3.89 (2H, t, 76.0, CH2N), 
2.64 (2H, t, 76.6, CH2CO), 1.95 (4H, m, CF^CHgN, C7&CH2CO).
The solvent was evaporated in vacuo fiom the more polar product to give the title 
compomid (34) as a pale yellow oil (0.072g, 5.6%). One spot by TLC, Rf 0.1 
(DCM:MeOH 95:5); Ôh (500MHz, CDCI3): 8.20 (IH, bs, NHTf), 6.62 (2H, bs, NH2), 3.41 
(2H, m, NH2CÆ2), 3.25 (2H, m, C ^N H Tf), 3.01 (2H, t, 76.3, CH28), 2.21 (2H, t, 77.2, 
SCOCH2), 1.73 (2H, m, SC0 CH2C ^ 2), L64 (2H, m, C ^ C H 2NHTf); ôc (125MHz, 
CDCI3): 199.80 (CO), 120.03 (q,7322, CF3), 43.69 (NH2CH2), 43.55 (CHgNHTf), 39.25 
(CH2S), 35.50 (SCOCH2), 28.85 (SCOCH2CH2), 22.49 (O Î2CH2NHTf); m/z (GCMS,
El): 308 (M%  232 (M"" -  SCH2CH2NH2), 204 (M^ -  COSCH2CH2NH2), 162 
(CH2NHSO2CF3).
Compound (34) was slightly impme by ^H NMR, so separation by colmnn 
chi omatogi aphy on alumina was attempted, but it was not stable on almnina. A review of 
the spectra for the cmde product and compoimd (34) suggest that it was also slightly 
imstable on silica.
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5-Trifluoromethaiiesulfonylamino-peiitanoic acid (2,2-diethoxy-ethyl)-ainide, (31)
(30) (0.150g, 0.648miiiol) in DCM (3.5ml) was cooled to -46°C in a 3-necked flask. 
Pyiidine (0.209ml, 0.205g, 2.594mmol), amino acetaldehyde diethylacetal (0.094ml, 
0.086g, 0.648mmol), and DCM (3.5ml) were added and the solution stiiTed for 30 
minutes at -46°C, then overnight at room temperatme. A satmated solution of NaHCOs 
(aq) (15ml) was added and the organic phase separated, then the product extracted from 
the aqueous phase with DCM (3 x 5ml). The combined organic phase was washed with 
water (10ml) and the organic phase sepaiated, then the product extracted from the 
aqueous phase with DCM (3 x 5ml). The combined organic phase was diied (MgS04), 
filtered through Celite and the solvent evaporated imder high vacuum at 55°C to give the 
title compound (31) as a yellow oil (0.212g, 89.8%). 5h (500MHz, CDCI3): 6.07 (2H, bs, 
NHTf, NHCO), 4.50 (IH, t, 75.0, CH), 3.70 (2H, m, CH3CH2), 3.55 (2H, m, CHgCTTz'), 
3.37 (2H, t, 75.4, CHCTTgNH), 3.28 (2H, m, CTfzNHTf), 2.25 (2H, t, 77.0, COCH2), 1.73 
(2H, m, COCH2C772), 1.65 (2H, m, C772CH2N), 1.21 (6H, t, 77.0, CH3); m/z (Cl); 365 = 
M"" + H, 364 = 319 = M* -  OEt, 250 = IVT -  OEt -  CF3. 231 = NT -  Tf.
5-TrifluoromethanesuIfonylamino-peiitanoie acid benzylamide, (39)
0 0II>rtr inF (39)
A solution of (30) (0.022g, 0.095mmol) and benzylamine (0.01ml, O.Olg, 0.095mmol) in 
DCM (10ml) was stiiTed in a 3-necked flask overnight at room temperatme. 3M HCl (aq) 
(10ml) was added and the organic phase separated, then the product extracted from the 
aqueous phase with DCM (3 x 5ml). The combined organic phase was exti'acted with 3M 
HCl (aq) (10ml) and the organic phase separated, then the product extracted firom the 
aqueous phase with DCM (3 x 5ml). The combined organic phase was dried (MgS04), 
filtered thiough Celite and the solvent was evaporated in vacuo to give the title compound 
(39) as a yellow/orange liquid (O.OlOg, 38.0%). Vmax (neat)/cm‘  ^ 3300 and 3068 (NH 
stretch of 2° amide), 1650 (C=0 stretch of 2° amide), 1538 (NH bend of 2° amide), 1456 
(CH2 scissoring bend), 1372 and 1148 (-SO2NH-), 1230 and 1192 (CF3), 1080 (CF3). Ôh
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(500MHz, CDCI3): 7.29 (5H, m, Ph), 6.93 (IH, bs, NHTf), 5.94 (IH, bs, NHCO), 4.41 
(2H, bs, PhCH2), 3.28 (2H, bs, C%NHTf), 2.26 (2H, bs, NCOCH2), 1.76 (2H, bs, 
NCOCH2C772), 1.65 (2H, bs, Ci/zCHjN); Sc (125MHz, CDCI3): 173.22 (CO). 138.02, 
129.02,128.03,127.91 (Ph), 120.05 (q, J322, CF3), 44.02 (PI1CH2), 43.78 (CH2NHTf), 
35.46 (NCOCH2), 29.58 (CH2CH2N). 21.83 (NCOCH2CH2); m/z (Cl); 339 (M+ + H).
5-Trifluoromethanesulfonylamino-pentanoic acid ethyl ester, (40)
A solution of (30) (0.0216g, 0.934mmol) and NaaCOs (0,04g, 0.377mmol) in EtOH 
(10ml) were stirred in a 3-necked flask overnight at room temperature. The solvent was 
evaporated in vacuo and the solid re-dissolved in DCM (10ml) and H2O (10ml) and the 
organic phase separated, then the product extracted h'om the aqueous phase with DCM (3 
X 10ml). The combined organic phase was dried (MgS04), filtered tluough Celite and the 
solvent evaporated in vacuo to give the title compound (40) as a yellow/brown oil 
(0.020g, 76.9%). One spot by TLC, Rf 0.9 (Pet. ether; AcOEt 30;70); (Found; C, 36.6%; 
H, 5.5%; N, 4.6%. C8H 14F3NO4S requires C, 34.7%; H, 5.1%; N, 5.05%); Vmax (neat)/cm'^ 
3238 (NH stretch of 2° amide), 2853 (C-H stretch in ether), 1378 and 1148 (-SO2NH-), 
1233 and 1193 (CF3), 1078 (CF3 and C-O stretch in ether). 5h (500MHz, CDCI3): 5.57 
(IH, bs, NH), 4.15 (2H, q, 77.1, CHgCT^), 3.31 (2H, m, CH2N), 2.37 (2H, t, 76,8, 
0 =CCH2), 1.72 (2H, m, 0 =CCH2C772), 1.66 (2H, m, C772CH2N), 1.27 (m, CH3); 6c 
(125MHz, CDCI3): 174.10 (C=0), 120.08 (q, 7321, CF3), 61.13 (CH3CH2), 44.21 
(CH2N), 33.67 (0 =CCH2), 30.01 (CH2CH2N), 21.48 (CMCCH2CH2), 14.51 (CH3); m/z 
(Cl); 278 (M+ + H), 232 (M^ -  OEt).
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(*S)-2-(5-TrifluorometIiauesulfoiiylainmo-peutanoylamiuo)-propionic acid ter/-butyl
ester, (41)
A solution of (30) (0.23 Ig, Immol) in DCM (5ml) was cooled to -40°C in a 3-necked 
flask. Pyiidine (0.08ml, 0.079g, limnol) and Z-alanine r-butyl ester hydrochloride 
(0.182g, Immol) were added and the solution stirred for 30 minutes at -40°C, then 
overnight at room temperature. A saturated solution of NaHCOa (aq) (20ml) was added, 
the organic phase separated and the product extracted hom the aqueous phase with DCM 
(3 X 5ml). The combined organic phase was washed with water (10ml), the organic layer 
separated and the product extracted fiom the aqueous phase with DCM (3 x 5ml). The 
combined organic phase was dried (MgSO#), filtered tluough Celite and the solvent 
evaporated in vacuo to give a yellow/orange oil. This contained pyridine by TLC and 
NMR so was put under high vacuimi at 55°C for 1.5 hours to give a pale yellow oil 
(0.336g). TLC and NMR of this crude product showed 2 main products, with 2 small 
impurities. The cmde product was absorbed on 1.176g silica, then sepaiated by column 
cluomatogiaphy (6.72g silica, first 70ml = Pet. Ether, second 270ml = Pet. Ether:AcOEt 
70:30, tliird 50ml = Pet. EtheriAcOEt 50:50, fourth 255ml = AcOEt), to give two main 
products. The solvent was evaporated in vacuo from the least polar product to give (30) as 
a yellow oil (0.029g, 12.6%). Ôh (500MHz, CDCI3): 3.89 (2H, t, 76.0, CH2N), 2.65 (2H, 
t, 76.7, CH2CO), 1.95 (4H, m, C772CH2N, C%CH2C0 ); m/z (GCMS, El): 232 (M" + H), 
231 (M*), 203 (CH2CH2CH2CH2NSO2CF3), 175 (CH2CH2NSO2CF3), 162 (M+ -  CF3), 69 
(CF3).
The solvent was evaporated in vacuo fiom the more polar product to give the title 
compound (41) as a clear, coloiuless oil (0.270g, 71.7%). [a f^  -49 .38  [c 0.08, CH2CI2, 
1-dl]; (Found: C, 41.4%; H, 6.3%; N 7.3%. C13H23F3N2O5S requires C, 41.5%; H, 6.2%; 
N, 7.4%); Vmax (neat)/cnT^ 3403 (NH stretch of amine), 3303 and 3093 (NH stretch of 2° 
amide), 2982 and 2881 (CH3), 2940 and 2830 (CH2), 1728 (C=0 stretch of ester), 1651 
(C=0 of 2° amide), 1536 (NH bend of acyclic 2° amide), 1371 and 1152 (-SO2NH-), 
1231, 1192 and 1081 (CF3); ôn (500MHz, CDCI3): 7.21 (IH, bs, NHTf), 6.34 (IH, d, 7
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7.3, CONH), 4.43 (IH, m, CH), 3.29 (2H, t, y  6.3, NHC%), 2.28 (2H, t, /7 .0 , CH2CO),
1.74 (2H, m, CH2CH2CO), 1.65 (2H, m, NHCH2CH2), 1.47 (9H, s, t-butyl), 1.36 (3H, d, J
7.2, CHCH3); 5c (125MHz, CDCI3): 172.84 (CHCO2), 172.78 (CH2CO), 120.04 (q ,/3 2 2 , 
CF3), 82.57 (0C(CH3)3), 48.89 (CH), 43.81 (NHCH2), 35.32 (CH2CO), 29.36 
(NHCH2CH2), 28.06 (0 C(CH3)3), 21.92 (CH2CH2CO), 18.47 (CHCH3); m/z (Cl); 377 
(M+ + H), 361 (M+ -  CH3), 321 (M" -  C(CH3)3 + 2H).
(»S)-2-(5-Trifluoromethanesulfonylamiiio-peiitaiioylammo)-l, 5-pentaiiedioic acid 
dimethyl ester, (42)
(42)
A solution of (30) (0.108g, 0.467inniol) in DCM (2.5ml) was cooled to -40°C in a 3- 
necked flask. Pyridine (0.038ml, 0.037g, 0.467mmol) and Z-gliitamic acid dimethyl ester 
hydrochloride (0,099g, 0.467mmol) were added and the solution stin*ed for 30 minutes at 
-40°C, then overnight at room temperature. A satmated solution of NaHCOs (aq) (10ml) 
was added, the organic phase separated and the product extracted from the aqueous phase 
with DCM (3 X 2.5ml). The combined organic phase was washed with water (5ml), the 
organic phase separated and the product extracted from the aqueous phase with DCM (3 x 
2.5ml). The combined organic phase was dried (MgS04), filtered tluough Celite and the 
solvent evaporated in vacuo to give a yellow/orange oil. This contained pyiidine by TLC 
and NMR so was put under high vacuum at 55°C for 2 horns to give a yellow/orange 
wax (0.112g). This crude product was absorbed on 0.39g silica, then separated by column 
cluomatography (2.5g silica, first 50ml = Pet. Ether, second 290ml = Pet. Ether:AcOEt 
70:30, third 136ml = Pet. Ether: AcOEt 60:40, fourth 250ml = AcOEt), to give two main 
products. The solvent was evaporated in vacuo fiom the least polar to give (30) as a 
yellow/orange oil (0.022g, 20.4%). Ôh (500MHz, CDCI3): 3.89 (2H, t, J6 .0 , CH2N), 2.65 
(2H, t, y  6.7, CH2CO), 1.95 (4H, m, CH2CH2N, CH2CH2CO); m/z (GCMS, El): 232 (M+ +
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H), 231 (M ^, 203 (CH2CH2CH2CH2NSO2CF3), 175 (CH2CH2NSO2CF3), 162 (M+ -  
CF3), 69 (CF3).
The solvent was evaporated in vacuo from the more polar* product to give the title 
compound (42) as a clear, colourless oil (0.080g, 42.2%). +11.63 [c 0.43, CH2CI2,
1-dl]; One spot by TLC, Rf 0.2 (Pet. ether:AcOEt 40:60); (Found C, 38.7%; H, 5.45%; N, 
6.4%. C13H21F3N2O7S requires C, 38.4%; H, 5.2%; N, 6.9%); Vmax (neat)/cm“^ 3278 and 
3089 (NH stretch of 2° amide), 2957 (CH2 asymmetric stretch), 2868 (CH2 symmetric 
stretch), 1741 (C=0 stretch of ester), 1653 (0= 0  stretch of 2° amide), 1538 (NH bend of 
acyclic 2° amide), 1440 (CH2 scissoring bend), 1374 and 1150 (-SO2NH-), 1230, 1188 
and 1080 (CF3); Ôh (500MHz, CDCI3): 6.72 (IH, bs, NHTf), 6.55 (IH, d, J7 .6 , CONH), 
4,59 (IH, rn, CH), 3.76 (3H, s, CBCOiCH^X 3.69 (3H, s, CHgCOzC^), 3.30 (2H, t, J6 A , 
NHCTTz), 2.41 (2H, rn, CH2CO2), 2.31 (2H, t, J6 .9 , C772CONH), 2.19 (IH, m, CHC%), 
2,02 (IH, rn, C H C ^ ') , 1.75 (2H, rn, C772CH2CONH), 1.65 (2H, m, NHCH2C7Z2);
ÔC (125MHz, CDCI3): 173.81 (CHCO2), 173.40 (CH2CO2), 172.65 (CONH), 120.04 (q, J  
321, CF3), 52.83 (CHCO2CH3), 52.19 (CH2CO2CH3), 52.02 (CH), 43.80 (NHCH2), 35.22 
(CH2CONH), 30.28 (CH2CO2), 29.32 (NHCH2CH2), 27.04 (CHCH2), 21.82 
(CH2CH2CON); m/z (Cl): 408 (M+ + 2H), 407 (M" + H), 375 (M"" -  OMe).
(iS)-l“(5-Trifluoromethanesulfonylammo-peiitanoyl)-pyiTolidiiie-2-carboxyIic acid 
benzyl ester, (43)
(43)
NH
A solution of (30) (0.108g, 0.467rmnol) in DCM (2.5rnl) was cooled to -40°C in a 3- 
necked flask. Pyridine (0.038rnl, 0.037g, 0.467mrnol) and L-prolme benzyl ester
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hydrochloride (0.113g, 0.467mniol) were added and the solution stirred for 30 minutes at 
-40°C, then overnight at room temperature. A saturated solution of NaHCOs (aq) (10ml) 
was added, the organic phase separated and the product extracted from the aqueous phase 
with DCM (3 X 2.5ml). The combined organic phase was washed with water (5ml), the 
organic phase separated and the product extracted fr om the aqueous phase with DCM (3 x 
2.5ml). The combined organic phase was dried (MgS04), filtered tluough Celite and the 
solvent evaporated in vacuo to give a yellow/orange oil. Tliis contained pyridine by TLC 
and ^H NMR so was put mrder high vacumn at 55°C for 2 horns to give a yellow/orange 
oil (0.165g). The crude product was absorbed on 0.5g silica, then purified by column 
chromatography (3.75g silica, first 25rnl = Pet. Ether, second 170rnl = Pet. Ether:AcOEt 
90:10, third 50rnl = Pet. Ether:AcOEt 70:30, fomih 188rnl = Pet. Ether:AcOEt 40:60, fifth 
136rnl = AcOEt, sixth 519ml = AcOEt:MeOH 97:3), and the solvent evaporated in vacuo 
to give a clear, coloiuless oil (0.130g, 63.8%). This was crystallised from DCM, then the 
solid washed with hexane on a sintered filter fimnel to give the title compoimd (43) as a 
fine wlrite powder (0.1 lOg, 54.0%). A variable temperature ^H NMR was performed 
because the product exists as two rotamers (A + B). Mp 80° -  82°C; [ a f j  -  41.67 [c 0.12, 
CH2CI2, 1-dl]; One spot by TLC, Rf 0.4 (Pet. ether:AcOEt 40:60); Vmax (nujol mull)/crn‘  ^
3110 (NH stretch of 2° amide), 1740 (C=0 stretch of ester), 1630 (C=0 stretch of 2° 
amide), 1456 (CH2 scissoring bend), 1376 and 1159 (-SO2NH-), 1232, 1182 and 1065 
(CPs), 757 and 706 (oop bend of aromatic ring CH); Ôh (500MHz, d^-DMSO, 298K): 
(ratio rotamer A:B = 1:4) 9.33 (IH, bs, NH [A+B]), 7.34-7.39 (5H, m, Ph [A+B]), 5.18 
(2H, bs, OCH2 [B]), 5.11 (2H, rn, OCH2 [A]), 4.66 (IH, m, CH [B]), 4.34 (IH, rn, CH
[A]), 3.52 (2H, rn, CONCH2 [A + B]), 3.13 (2H, bs, NRCH2 [A]), 3.08 (2H, bs, NHC.%
[B]), 2.30 ( 2H, m, CH2CO [A]), 2.23 ( 2H, m, CH2CO [B]), 2.18 (2H, m, Ci72CH [A]), 
2.06 (2H, m, CTfiCH [B]), 1.91 (2H, rn, CH2CH2CB. [A]), 1.84 (2H, rn, CT^CHzCH [B]), 
1.52 (4H, bs, C772CH2CO, NHCH2C7Z2 [A]), 1.44 (4H, m, C7^CH2C0, NHCH2CE2 [B]); 
NMR ÔH (500MHz, d^-DMSO, 423K): 8.61 (IH, bs, NH), 7.32-7.38 (5H, m, Ph), 5.15 
(2H, bs, OCH2), 4.48 (IH, rn, CH), 3.55 (2H, m, CONCH2), 3.16 (2H, bs, N H C ^), 2.28 
(2H, rn, CH2CO), 2.23 (2H, m, Cl^CH), 1.94 (2H, bs, C772CH2CH), 1.61 (4H, bs, 
C772CH2CO, NHCH2C%); 6c (125MHz, CDCI3, 298K): 172.34 (CO [A]), 135.85 (CO 
[A]), 172.10 (CO [B]), 135.38 (CO [B]), 128.36 -  128.98 (Ph [A + B]), 120.14 (q, /3 2 0 , 
CF3 [A+B]), 67.66 (OCH2 [B]), 67.15 (OCH2 [A]), 59.78 (CH [B]), 59.15 (CH [A]),
47.34 (OCNCH2 [A]), 46.84 (OCNCH2 [B]), 43.66 (NHCH2 [A + B]), 33.52 (CH2CO
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[A]), 33.37 (CH2CO [B]), 31.59 (NHCH2CH2 [B]), 29.58 (CHCH2 [B]), 29.49 
(NHCH2CH2 [A]), 29.34 (CHCH2 [A]), 24.94 (CHCH2CH2 [A]), 22.72 (CHCH2CH2 [B]),
20.74 (CH2CH2CO [B]), 20.57 (CH2CH2CO [A]); Foimd (CI): 437.1360 (M+ + H), 
C18H24F3N2O5S requires 437.1353; m h  (CI): 438 (M* + 2H), 437 (M* + H), 301 (M* -  
CO2CH2PI1).
(»S)-3-Phenyl-2-(5-trifluoromethanesulfonylamiiio-pentanoylammo)"l-propioiiic acid 
methyl ester, (44)
(44)
Pyridine (0.070ml, 0.068g, 0.865mmol) was added to a solution of (30) (0.2g,
0.865nimol) in DCM (2ml) in a reaction vessel and the mixture was cooled to -42°C. 7,- 
phenylalanine methyl ester hydrochloride (0.205g, 0.952mmol) was added and the 
solution stiiTed for 30 minutes at -40°C, then overnight at room temperature. A saturated 
solution of NaHCOs (aq) (17.5ml) was added, the organic phase separated and the product 
extracted fi'oni the aqueous phase with DCM (3 x 4ml). The combined organic phase was 
washed with water (8ml), the organic phase separated and the product extracted from the 
aqueous phase with DCM (3 x 4ml). The combined organic phase was dried (MgSÜ4), 
filtered thiough Celite and the solvent evaporated in vacuo to give a yellow liquid. This 
contained pyridine by TLC so it was evaporated using a Genevac EZ-2 at 52°C on setting 
“med b.p.” for 1.5 houis to give the title compound (44) as a yellow oil (0.35g, 98.6%).
+22.22 [c 0.18, CH2CI2,1-dl]; (Found C, 48.25%; H, 5.4%; N, 6.7%. 
C16H21F3N2O5S requires C, 46.8%; H, 5.2%;N, 6 .8%); Vmax (neat)/cni* 3298 and 3066 
(NH stretch of 2° amide), 2955 (CH2 asymmetric stretch), 2879 (CH2 symmetric stretch), 
1742 (C=0 stretch in aliphatic ester), 1652 (C=0 stretch of 2° amide), 1532 (NH bend of 
2° amide), 1439 (CH2 scissoring bend), 1373 and 1149 (-SO2NH-), 1230,1191 and 1081 
(CF3), 746 and 702 (oop bend of aromatic ring CH); NMR Ôh (500MHz, d^-DMSO, 
298K); (ratio rotamer A:B = 1:4) 8.29 (IH, d, J7 .8 , N7TCH [A +B]), 7.17 -  7.29 (5H, m,
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Ph [A +B]), 6 -  7.1 (IH, bs, NHTf [A +B]), 4.46 (IH, m, CH [A +B]), 3.59 (3H, s, CHj 
[A]), 3.58 (3H, s, CHj [B]), 3.07 (3H, t, J 6 .8, NHC%  [A +B]), 3.02 (IH, d of d, J5 .4 , 
13.7, CHîPh’ [A]), 2.87 (IH, d of d, J 9 .7 ,13.7, CH^Ph [A], CHzPh' [B]), 2.79 (IH, d of 
d, J 7 .2 ,13.4, CHzPh [B]), 2.07 (2H, m, CH2CO [A +B]), 1.44 (2H, m, CTTiCHiCO [A + 
B]), 1.36 (2H, m, NHCH2CH2 [A + B]); NMR 6» (500MHz, d®-DMSO, 398K): 7.66 (IH, 
bs, NHCH), 7.17 -  7.26 (5H, m, Ph), 5.9 -  6.5 (IH, bs, NHTf), 4.55 (IH, ra, CH), 3.60 
(3H, s, CH3), 3.09 (2H, t, J6 .3 , NHC%), 3.04 (IH, d of d, J5 .9 , 14.0, CHjPh’), 2.92 (IH, 
d o fd , J8 .4 , 14.1, CHzPh), 2.10 (2H, m, CH2CO), 1.49 (4H, m, C^CHgCO, 
NHCH2C7Ï2); 5c (75.5MHz, CDCI3): 172.61 (CO[A+B]), 172.30 (CO[A+B]), 137.20, 
135.69,129.28, 129.16,128.72, 128.61, 127.28,126.88 (Ph [A+B]), 119.81 (q, J321 , CF3 
[A+B]), 55.81 (CH [B]), 53.07 (CH [A]), 52.53 (CH3 [A]), 52.00 (CH3 [B]), 43.49 
(NHCH2 [A+B]), 41.11 (CHCH2 [B]), 37.76 (CHCH2 [A]), 34.84 (CH2CO [A+B]), 28.97 
(NHCH2CH2 [A+B]), 21.26 (CH2CH2CO [A+B]); LCMS: 100% purity on LC, m/z (ESI): 
449 (M+ + K), 433 (M+ + Na),411 (M+ + H).
(iS)-4-MethyI-2-(5-trifluoromethaiiesulfoiiylamino-pentanoylammo)-l-pentanoic acid 
methyl ester, (45)
O
(45) O
Pyridine (0.070ml, 0.068g, 0.865mmol) was added to a solution of (30) (0.2g, 
0.865mmol) in DCM (2ml) in a reaction vessel and the mixture was cooled to -42°C. L- 
leucine methyl ester hydrocliloride (0.173g, 0.952nunol) was added and the solution 
StiiTed for 30 minutes at -40°C, then overnight at room temperatui'e. A satmated solution 
of NaHCOs (aq) (17.5ml) was added, the organic phase separated and the product 
extracted from the aqueous phase with DCM (3 x 4ml). The combined organic phase was 
washed with water (8ml), the organic phase separated and the product extracted fr om the 
aqueous phase with DCM (3 x 4ml). The combined organic phase was dried (MgS04), 
filtered tlirough Celite and the solvent evaporated in vacuo to give a yellow liquid. This
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contained pyiidine by TLC so it was evaporated using a Genevac EZ-2 at 50°C on setting 
“med b.p.” for 2 hoius to give the title compound (45) as a yellow oil (0.298g, 91.6%).
+ 9.09 [c 0.11, CH2CI2, 1-dl]; One spot by TLC, Rf 0.2 [Heptane:AcOBt 50:50]; 
Vmax (neat)/cm'^ 3289 and 3085 (NH stretch of 2° amide), 2961 (CH2 asymmetric stretch), 
2872 (CH2 symmetric stretch), 1733 (C=0 stretch in aliphatic ester), 1650 (C=0 stretch 
of 2° amide), 1536 (NH bend of 2° amide), 1440 (CH2 scissoring bend), 1373 and 1149 
(-SO2NH-), 1261 (C-C(=0)-0 stretch of ester), 1230,1188 and 1081 (CF3); Ôh (500MHz, 
CDCI3): 6.56 (IH, bs, NHTf), 5.94 (IH, d, J8 .1 , CONH), 4.61 (IH, m, NHCiT), 3.75 (3H, 
s, OCH3), 3.30 (2H, m, NHCHg), 2.31 (2H, t, J6 .7 , CH2CO), 1.80 (2H, m, C772CH2CO), 
1.66 (4H, m, NHCH2C %  CHCH2, Ci7(CH3)2), 1.54 (IH, m, CHCHg'), 0.94 (6H, m, 
CH(CH3)2); 6c (125MHz, CDCI3): 174.20 (CO2CH3), 173.19 (CONH), 119.99 (q, J321, 
CF3), 52.72 (OCH3), 51.05 (NHCH), 43.72 (NHCH2), 41.48 (CHCH2), 35.04 (CHgCO), 
29.92 (NHCH2CH2), 25.14 (CH(CH3)2), 22.99 (CHCH3), 21.99 (CHCH3’). 21.59 
(NHCH2CH2CH2); Found (Cl) 377.1353 (M+ + H), C13H24F3N2O5S requires 377.1353; 
m/z (Cl) 377 (M" + H), 345 (M+ -  OMe), 317 (M*^  -  COzMe); LCMS: 100% purity on 
LC, m/z (ESI): 377 (M"" + H), 399 (M" + Na), 415 (M^ + K).
(,S)~3-Methyl-2-(5“trifluoromethanesuIfonylamino-peiitaiioyIammo)-l-butyric acid 
methyl ester, (46)
Pyiidine (0.070ml, 0.068g, 0.865imnol) was added to a solution of (30) (0.2g,
0.865mmol) in DCM (2ml) in a reaction vessel and the mixture was cooled to -42°C. L~ 
valine methyl ester hydi'ochloiide (0.160g, 0.952imnol) was added and the solution stirred 
for 30 minutes at -40°C, then overnight at room temperatme. A saturated solution of 
NaHCOs (aq) (17.5ml) was added, the organic phase separated and the product extiacted 
from the aqueous phase with DCM (3 x 4ml). The combined organic phase was washed 
with water (8ml), the organic phase separated and the product extracted from the aqueous 
phase with DCM (3 x 4ml). The combined organic phase was dried (MgS04), filtered
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through Celite and the solvent evaporated in vacuo to give a yellow liquid. This contained 
pyridine by TLC so it was evaporated using a Genevac EZ-2 at 52°C on setting “med 
b.p.” for 1.5 hours to give tlie title compoimd (46) as a yellow oil (0.244g, 77.9%).
[ a f ] ‘ -5 .0 0 [c  0.20, CH2CI2, 1-dl]. One spot by TLC, iJf 0.3 [Pet. ether:AcOEt 50:50]; 
Vimx (neat)/cm'' 3300 and 3094 (NH stretch of 2° amide), 2965 (CH2 asymmetric stretch), 
2880 (CH2 symmetric stietch), 1733 (C=0 stretch in aliphatic ester), 1651 (C=0 stretch 
of 2° amide), 1535 (NH bend of 2“ amide), 1439 (CH2 scissoring bend), 1374 and 1150 
(-SO2NH-), 1264 (C-C(=0)-0 stretch of ester), 1230, 1188 and 1081 (CF3); 8» (500MHz, 
CDCI3): 7.24 (IH, bs, TfNH), 6.43 (IH, d, J 8.8 , N77CH), 4.52 (IH, d of d, J5.2, 8.8, 
NHC/1). 3.74 (3H, s, OCH3), 3.28 (2H, t, J6.5, NHC%), 2.31 (2H, t, J7 .1 , CH2CO), 2.15 
(IH, m, 1.73 (2H, m, C ^C H iCO ), 1.64 (2H, m, NHCHjCTTj), 0.93 (3H, d, J
6.9, CHCIÏ3). 0.90 (3H, d, J6 .9 , CHC% '); 5c (75.5MHz, CDCI3): 173.03 (CO2CH3), 
172.82 (CONH), 119.81 (q, 7244, CF3), 57.18 (NHCH), 52.33 (OCH3), 43.55 (NHCH2), 
34.97 (CH2CO), 31.03 (CH(CH3)2), 29.06 (NHCH2CH2), 21.37 (CH2CH2CO), 18.97 
(CHCH3). 17.79 (CHCH3’); Found (Cl) 363.1173 (M+ + H), C12H22F3N2O5S requires 
363.1196; m/z (Cl) 363 (M'" + H), 331 (M +- OMe), 303 ((M" -  C02Me).
5-Trifluoromethanesulfonylainmo-pentanoic acid ((iS)-l-hydroxymethyl-3-methyl- 
butyl)-amide, (47)
o
OH
H(47)
Pyiidine (0.052ml, 0.051g, 0.641mmol) was added to a solution of (30) (0.148g, 
0.641mmol) in DCM (1.6ml) in a reaction vessel and the mixtme was cooled to -42°C. L- 
leucinol (0.075g, 0.641mmol) was added and the solution stined for 30 minutes at -42°C, 
then overnight at room temperatm e. A satmated solution of NaHCOs (aq) (13ml) was 
added, the organic phase sepaiated and the product extracted from the aqueous phase with 
DCM (3 X 3ml). The combined organic phase was washed with water (6ml), the organic 
phase separated and the product extracted fr om the aqueous phase with DCM (3 x 3ml).
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The combined organic phase was dried (MgS04), filtered through Celite and the solvent 
evaporated in vacuo to give a clear very pale yellow liquid. This contained pyridine by 
TLC so was put imder high vacuum at 50°C for 2 horns to give the title compoimd (47) as 
a clear very pale yellow liquid (0.1 l lg , 49.7%). -  20.45 [c 0.44, CH2CI2, 1-dl];
One spot by TLC, Rf 0.3 (AcOEt); Vmax (neat)/ciiT^ 3300 and 3092 (NH stretch of 2° 
amide), 2959 (CH2 asymmetric stretch), 2878 (CH2 symmetric stietch), 1651 (C=0 
stretch of 2° amide), 1543 (NH bend of 2° amide), 1470 (CH2 scissoring bend), 1371 and 
1149 (-SO2NH-), 1230, 1193 and 1080 (CF3); Ôh (500MHz, CDCI3): 5.90 (IH, d, J 8 .6 , 
CONH), 5 (IH, bs, TflSlH), 4.09 (IH, m, NHCiT), 3.70 (IH, d of d, J3 .5 , 11.3, CTfgOH), 
3.45 (IH, d of d, J6.9, 11.3, CiTsOH’), 3.28 (2H, m, N H C %  2.26 (2H, m, Ci^sCONH), 
1.73 (2H, m, NHCH2CH2C772), 1.62 (3H, m, C77(CH3)2, NHCHzCTfs), 1.31 (IH, m, OH), 
1.30 (2H, m, C H O IC E ), 0.92 (6H, t, J 7 , CH(C.%)2); ôc (125MHz, CDCI3): 174.23 
(CONH), 120.07 (q, J321 , CF3), 65.78 (CH2OH), 50.05 (NHCH), 43.81 (NHCH2), 40.37 
(CHCH2CH), 35.57 (CH2CONH), 29.17 (NHCH2CH2), 25.09 (NHCH2CH2CH2), 23.17 
(CH(CH3)2), 22.26 (CH3), 22.19 (CH3’); Found (Cl): 349.1405 (M^ + H), C12H24F3N2O4S 
requires 349.1403. m/z (Cl): 350 (M+ + 2H), 349 (M^ + H), 331 (M+ -  OH), 317 (M+ -  
CH2OH).
5-Trifluoromethaiiesulfoiiylamino-pentanoic acid ((5)-l-hydroxymethyl-3-methyl- 
butyl)-amide, (47)
The previous procedine of (47) was repeated, but with 1.1 equivalents of X-leucinol 
(0.083g, 0.705nnnol). This gave the title compoimd (47) as a clear, pale yellow oil 
(0.122g, 54.6%). One spot by TLC, Rf 0.3 (AcOEt); NMR Ôh (500MHz, CDCI3): 5.90 
(IH, d, / 8 .6, CONH), 4.09 (IH, m, NHCiT), 3.70 (IH, d of d, J3 .5 , 11.3, C ^O H ), 3.45 
(IH, d of d, J 6 .9 ,11.3, C ^ 20H’), 3.28 (2H, m, NHC^z), 2.26 (2H, m, C^CO N H ), 1.73 
(2H, m, NHCH2CH2C%), 1.62 (3H, m, C77(CH3)2, NHCH2(% ) ,  1.31 (IH, m, OH), 1.30 
(2H, m, CHC1%CH), 0.92 (6H, t, J l ,  CH(CF3)2).
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5-Tnfluoromethanesulfonylammo-pentanoic acid ((5)-l-benzyi-2-hydroxy-ethyl)- 
amide, (48)
Pyridine (0.052ml, 0.05Ig, 0.641mmol) was added to a solution of (30) (0.148g,
0.64Immol) in DCM (1.6ml) in a reaction vessel and the mixtme was cooled to -42°C. L- 
phenylalaninol (0.097g, 0.64 Immol) was added and the solution stirred for 30 minutes at 
-40°C, then overnight at room temperatm e. A satmated solution of NaHCOs (aq) (13ml) 
was added, the organic phase separated and the product extracted from the aqueous phase 
with DCM (3 X 3ml). The combined organic phase was washed with water (6ml), the 
organic phase separated and the product extiacted from the aqueous phase with DCM (3 x 
3ml). The combined organic phase was dried (MgS04), filtered tluough Celite and the 
solvent evaporated in vacuo to give a clear, pale yellow liquid. This contained pyridine by 
TLC so was put under high vacumn at 50°C for 4 horns to give a clear very pale yellow 
oil (0.160g). TLC showed 3 products and NMR showed the product to be impure, so it 
was pmifred on a preparative TLC plate (20cm x 20cm SiOs, AcOEt), to give two main 
products. The solvent was evaporated in vacuo from the least polar (Rf 0.417 — 0.669), to 
give the title compomid (48) as a clear, colourless oil (0.052g, 21.2%). -10.53 [c
0.38, CH2CI2, 1-dl]; One spot by TLC, Rf 0.4 [AcOEt]; Vmax (neat)/cm‘  ^ 3308 and 3089 
(NH stietch of 2° amide), 2939 (CH2 asymmetric sti*etch), 2878 (CH2 synmietric stretch), 
1649 (C=0 stretch of 2® amide), 1537 (NH bend of 2® amide), 1371 and 1148 (-SO2NH-), 
1230, 1191 and 1080 (CF3), 748 and 702 (oop bend of aromatic ring CH); Ôh (500MHz, 
CDCI3): 7.17 -  7.30 (5H, m, Ph), 6.05 (IH, d, J8 .2 , CONH), 4.23 (IH, s, CH), 3.75 (IH, 
s, SO2NH), 3.68 (IH, d ofd, J3 .3  and 11.1, C%OH), 3.53 (IH, d of d, /5 .9  and 11.0, 
CH2OH'), 3.18 (2H, m, NHCj%), 2.84 (IH, d of d, J6 .9  and 13.8, C ^ P h ), 2.78 (IH, d of 
d, J7 .7  and 13.8, CTfzPh'), 2.16 (2H, m, CH2CO), 1.62 (2H, m, CH2CH2CO), 1.49 (2H, 
m,NHCH2C ^ 2); ÔC (125MHz, CDCI3): 174.04 (CO), 137.66, 129.34, 128.83,126.92 
(Ph), 120.05 (q, J322, CF3), 64.06 (CH2OH), 52.76 (CH), 43.74 (NHCH;), 37.28
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(CHîPh), 35.50 (CH2CO), 29.02 (NHCH2CH2), 22.06 (CH2CH2CO); Found (CI) 
383.1243 (M+ + H), C15H22F3N2O4S requnes 383.1247; m h  (Cl) 384 (M'" + 2H), 383 (M" 
+ H), 365 (M *-O H ).
The solvent was evaporated in vacuo from tlie more polar product (Rf 0.771 — 0.863) to 
give 5-trifluoromethauesulfonyIamino-pentanoic acid (5)-3-phenyl-2-(5- 
trifluoromethanesulfonylamino-l-pentanoylainino)-propyl ester, (49) as a clear, 
colourless oil (0.025g, 6.4%).
(49)
One spot by TLC, Rf 0.4 [Pet. EÜier:AcOEt 50:50]; Vmax (neat)/cm~’ 3306 and 3089 (NH 
stietch of 2° amide), 2953 (CH2 asymmetric stretch), 2857 (CH2 symmetric stretch), 1721 
(C=0 stretch of ester), 1652 (C=0 stietch of 2“ amide), 1536 (NH bend o f 2° amide), 
1371 and 1148 (-SO2NH-), 1229,1190 and 1079 (CF3), 749 and 702 (oop bend of 
aromatic ling CH); 8» (500MHz, CDCI3): 7.17 -  7.33 (5H, m, Ph), 6.63 (IH, bs, NHTf), 
6.13 (IH, bs, NHTf), 5.67 (IH, d, J8 .9 , OCNH), 4.52 (IH, m, CH2O), 4.51 (IH, m, CH), 
4.25 (IH, m, CH2O’), 3.21 (2H, m, NHC%), 3.19 (2H, m, NHCH2), 2.87 (IH, d o f d, J  
14.0, 6 .6, CH2Ph), 2.76 (IH, d of d, 714.0,7.9, CH2PI1’), 2.39 (2H, m, COCH2), 2.15 
(2H, m, COCH2), 1.81 (2H, bs, NHCH2CH2), 1.70 (2H, m, COCH2CH2), 1.61 (2H, m, 
COCH2CH2), 1.46 (2H, bs, NHCH2CH2); 8c (125MHz, CDCI3): 173.39 (CO), 173.27 
(CO), 127.04-136.44 (Ph), 119.81 (q,7321, CF3), 119.76 (q,7321, CF3), 65.71 
(CH2O), 49.49 (CH), 43.90 (NHCH;), 43.57 (NHCH;), 37.48 (CH2Ph), 35.47 (COCH2), 
33.48 (COCH2), 28.94 (NHCH2CH2), 28.86 (NHCH2CH2), 21.79 (COCH2CH2), 21.50 
(COCH2CH2); Found (Cl) 614.1462 (iVf + H), C21H30F6N3O7S2 requires 614.1424; m h  
(Cl) 615 (M’" + 2H), 614 (M* + H), 365 (M* -  0C0(CH;)4NHTf).
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Hydrazino ethyloxalate hydrochloride, (57)
HCl ■ H„N
TEA (10.0ml, 7.22g, 71.4mmol) was added to a solution of ^ -butyl carbazate (4.72g, 
35.7mmol) in anhydimis DCM (150ml) and the reaction cooled with an ice-water bath. 
Ethyl oxalyl chloride (4.78ml, 5.84g, 8.88mmol) was added slowly to the reaction and the 
reaction was allowed to warm to room temperature wliilst bemg stirred overnight. A 
saturated solution of citric acid (aq) (25ml) and water (75ml) was added, the organic 
phase separated and the product extracted from the aqueous phase with DCM (3 x 50ml). 
The combined organic phase was exti acted with a saturated solution of NaHCOs (aq) 
(150ml), the organic phase sepai ated and the product extracted from the aqueous phase 
with DCM (3 X 50ml). The combined organic phase was dried by passing tluough a 
hydi'ophobic frit and the solvent evaporated in vacuo to give a viscous yellow oil (9.16g).
5 to 6M hydrochloric acid in propan-2-ol (23.4ml total) was added to the BOC-protected 
cmde product and tire reaction stiiTcd at room temperature for 45 minutes. The solvent 
was evaporated in vacuo to give a pale yellow powder. This was washed with diethyl 
ether on a sintered funnel, then dried under high vacumn at 40°C to give the title 
compoimd (57) as a white powder (3.581g, 59.5%). Mp 112° -  113°C (from diethyl 
ether); One spot by TLC, i?f 0.5 [AcOEt:MeOH 30:70]; Vmax (nujol mull)/cm’^  3191 (NH 
stretch of 2° amide), 1681 (C=0 stretch in ester), 1184 (asymmetiic C-C(=0)-0 stretch of 
ester); NMR Ôh (500MHz, MeOD): 4.38 (2H, m, CH2), 1.38 (3H, t, /7 .1 , CH3); ôc (from 
HMQC) (75.5MHz, MeOD): 64.34 (CH2), 14.34 (CH3); m/z (Cl) 133 (M+ + H).
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(2*S) (N’-Ethyloxyoxalyl)-2-(N-ter^-butyloxycarbonyl)pyrroIidine-2~acetic acid
hydrazide, (59).82
PyBOP* (0.286g, 0.55mmol), Boc-Pio-OH (0.108g, 0.5mmol) and DIPEA (0.261ml,
0.194g, l.Sminol) in DMF (4ml) was added to (57) (O.lOlg, 0.6mmol) in DMF (2ml) and 
the reaction stin*ed at room temperature for 22hours. The solvent was evaporated in vacuo 
to give a yellow oil. This was dissolved in DCM (8ml) and extracted with a satmated 
solution of citric acid (aq) (0.8ml) and water (2.4ml), the organic phase separ ated and the 
product extracted from the aqueous phase with DCM (3 x 2ml). The combmed organic 
phase was extracted with a satmated solution of NaHCOs (aq) (4.8ml), the organic phase 
separated and the product extracted from the aqueous phase with DCM (3 x 2ml). The 
combined organic phase was dried by passing tluough a hydrophobic frit and the solvent 
evaporated in vacuo to give a pale yellow wax (0.413g). This crude product was purified 
by “CombiFlash®” column cluomatography (12g pre-packed Si02  colimin, gradient 
elution. Heptane:AcOEt 50:50 100% AcOEt over 20 minutes, then 100% AcOEt for 5
minutes), and the solvent evaporated in vacuo to give the title compoimd (59) as a clear, 
colourless oil (0.023g, 14.0%). One spot by TLC, 0.2 [AcOEt]; Vmax (CDCI3 frhn)/crn'^ 
3240 (NH stretch of 2° amide), 2979 (CH3 asymmetric stretch), 2931 (CH2 asymmetric 
and symmetric stretch), 2881 (CH3 symmetric stretch), 1679 (C=0 stretch in ester), 1479 
(NH bend), 1455 (CH3 asyrmnefric bend), 1368 (CH3 symmetric bend), 1249 and 1164 
(asymmetric C-C(=0)-0 stretch of ester); Ôh (500MHz, CDCI3): 9.39 (IH, bs, NH), 9.12 
(IH, bs, NH), 4.41 (2H, q, J7.2, CH2CK3I  4.38 (IH, bs, CH), 3.47 (IH, bs, NCH2), 3.35 
(IH, bs, NCH2'), 2.34 (IH, bs, C H C ^), 2.17 (IH, bs, NCH2C772), 1.97 (IH, bs, 
CHC^z'), 1.88 (IH, bs, NCH2CE23 , 1.47 (9H, s, r-butyl), 1.41 (3H, t, J7 .1 , CH2C773);
ÔC (125MHz, CDCI3): 169.55 (CO), 158.53 (CO), 156.89 (CO), 153.11 (CO), 81.08 
(C(CH3)3), 64.10 (CH2CH3), 58.77 (CH), 47.32 (NCH2), 29.90 (CHCH2), 28.56 
(C(CH3)3), 24.75 (NCH2CH2), 14.14 (CH2CH3); Found (Cl) 274.1038 (M+ -  t-butyl + 
2H), C10H16N3O6 requires 274.1034; Found (Cl) 230.1185 (M* -  BOC + 2H), C9H16N3O4
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requires 230.1135; m/z (Cl) 274 (M+ -  t-butyl + 2H), 230 (M* -  BOG + 2H); m/z (ESI): 
352 (M+ + Na), 230 (M*" -  BOG + 2H).
(2»S) (N’-Ethyloxyoxalyl)“2“(^er/“butyloxycarbonyl)amino-'3-pheiiylpropaiioic acid 
hydrazide, (61).*^
(61)
PyBOP® (0.662g, 1.273mmol), Boc-Phe-OH (0.338g, 1.273nimol) and DIPEA (0.665ml, 
0,494g, 3.82mmol) in DMF (10ml) was added to (57) (0.236g, 1.4mmol) in DMF (5ml) 
and the reaction stiiTed at room teniperatme for 22.5hoirrs. The solvent was evaporated in 
vacuo to give a white solid. This was dissolved in DCM (20ml) and extracted with a 
satinated solution of citric acid (aq) (2ml) and water (6ml), the organic phase separated 
and the product extiucted fi'om the aqueous phase with DCM (3 x 5ml). The combined 
organic phase was extracted with a satur ated solution of NaHCOs (aq) (12ml), the organic 
phase separated and the product extr acted from the aqueous phase with DCM (3 x 5rnl). 
The combined organic phase was dried by passing thr ough a hydrophobic frit and the 
solvent evaporated in vacuo to give a white solid (0.88g). This craide product was pmified 
by colrmm clrromatogr aphy (16.9g SiOz, first 51 ml = 100% Pet. Ether, second 527rnl = 
Pet. EtheriAcOEt 60:40), and the solvent evaporated in vacuo to give the title compound 
(61) as a white wax (0.09g, 18.6%). One spot by TLC, 0.6 [Pet. ether:AcOEt 30:70]; Ôh 
(500MHz, CDCI3): 9.61 (2H, bs, NHNH, NHNH), 7.21-7.32 (5H, m, Ph), 4.95 (IH, bs, 
Ni7CH), 4.48 (IH, bs, CH), 4.38 (2H, q, J7 .1 , CFfzCHg), 3.17 (IE , d of d, / 6 . 6 , 14.0, 
CHCTfz), 3.08 (IH, rn, CHCT^'), 1.40 (9H, s, t-butyl), 1.37 ( 3H, t, J7 .2 , CHzCiTs); 
LCMS: 100% puiity on LG, m/z (ESI): 402 (M+ + Na), 280 (M* -  BOG + 2H).
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Hydrazino ethyloxalate, (54)
TEA (2.08ml, 1.50g, 14.8mmol) was added to a solution of r-butyl carbazate (0.98g, 
7.4imnol) in anhydrous DCM (50ml) and the reaction cooled with an ice-water bath.
Ethyl oxalyl chloride (0.99ml, 1.21g, 8.88imnol) was added slowly to the reaction and the 
reaction was allowed to warm to room temperature whilst being stined for 22.5 horns. A 
satur ated solution of citric acid (aq) (5ml) and water (15ml) was added, the organic phase 
separated and the product extracted from the aqueous phase with DCM (3 x lOrnl). The 
combined organic was extracted with a saturated solution of NaHCOs (aq) (30ml), the 
organic phase separated and the product extracted from the aqueous phase with DCM (3 x 
10ml). The combined organic phase was dried (MgS04 ), filtered tlnough Celite and the 
solvent evaporated in vacuo to give a yellow oil (2.09g). 20% TEA in DCM (lOrnl total) 
was added to the BOC-protected crude product and the reaction stood for 15 minutes with 
occasional swirling. The solvent was evaporated in vacuo to give a white solid. This was 
dissolved in acetonitrile (40rnl) and separated into 2 portions, each of wliich was added to 
a lOg Isolute SCX-2 colurmi (that had been satmated with acetonitrile). Each colunrn was 
washed with acetonitrile (30ml). Each colrumr was then treated with 2 x 2M TEA in 
acetonitrile (25ml) and the filtrate collected. The solvent was evaporated in vacuo to give 
the title compound (54) as a yellow oil (0.86g, 88.0%). NMR Ôh (500MHz, CDCI3); 8.27 
(IH, bs, NH), 4.37 (2H, q, J7 .1 , CH2), 4.15 (2H, bs, NH2), 1.39 (3H, t, J l . l ,  CH3); 
LCMS: 91.7% purity on LC, m/z (ESI): 155 (M^ + Na), 133 (M^ + H).
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(2.S) (N’-Ethyloxyoxalyl)-2-(ter^-butyloxycarbonyl)amino-3-phenylpropanoic acid
hydrazide, (61).®^
(61)
PyBOP® (0.662g, 1.273mmol), Boc-Phe-OH (0.338g, 1.273niniol) and DIPEA (0.665ml, 
0.494g, 3.82mmol) in DMF (10ml) was added to (54) (0.185g, 1.4mmol) in DMF (5ml) 
and the reaction stiiTed at room temperatnre for 5hours. The solvent was evaporated in 
vacuo to give a yellow oil. This was dissolved in DCM (20ml) and extiacted with a 
saturated solution of citiic acid (aq) (1ml) and water (3ml), the organic phase separated 
and the product extracted from the aqueous phase with DCM (3 x 5ml). The combined 
organic phase was extracted with a saturated solution of NaHCOs (aq) (6ml), the organic 
phase separated and the product extracted fi.*om the aqueous phase with DCM (3 x 5ml). 
The combined organic phase was dried by passing tlirough a hydrophobic frit and the 
solvent evaporated in vacuo to give a yellow oil (1.167g). This cmde product was purified 
by column chromatography (17.2g Si02 , first 289ml = Pet. Ether:AcOEt 50:50, second 
153ml = Pet. Ether;AcOEt 30:70), and the solvent evaporated in vacuo to give the title 
compomid (61) as a white solid (0.295g, 61.1%). One spot by TLC, Rf 0.6 [Pet ether: 
AcOEt 30:70]; (CDCI3 film)/cin‘' 3271 (NH stretch of 2° amide), 2972 (CH3 
asymmetric stretch), 2928 (CH2 asymmetric arid symmetric stretch), 2871 (CH3 
symmetric stretch), 1719 arid 1683 (C=0 stretch in ester), 1497 (NH bend), 1455 (CH3 
asymmetric bend), 1368 (CH3 symmetric bend), 1166 (asymmetric C-C(=0)-0 stretch of 
ester); 3» (500MHz, CDCI3): 9.32 (IH, bs, NHNH), 8.82 (IH, bs, NHNH), 7.21-7.32 (5H, 
m, Ph), 4.95 (IH, bs, NTfCH), 4.48 (IH, bs, CH), 4.38 (2H, q, J7 .1 , C/fjCHj), 3.17 (IH, 
d of d, / 6 .6, 14.0, CHC%), 3.08 (IH, m, CHC% '), 1.40 (9H, s, t-butyl), 1,37 ( 3H, t, J
7.2, CHzCgs); 5c (125MHz, CDCI3): 168.55 (CO), 158.79 (CO), 155.89 (CO), 152.71 
(CO), 136.01, 129.49,129.08, 127.49 (Ph), 81.24 (C(CHs)3), 63.88 (CH2CH3), 54.59 
(CH), 37.67 (CHCH2), 28.44 (C (Œ j)3), 14.17 (CH2CH3); Found (Cl) 380.1822 (NT +
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H), C 18H26N3O6 reqmres 380.1816; m/z (CI) 380 (M* + H), 324 (M^ -  t-butyl + 2H), 280 
(M+ -  BOC + 2H).
Ethyl-5-[(*S)-l-[(te/*^butyloxycarbonyl)amino]-2-phenylethyl]-l,3,4-oxadiazole-2-
carboxylate, (64).82
N—N(64)
61 (0.277g, 0.73iîimol) and Burgess Reagent (0.209g, 0.876nmiol) were refluxed in 
anhydrous THF (lOinl) for 16 hours 25minutes*. Reaction was incomplete so Burgess 
Reagent (0.174g, 0.73mmol) was added and the reaction refluxed for 22 hours. The 
reaction was incomplete so Buigess Reagent (0.870g, 3.65imnol) was added and the 
reaction refluxed for 4 hours 40 minutes. The solvent was evaporated in vacuo to give a 
yellow oil. This was dissolved in DCM (25ml) and washed with water (25ml), the organic 
phase separated, then the product exti*acted h'om the aqueous phase with DCM (3 x 5ml). 
The combined organic phase was dried by passing thiough a hydiophobic h it and the 
solvent evaporated in vacuo to give a yellow/red oil (0.573g). This crude product was 
pmified by “CombiFlash®” colmnn clnomatogiaphy (12g pre-packed SiOz colunm, 
gradient elution, 100% Heptane Heptane;AcOEt 50:50 over 30 minutes), and the 
solvent evaporated mider high vacuimi at 40°C to give the title compound (64) as white 
crystals (0.170g, 64.4%). Mp 111°- 113°C (fi'om Heptane:AcOEt 50:50); One spot by 
TLC, Rf 0.7 [Heptane:AcOEt 50:50]; Vmax (nujol mull)/cm'^ 3350 (NH stretch of 2° 
amide), 2995 (CH3 asymmetric stretch), 2930 (CH2 asymmetric and symmetiic stretch), 
2855 (CH3 symmetiic stretch), 1747 and 1694 (C=0 stietch in ester), 1521 (NH bend), 
1252 and 1167 (asymmetric C-C(=0)-0 stretch of ester); 5h (300MHz, CDCI3): 7.10-7.31 
(5H, m, Ph), 5.35 (IH, bs, CH), 5.26 (IH, d, J8 .5 , NH), 4.50 (2H, q, J7.1, C772CH3), 3.31 
(IH, d of d, J6 .1 , 13.9, CHCTTz), 3.08 (IH, d of d, J 7 .1 ,13.9, CHCT^'), 1.44 ( 3H, t, J
7.2, CH2C773), 1.39 (9H, s, t-butyl); 6c (75MHz, CDCI3): 168,91 (CHC(O)N), 157.23 
(CO2CH2), 155.12 (CO), 154.50 (CO), 135.29, 129.63, 129.17, 127.78 (Ph), 81.06
168
(C(CH3)3), 63.95 (CH2CH3), 48.98 (CH), 39.96 (CHCH2), 28.56 (€ (0 1 3 )3), 14.40 
(CH2O I 3); Found (Cl) 362.1696 (M* + H), C 18H24N3O5 requires 362.1710; LCMS; 100% 
purity on LC, m/z (ESI); 400 (M^ + K), 384 (M'" + Na), 306 (M+ -  BOC + 2H).
(25) (N'-Ethyloxyoxalyl)-2-(^er^-butyloxycarbonyI)ammopropanoic acid hydrazide,
(66).82
NH: o
(66)
PyBOP® (0.287g, 0.551mraol), Boc-Ala-OH (0.104g, 0.551itutio1) and DIPEA (0.287ml, 
0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in DMF (2ml) 
and the reaction stiiTed at room temperature for 9 horns.
The solvent was evaporated using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 
1.5 hours to give a yellow liquid/oil. This was dissolved in DCM (8.5ml) and extracted 
with a saturated solution of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase 
separ ated and the product extracted from the aqueous phase with DCM (3 x 4ml). The 
combined organic phase was extracted with a saturated solution of NaHCOs (aq) (3ml), 
the organic phase separated and the product exfracted from the aqueous phase with DCM 
(3 X 3ml). The combined organic phase was dried by passing thiough a hydrophobic frit 
and the solvent evaporated in vacuo to give a yellow oil. This crude product was pmified 
by “CombiFlash®” column cliromatography (12g pre-packed SiOa column, gradient 
elution, 100% Heptane —> Heptane: AcOEt 40:60 over 30 minutes), and the solvent 
evaporated in vacuo to give the title compomid (66) as a clear, colomless oil (0.16g, 
95.7%). One spot by TLC, 0.3 [Heptane:AcOEt 20:80]; Vmax (CDCI3 fihn)/cnT* 3309 
(NH stretch of 2° amide), 2984 (CH3 asymmetric stretch), 2936 (CH2 asymmetric and 
symmetric stietch), 1723 and 1690 (C=0 sti'etch in ester), 1504 (NH bend), 1455 (CH3 
asymmetric bend), 1370 (CH3 symmetric bend), 1252 and 1165 (asymmetric C-C(=0)-0 
stretch of ester); Ôh (500MHz, CDCI3): 9 (2H, bs, CHCONFf, NHCOCO), 5.09 (IH, bs, 
NTfCH), 4.38 (2H, q, J7 .1 , CH2CH3), 4.32 (IH, bs, CH), 1.45 (9H, s, t-butyl), 1.42 (3H, 
d, J7 .1 , CHCiA), 1.39 (3H, t, J7 .1 , CHzCFfs); 6c (125MHz, CDCI3): 170.27 (CO),
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158.86 (CO), 156.04 (CO), 153.17 (CO), 81.12 (C(CH3)3), 63.83 (CH2CH3), 48.91 (CH), 
28.50 (C(CH3)3), 17.58 (CHCH3), 14.15 (CH2CH3); Foimd (Cl) 304.1460 (M"" + H), 
C12H22N3O6 requires 304.1503; m/z (Cl) 304 (M+ + H), 248 (M"" -  t-butyl + 2H), 204 (M^ 
-  BOC + 2H).
Ethyl-5-[(5)-l-[(ter^-butyloxycarbonyl)amino]ethyl]-l,3,4-oxadiazole-2-carboxylate,
(67).^^
NH
(67)
66 (0.085g, 0.280mmol) and Burgess Reagent (0.133g, 0.560inmol) were refluxed in 
anhydi'ous THF (4.2ml) over the weekend. Reaction was incomplete so Burgess Reagent 
(0.133g, 0.560mmol) was added and the reaction refluxed for 18 horns. The solvent was 
evaporated in vacuo to give a yellow/brown oil. This was dissolved in DCM (9.6ml) and 
washed with water (9.6ml), the organic phase separated, then the product extracted from 
the aqueous phase with DCM (3 x 2ml). The combined organic phase was dried by 
passing tlirough a hydrophobic frit and the solvent evaporated in vacuo to give a yellow 
oil (0.173g). This cmde product was pmified by column chiomatography (6.5g Si02 , 
DCMiAcOEt 30:70), and the solvent evaporated imder high vacuum at 45°C to give a 
yellow oil (0.056g). This was further purified on a preparative TLC plate (20cm x 20cm 
Si02 , DCMiAcOEt 30:70), to give the title compomid (67) as a white solid/liquid (0.049g,
61.3%). One spot by TLC, R{ 0.5 [DCM:AcOEt 80:20]; (CDCI3 film)/cin' 3439 and 
3336 (NH stretch of 2° amide), 2984 (CH3 asymmetiic stietch), 2930 (CH2 asynnnetric 
and symmetiic stretch), 1750 and 1712 (C=0 stretch in ester), 1504 (NH bend), 1454 
(CH3 asymmetric bend), 1250 and 1154 (asyimnetric C-C(=0)-0 stretch of ester); 5h 
(500MHz, CDCI3): 5.15 (2H, bs, NH, CH), 4.52 (2H, q, J l . l ,  C7:^CH3),1.63 (3H, d, /
6.9, CHC773), 1.45 (3H, t, J7 .1 , CH2CF3), 1.45 (9H, s, t-butyl); 8c (125MHz, CDCI3):
169.86 (CO), 157.16 (CO), 154.85 (CO), 154.42 (CO), 80.96 (C(CH3)3), 63.81 (CH2CH3), 
43.58 (CH), 28.46 (C(CH3)3), 19.95 (CHCH3), 14.27 (CH2CH3); Found (Cl) 286.1330 
(M+ + H), C12H20N3O5 requires 286.1397; m/z (Cl) 286 (M^ + H), 230 (M^ -  t-butyl + 
2H).
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(2S) (N'“Ethyloxyoxalyl)-2-(^er^-butyloxycarbonyl)amiiio-3-benzyloxypropaiioic acid
hydrazide, (69).82
(69)
PyBOP (0.287g, 0.55Imniol), Boc-Ser(Bn)-OH (0.163g, 0.55 Inmiol) and DIPEA 
(0.287ml, 0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in 
DMF (2ml) and the reaction stirred at room temperature for 9 hours. The solvent was 
evaporated using a Genevac EZ-2 at 45*^0 on setting “low/med b.p.” for 1.5 hours to give 
a yellow oil. This was dissolved in DCM (8.5ml) and extracted with a satmated solution 
of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the product 
extracted from the aqueous phase with DCM (3 x 4ml). The combined organic phase was 
extracted with a satmated solution of NaHCOs (aq) (3ml), the organic phase separated and 
the product extiacted hom  the aqueous phase with DCM (3 x 3ml). The combined organic 
phase was dried by passing tlirough a hydrophobic frit and the solvent evaporated in 
vacuo to give a yellow oil. This crude product was pmified by column chiomatography 
(18g SiOz, DCMiAcOEt 50:50), and the solvent evaporated imder high vacumn at 45°C to 
give the title compomid (69) as a clear, colomless oil (0.145g, 64.3%). One spot by TLC, 
Rf 0.5 [DCM: AcOEt 50:50]; Vmax (CH2CI2 film)/cm'^ 3275 (NH stretch of 2° amide),
2980 (CH3 asynnnetric stretch), 2937 (CH2 asymmetiic and syimnetiic stretch), 2871 
(CH3 symmetric stretch), 1720 and 1691 (C=0 stretch in ester), 1497 (NH bend), 1455 
(CH3 asynnnetiic bend), 1368 (CH3 synmietric bend), 1251 and 1165 (asymmetric 
C-C(=0)-0 stretch of ester); Ôh (500MHz, CDCI3): 9.31 (2H, bs, CHCON77, NHCOCO), 
7.28-7.36 (5H, m, Ph), 5.43 (IH, d, J6.0, N77CH), 4.57 (IH, d (AB quartet), J  12.0, 
PI1CH2), 4.56 (IH, d (AB quartet), J  12.0, PhCH2'), 4.46 (IH, bs, CH), 4.38 (2H, q, J6 .9 , 
CH2CH3), 3.91 (IH, bs, CHCE2), 3.63 (IH, m, CHCI^'), 1.45 (9H, s, t-butyl), 1.39 (3H, 
t, J6 .9 , CH2CJT3); 5c (125MHz, CDCI3): 167.80 (CHCO), 158.82 (COCO2), 155.76 (CO),
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152.75 (CO), 137.22,128.76,128.28,128.15 (Ph), 81.07 (C(CH3)3), 73.86 (CHzPh), 
69.27 (CHC%), 63.81 (CH2CH3), 53.32 (CH), 28.45 (C(CH3)3), 14.15 (CH2CH3); Found 
(El) 409.1805 (M*"), C19H27N3O7 requkes 409.1844; m/z (Cl) 410 (M+ + H), 366 (M+ -  
OEt + 2H), 354 (M +- (-butyl + 2H), 338 (IVf -  OC(CH3)3 + 2H), 310 (M^ -  BOC + 2H).
(2i?) (N’-Ethyloxyoxalyl)-2-(^ei*^-butyloxycarbonyl)amino-3-benzylsuIfanylpropanoic
acid hydrazide, (71).82
(71)
PyBOP® (0.287g, 0.551mmol), Boc-Cys(Bn)-OH (0.172g, 0.551miiiol) and DIPEA 
(0.287ml, 0.213g, 1.65nimol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in 
DMF (2ml) and the reaction stirred at room temperatnre for 9 horns. The solvent was 
evaporated using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 hours to give 
a yellow liquid/oil. This was dissolved in DCM (8.5ml) and extracted with a saturated 
solution of citiic acid (aq) (0.5ml) and water (1.5ml), the organic phase sepaiated and the 
product extiacted from the aqueous phase with DCM (3 x 4ml). The combined organic 
phase was exti acted with a saturated solution of NaHCOs (aq) (3ml), the organic phase 
separated and the product extracted fr om the aqueous phase with DCM (3 x 3ml). The 
combined organic phase was diied by passing through a hydrophobic frit and the solvent 
evaporated in vacuo to give a yellow viscous oil. This crude product was purifred by 
“CombiFlash®” column chromatography (12g pre-packed 810% column, gradient elution, 
100% Heptane —> Heptane:AcOEt 40:60 over 30 minutes), and the solvent evaporated in 
vacuo to give a white solid (0.12g). This had co-run on the column with a slight impuiity, 
so was dissolved in AcOEt, pmified tlnough a pad of Si02  (AcOEt), and the solvent 
evaporated in vacuo to give the title compomid (71) as a clear, colomless oil (0.108g, 
46.1%). One spot by TLC, iff 0.55 [Pet. Etber;AcOEt 30:70]; v,™* (CDCI3 fihn)/cm‘' 3262
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(NH stretch of 2° amide), 2983 (CH3 asymmetric stretch), 2933 (CH; asymmetric and 
syimnetric sketch), 1720 and 1694 (0 = 0  stretch in ester), 1495 (NH bend), 1455 (CH3 
asymmetric bend), 1370 (CH3 syimnetric bend), 1251 and 1165 (asymmetric C-C(=0)-0 
Sketch of ester); Sh (500MHz, CDCis): 8.6 (2H, bs, CHCONH, NHCOCO), 7.22-7.33 
(5H, m, Ph), 5.43 (IH, hs, N7ÏCH), 4.43 (IH, bs, CH), 4.36 (2H, q, /7 .1 , C%CH3), 3.75 
(2H, s, C%Ph), 2.84 (2H, d, J6 .4 . CHC%), 1.44 (9H, s, t-butyl), 1.36 (3H, t, J7 .1 , 
CH;C%); 5c (125MHz, CDCI3): 168.40 (CO), 158.81 (CO), 155.76 (CO), 153.14 (CO), 
137.88,129.20, 128.83,127.48 (Ph), 81.09 63.79 (CH2CH3), 52.66 (CH),
36.68 (CHaPh), 33.32 (CHCH;), 28.46 (C(CH3)3). 14.11 (CH2CH3); Foimd (El) 425.1606 
(M+), C19H27N3O6S requkes 425.1615; m/z (Cl) 426 (M+ + H), 370 (M+ -  t-butyl + 2H), 
326(M ^-B O C  + 2H).
(2 *S) [N*-Ethyloxyoxalyl)-2-(^er^-butyloxycarbonyl)amino-4-methylpeiitaiioic acid 
hydrazide, (73).^”
(73)
PyBOP® (0.572g, l.liimiol), Boc-Leu-OH (0.254g, l.limnol) and DIPEA (0.575ml, 
0.427g, 3.3mniol) in DMF (10ml) was added to (54) (0.160g, 1.21 mmol) in DMF (3ml) 
and the reaction stined at room temperatnre for 5 hours. The solvent was evaporated in 
vacuo to give a yellow oil. This was dissolved in DCM (17ml) and extracted with a 
saturated solution of citric acid (aq) (0.9ml) and water (2.7ml), the organic phase 
sepaiated and the product extracted from the aqueous phase with DCM (3 x 4ml). The 
combined organic phase was extracted with a saturated solution of NaHCOs (aq) (5.4ml), 
the organic phase separated and the product extracted fr om the aqueous phase with DCM 
(3 X 4ml). The combined organic phase was dried by passing tlnough a hydrophobic frit 
and the solvent evaporated in vacuo to give a yellow oil (1.01 g). This crude product was 
pmified by colimni cinematography (20g Si0 2 , first 195ml = Pet. Ether:AcOEt 60:40, 
second 111ml = Pet. Ether:AcOEt 50:50), and the solvent evaporated imder high vacumn
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at 45°C to give the title compoiuid (73) as a white solid (0.283g, 74.5%). One spot by 
TLC, Rf 0.3 [Pet. ether:AcOEt 50:50]; Vmax (CDCI3 film)/cm'^ 3264 (NH stretch of 2° 
amide), 2962 (CH3 asymmetric stretch), 2928 (CH2 asymmetric and syimnetric stretch), 
2872 (CH; symmetric stretch), 1721 and 1679 (C=0 stretch in ester), 1508 (NH bend), 
1456 (CH; asymmetric bend), 1368 (CH; symmetric bend), 1258 and 1164 (asymmetric 
C-C(=0)-0 stretch of ester); 5h (500MHz, CDCI3): 9.60 (2H, bs, CHCONH, NHCOCO), 
5.21 (IH, d, J7.0, N77CH), 4.37 (2H, q, J7 .1 , CH2CH3), 4.36 (IH, bs, NHCfl), 168 (2H, 
m, CH(CH;)2, CHC%CH), 1.57 (IH, bs, CHC%CH'), 1.43 (9H, s, t-butyl), 1.38 (3H, t, J
7.1, CH2CH3); 0.96 (3H, d, J6 .4 , CHCTÏj), 0.93 (3H, d, J6.3, CHC%); 8c (125MHz, 
CDCI3): 170.50 (CO), 158.93 (CO), 156.15 (CO), 153.30 (CO), 80.81 (C(CH;);), 63.68 
(CH2CH;), 51.71 (NHCH), 40.95 (C H Œ 2CH), 28.48 (C(CH;)3), 24.82 (CH(CH3)2),
23.06 (CHCH;), 22.02 (CHCH;), 14.11 (CH2CH3); Fomid (Cl) 346.1960 (IvT + H), 
C15H28N3O6 requires 346.1973; m/z (Cl) 346 (M’*' + H), 290 (M* -  t-butyl + 2H), 246 (M* 
- B 0 C  + 2H).
(2*S) (N'-Ethyloxyoxalyl)-2-(ter^-butyloxycarbonyl)amino-6- 
(benzyloxycarbonyl)ammohexanoic acid hydrazide, (75)
HN
(75)
PyBOP® (0.287g, 0.551mmol), Boc-Lys(Z)-OH (0.21 Og, 0.551mmol) and DIPEA 
(0.287ml, 0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606nnnol) in 
DMF (2ml) and the reaction stined at room temperatine for 9 horns. The solvent was
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evaporated using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 hours to give 
a yellow liquid/oil. This was dissolved in DCM (8.5ml) and extiacted with a satmated 
solution of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the 
product extiacted from the aqueous phase with DCM (3 x 4ml). The combined organic 
phase was extiacted with a satmated solution of NaHCOa (aq) (3ml), the organic phase 
separated and the product extracted fr om the aqueous phase with DCM (3 x 3ml). The 
combined organic phase was dried by passing tlirough a hydrophobic fr it and the solvent 
evaporated in vacuo to give a yellow oil. This cmde product was purified by 
“CombiFlash®” column cliromatography (12g pre-packed Si02  colmnn, gradient elution, 
100% Heptane —> Heptane:AcOEt 30:70 over 30 minutes), and the solvent evaporated 
mider high vacumn at 45°C to give the title compomid (75) as a clear, colomless oil/solid 
(0.18g, 66.1%). One spot by TLC, Rf 0.3 [Heptane:AcOEt 20:80]; Vmax (CDCI3 fihn)/ciiT^ 
3478 and 3414 (NH stretch of 2° amide), 2982 (CH3 asynnnetric stretch), 2940 (CH2 
asynnnetric and symmetric strctch), 1695 (C=0 stretch in ester), 1517 (NH bend), 1456 
(CH3 asynnnetric bend), 1369 (CH3 symmetric bend), 1252 and 1166 (asynnnetric 
C-C(=0)-0 stretch of ester); Ôh (500MHz, CDCI3): 9.66 (2H, bs, CHCONFf, NHCOCO),
7.26-7.33 (5H, m, Ph), 5.61 (IH, bs, NLTCH), 5.23 (IH, bs, N^CHz), 5.07 (2H, s, Cif2Ph), 
4.31 (2H, q, J7 .1 , C.7/2CH3), 4.27 (IH, bs, CH), 3.14 (2H, bs, NHC772), 1.80 (IH, bs, 
CHC^z), 1.67 (IH, bs, CHC772'), 1.48 (3H, m/bs, C772CH2NH, CHCH2C%), L39 (lOH, 
s, t-butyl, CHCH2CF/2'), 1.31 (3H, t, /7 .1 , CH2CJT3); ôc (125MHz, CDCI3): 170.92 (CO), 
158.96 (CO), 156.95 (CO), 156.21 (CO), 154.38 (CO), 136.72, 128.61, 128.17, 127.92 
(Ph), 80.63 (C(CH3)3), 66.75 (CHzPh), 63.82 (CH2CH3), 53.05 (CH), 40.52 (CH2NH), 
31.82 (CHCH2), 29.36 (CH2CH2NH), 28.41 (0 (0 1 3 )3), 22.42 (CHCH2CH2), 13.94 
(CH2CH3); Found (Cl) 495.2450 (IVT + H), C23H35N4O8 requires 495.2449; m/z (Cl) 495 
(M* + H), 439 (M+ -  t-butyl + 2H), 395 (M^ -  BOC + 2H). LCMS: 100% purity on LC, 
m/z (ESI): 517 (M^ + Na). 395 (M* -  BOC + 2H).
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(25) (N’-Ethyloxyoxalyl)-2-(ter^butyloxycarbonyl)amino-5-
(benzyloxycarbonyl)ammopentaiioic acid hydrazide, (77)
NH
(77)
PyBOP (0.287g, 0.551mmol), Boc-Om(Z)-OH (0.202g, 0.551minol) aiid DIPEA 
(0.287ml, 0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in 
DMF (2ml) and the reaction stined at room temperature for 9 hoiu's. The solvent was 
evaporated using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 horns to give 
a yellow liquid/oil. This was dissolved in DCM (8.5ml) and extracted with a saturated 
solution of citiic acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the 
product extracted from the aqueous phase with DCM (3 x 4ml). The combined organic 
phase was extracted with a satmated solution of NaHCOa (aq) (3ml), the organic phase 
separated and the product extracted from the aqueous phase with DCM (3 x 3ml). The 
combined organic phase was dried by passing tluougli a hydrophobic frit and the solvent 
evaporated in vacuo to give a pale yellow oil. This cmde product was purified by 
“CombiFlash®” column clnomatography (12g pre-packed SiOi column, gradient elution, 
100% Heptane Heptane: AcOEt 30:70 over 30 minutes), and the solvent evaporated 
under high vacuum at 45°C to give the title compound (77) as a clear, colourless oiFsolid 
(0.192g, 72.5%). One spot by TLC, RfQ.2 [Heptane:AcOEt 20:80]; Vmax (CDCI3 
film)/cm'^ 3322 (NH stietch of 2° amide), 2981 (CH3 asymmetiic stietch), 2939 (CH% 
asymmetric and symmetric stretch), 1695 (C=0 stretch in ester), 1517 (NH bend), 1454 
(CH3 asymmetric bend), 1369 (CH3 symmetric bend), 1255 and 1164 (asymmetric 
C-C(=0 ) - 0  stretch of ester); Ôh (500MHz, CDCI3): 9.3 (2H, bs, CHCONiT, NHCOCO),
7.27-7.34 (5H, m, Ph), 5.36 (IH, bs, NiTCH), 5.16 (IH, bs, NFCH2), 5.10 (IH, d (AB
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quartet), J  12.2, P h C % , 5.08 (IH, d (AB quartet), J  12.2, PliC% '), 4.41 (IH, bs, CH),
4.35 (2H, q, J7 .1 , C ^C H s), 3.35 (IH, ni, NHC%), 3.16 (IH, in, NHCT^'), 1.85 (IH, 
m/bs, CHCTTz), 1.61 (3H, m/bs, CHC^% CTACHzNH), 1.42 (9H, s, t-butyl), 1.35 (3H, t, 
J7 .1 , CHiC/A); ÔC (125MHz, CDCI3): 170.54 (CO), 158.98 (CO), 157.40 (CO), 156.12 
(CO), 153.81 (CO), 136.69, 128.70, 128.30 (Ph), 80.69 (C(CH3)3), 67.09 (CH2PI1), 63.80 
(CH2CH3), 51.98 (CH), 39.88 (CH2NH), 29.90 (CHCH2), 28.49 (C (O i3)3), 26.23 
(CH2CH2NH), 14.10 (CH2CH3); Found (Cl) 481.2299 (M^ + H), C22H33N4O8 requires 
481.2293; m/z (Cl) 481 (M+ + H), 425 (M^ -  t-butyl + 2H), 381 (M"" -  BOC + 2H). 
LCMS: 100% purity on LC, m/z (ESI): 519 (M+ + K), 503 (M^ + Na), 381 (M^ -  BOC + 
2H).
(2S) [N’“Ethyloxyoxalyl)“2-(/er^-butyloxycarboiiyI)amino-4-methylsulfaiiyl-botanoic 
acid hydrazide, (79)
(79)
PyBOP® (0.287g, 0.551mmol), Boc-Met-OH (0.137g, 0.551mmol) and DIPEA (0.287ml, 
0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in DMF (2ml) 
and the reaction stiiTed at room temperature for 9 horns. The solvent was evaporated 
using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 hours to give a yellow 
liquid/oil. This was dissolved in DCM (8.5ml) and extracted with a saturated solution of 
citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the product 
extr acted from the aqueous phase with DCM (3 x 4ml). The combined organic phase was 
extracted with a satm ated solution of NaHCOs (aq) (3rnl), the organic phase separated and 
the product extracted from the aqueous phase with DCM (3 x 3ml). The cornbmed organic 
phase was dried by passing thmugh a hydrophobic frit and the solvent evaporated in 
vacuo to give a yellow oil. This crude product was purifred by “CombiFlash®” colurmi 
chrornatography (12g pre-packed Si02  colmmi, gr adient elution, 100% Heptane —>■ 
Heptane:AcOEt 30:70 over 30 minutes), and the solvent evaporated under high vacuum at
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45°C to give the title compound (79) as a white solid/oil (0.09g, 44.9%). One spot by 
TLC, Rf 0.3 [Heptane:AcOEt 30:70]; Vmax (CDCI3 fihn)/cm ' 3247 (NH stretch of 2° 
amide), 2926 (CH2 asymmetric and syimnetric stretch), 2862 (CH3 symmetric stietch), 
1683 (C=0 stretch in ester), 1495 (NH bend), 1452 (CH3 asymmetric bend), 1368 (CH3 
symmetiic bend), 1261 and 1164 (asyimnetric C-C(=0)-0 stretch of ester); ôh (500MHz, 
CDCI3): 9.3 (2H, bs, CHCONi?, NHCOCO), 5.44 (IH, bs, NH CH ), 4.45 (IH, bs, CH),
4.37 (2H, q, J7 .1 , CH2CH3), 2.62 (2H, m, CHgS), 2.13 (IH, m, CHCHg), 2.11 (3H, s, 
SCH3), 1.99 (IH, m, CHCHzl, 1.43 (9H, s, t-butyl), 1.38 (3H, t, J7 .1 , CH2CH3);
ÔC (125MHz, CDCI3): 169.82 (CO), 158.89 (CO), 156.07 (CO), 153.73 (CO), 81.03 
(C(CH3)3), 63.83 (CH2CH3), 52.27 (CH), 31.70 (CHCH2), 30.23 (CH2S), 28.49 
(C(CH3)3), 15.54 (CH3S), 14.12 (CH2CH3); Found (El) 363.1460 (M+), C14H25N3O6S 
requires 363.1459; m/z (Cl) 364 (M^ + H), 308 (M"*" -  t-butyl + 2H), 264 (M^ -  BOC + 
2H).
(2S) (N'-EthyIoxyoxalyl-2-(^e/t-butyIoxycarbouyl)aminio-4-(beiizyloxycarbonyl) 
butauolc acid hydrazide, (81)
(81)
PyBOP® (0.287g, 0.551mmol), Boc-Glu(OBn)-OH (0.186g, O.SSlmmol) and DIPEA 
(0.287ml, 0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in 
DMF (2ml) and the reaction stirred at room temperature for 9 hours. The solvent was 
evaporated using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 hours to give 
a yellow liquid/oil. This was dissolved in DCM (8.5ml) and extracted with a saturated 
solution of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase sepaiated and the 
product extracted fi*om the aqueous phase with DCM (3 x 4ml). The combined organic
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phase was extracted with a saturated solution of NaHCOs (aq) (3ml), the organic phase 
sepaiated and the product extiacted from the aqueous phase with DCM (3 x 3ml). The 
comhined organic phase was dried by passing through a hydrophobic frit and the solvent 
evaporated in vacuo to give a yellow oil. This crude product was purified by 
“CombiFlash®” cohumi chiomatography (12g pre-packed Si02  coluimi, giadient elution, 
100% Heptane -> Heptane:AcOEt 40:60 over 30 minutes), and the solvent evaporated 
mider high vacuum at 45°C to give the title compomid (81) as a clear, colomless oil ■ 
(0.16g, 64.3%). One spot by TLC, Rt 0.5 [AcOEt]; v^x (CDCI3 3412 and 3280
(NH stretch o f 2° amide), 2982 (CH3 asymmetric stretch), 2938 (CH2 asymmetric and 
symmetric stretch), 1723 and 1691 (0 = 0  stretch in ester), 1500 (NH bend), 1456 (CH3 
asyrmnetiic bend), 1369 (CH3 symmetric bend), 1254 and 1167 (asymmetric C-C(=0)-0 
sketch of ester); Ôh (500MHz, CDCI3): 9.3 (2H, bs, CHCONff, NHCOCO), 7.29-7.35 
(5H, m, Ph), 5.63 (IH, d, J7 .4 , NiTCH), 5.10 (2H, s, C%Ph), 4.38 (IH, bs, CH), 4.33 
(2H, q, J7 .1 , CH2CH3), 2.54 (2H, bs, CH3CO), 2.17 (IH, m, CHC%), 2.01 (IH, m, 
CHCH2’). 1.39 (9H, s, t-butyl), 1.33 (3H, t, J7 .1 , CH2CH3); ôc (125MHz, CDCI3): 173.23 
(CO), 170.08 (CO), 158.89 (CO), 156.09 (CO), 154.11 (CO), 135.82, 128.71,128.58, 
128.42,128.38 (Ph), 80.77 (C(CH3)3), 66.77 (CH2Ph), 63.76 (CH2CH3), 52.45 (CH),
30.37 (CH2CO), 28.40 (CiCR^h), 27.54 (CHCH2), 14.00 (CH2CH3); Found (Cl)
452.1996 (M+ + H), C21H30N3O8 requires 452.2027; m/z (Cl) 452 (IVT + H), 396 (M+ -  
t-butyl + 2H), 352 (M+ -  BOC + 2H).
(25) (N'-Ethyloxyoxalyl)-2-(rcr^-butyloxycarbonyl)amino-3- 
(benzyloxycarbonyl)propanoie acid hydrazide, (83)
( 8 3 )
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PyBOP (0.287g, 0.55Ininiol), Boc-Asp(OBn)-OH (0.178g, 0.55Immol) and DIPEA 
(0.287ml, 0.213g, 1.65mmol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in 
DMF (2ml) and the reaction stiiTed at room temperature for 9 hours. The solvent was 
evaporated using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 hours to give 
a yellow liquid/oil. This was dissolved in DCM (8.5ml) and extracted with a satmated 
solution of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the 
product extracted from the aqueous phase with DCM (3 x 4ml). The combined organic 
phase was extracted with a satmated solution of NaHCOs (aq) (3ml), the organic phase 
separated and the product extracted fr om the aqueous phase with DCM (3 x 3ml). The 
combined organic phase was dried by passing tln ough a hydrophobic frit and the solvent 
evaporated in vacuo to give a yellow oil. This cmde product was pmified by 
“CombiFlash®” column chromatography (12g pre-packed 810% column, gradient elution, 
100% Heptane Heptane:AcOEt 40:60 over 30 minutes), and the solvent evaporated in 
vacuo to give a clear, colomless oil/solid (O.lg). This had co-nm on the column with a 
slight impmity, so was dissolved in AcOEt and purified tlnough a pad o f Si02  (AcOEt) to 
give the title compomid (83) as a clear, colomless oil (0.088g, 36.5%). One spot by TLC, 
i^f 0.6 [Pet. ether: AcOEt 30:70]; Vmax (CDCI3 film)/cm’  ^3314 (NH stretch of 2° amide), 
2983 (CH3 asynnnetiic stretch), 2926 (CH2 asymmetiic and syimnetric stretch), 1727 
(C=0 stretch in ester), 1500 (NH bend), 1370 (CH3 symmetiic bend), 1252 and 1164 
(asymmetiic C-C(=0)-0 stretch of ester); ôh (500MHz, CDCI3): 9.25 (2H, bs, CHCON77, 
NHCOCO), 7.31-7.38 (5H, m, Ph), 5.72 (IH, d, J7 .7 , NTfCH), 5.15 (2H, s, CH2PI1), 4.67 
(IH, bs, CH), 4.37 (2H, q, J7 .2 , CH2CH3), 3.01 (IH, d of d, J4 .9 , 17.1, CHCiTz), 2.83 
(IH, d o f d, J5 .9 , 17.1, C H C ^ ') , 1.45 (9H, s, t-butyl), 1.38 (3H, t, J7 .1 , CH2C773);
6c (125MHz, CDCI3): 171.41 (CO), 168.52 (CO), 158.83 (CO), 155.95 (CO), 153.19 
(CO), 135.43, 128.83, 128.66, 128.52 (Ph), 81.44 (C(CH3)3), 67.28 (CH2Ph), 63.79 
(CH2CH3), 49.70 (CH), 35.76 (CHCH2), 28.45 (C(CH3)3), 14.13 (CH2CH3); Found (El) 
437.1792 (M^), C20H27N3O8 requires 437.1793; m/z (El) 438 (M^ + H), 382 (M^ -  t-hutyl 
+ 2H), 338 (M+ -  BOC + 2H).
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(2iS) [N’-EthyloxyoxaIyl)-2-(to*^-butyloxycarbonyl)ammo-3-methyl-butanoic acid
hydrazide with diisopropylethylamine, (85)
o
(85)
PyBOP® (0.287g, O.SSlmmol), Boc-Val-OH (0.120g, O.SSlmmol) and DIPEA (0.287ml,
0.213g, L65nnTLol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in DMF (2ml) 
and the reaction stined at room temperatine for 9 horns. The solvent was evaporated 
using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 houi's to give a yellow 
liquid/oil. This was dissolved in DCM (8.5ml) and extracted with a satmated solution of 
citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the product 
extracted hom the aqueous phase witli DCM (3 x 4ml). The combined organic phase was 
extracted with a saturated solution of NaHCOs (aq) (3ml), the organic phase sepai ated and 
the product extracted from the aqueous phase with DCM (3 x 3ml). The combined organic 
phase was dried by passing tlnough a hydiophohic frit and the solvent evaporated in 
vacuo to give a white oil/solid. This crude product was purifred by column 
clnomatography (15g SiOa, first 204ml = DCM:AcOEt 80:20, second 102ml =
DCM:AcOEt 75:25, third 204ml = DCM: AcOEt 70:30), and the solvent evaporated mider 
high vacumn at 45°C to give the title compomid (85) + DIPEA as a clear, colomless 
oil/solid (0.198g). This was dissolved in DCM (8.5ml) and extracted with a satmated 
solution of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the 
product extracted from the aqueous phase with DCM (3 x 3ml). The combined organic 
phase was extracted with a satmated solution ofNaHCO] (aq) (3ml), the organic phase 
separated and the product extracted from the aqueous phase with DCM (3 x 3ml). The 
combined organic phase was diied by passing tlnough a hydrophobic frit and the solvent 
evaporated in vacuo to give the title compound (85) + DIPEA as a white oil/solid 
(0.160g). This product looked identical to before this additional acidic, then basic aqueous 
workup by NMR, and was associated with the same quantity of DIPEA judging fr om 
the NMR integrals. One spot by TLC, Rf 0.75 [AcOEt]; Vmax (CDCI3 frhn)/cm'^ 3328 
and 3200 (NH stretch of 2° amide), 2978 (CH3 asynnnetiic stretch), 2939 (CH2
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asymmetric and symmetric stietch), 2877 (CH3 symmetric stretch), 1720 and 1686 (C=0 
stretch in ester), 1504 (NH bend), 1368 (CH3 symmetric bend), 1248 and 1162 
(asymmetric C-C(=0)-0 stretch of ester); 5h (500MHz, CDCI3); 5.33 (IH, bs, NHCH),
4.36 (2H, q, J6 .9 , CH2CH3), 4.13 (IH, bs, NHCH), 3.73 (2H, m, NCH [DIPEA]), 3.20 
(2H, q, J7 .2 , NCH2 [DIPEA]), 2.14 (IH, bs, CH(CH3)2), 1.43 (24H, bs, t-butyl, 
NCH(CH3)2 [DIPEA], NCH2CH3 [DIPEA]), 1.37 (3H, t , /7 .0 ,  CH2CH3), l.OO (3H, d, J  
6 .6 , CHCH3), 0.97 (3H, d, 76.5, CHCH3); 8c (125MHz, CDCI3): 169.49 (CO), 159.26 
(CO), 156.19 (CO), 153.50 (CO), 80.54 (C(CH3)3), 63.55 (CH2CH3), 58.75 (NHCH), 
55.63 (NCH [DIPEA]), 43.60 (NCH2 [DIPEA]), 30.99 (CH(CH3)2), 28.46 ( € ( ^ 3)3), 
19.30 (CHCH3), 18.04 (CHCH3, NCH(CH3)2 [DIPEA]), 14.12 (CH2CH3), 12.77 
(NCH2CH3 [DIPEA]); m/z (Cl) 461 (M+ + DIPEA + H), 403 (M* + DIPEA -  t-butyl), 332 
(M+ + H), 276 (M* -  t-butyl +2H), 232 (M* -  BOC + 2H), 130 (DIPEA + H); m/z (ESI) 
460 (M+ + DIPEA), 404 (IVf + CH3NC(CH3)2); m/z (ESI) (MS^ m/z 460) 404 (M+ + 
CH2= '^ C ( C H 3)2), 360 (M* + CH2-NH); m/z (ESI) (MS' m/z 460 404) 360 (M+ +
CH2=NH); m/z (ESI) (MS'* m/z 460 404 360) 360 (M* + CH2=NH), 332 (M+ + H)
and 286 (M* -  OEt).
(26) [N’-Ethyloxyoxalyl)"2-(^gr^-butyloxycarbonyl)amino-3-methyl“pentanoic acid 
hydrazide with diisopropylethylamine, (87)
NHO
(87)
PyBOP (0.287g, 0.55 Inniiol), Boc-Ile-OH (0,127g, 0.55 Inm ol) and DIPEA (0.287ml,
0.213g, 1.65mniol) in DMF (4.5ml) was added to (54) (0.08g, 0.606mmol) in DMF (2ml) 
and the reaction stiiTed at room temperatme for 9 liouis. The solvent was evaporated 
using a Genevac EZ-2 at 45°C on setting “low/med b.p.” for 1.5 hours to give a yellow 
gel. This was initially insoluble in DCM, but was eventually soluble after leaving 
overnight in DCM. This was dissolved in DCM (8.5ml) and extracted with a satmated 
solution of citric acid (aq) (0.5ml) and water (1.5ml), the organic phase separated and the
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product extracted from the aqueous phase with DCM (3 x 4ml). The combined organic 
phase was extracted with a satmated solution of NaHCOa (aq) (3ml), the organic phase 
separated and the product extracted from the aqueous phase with DCM (3 x 3ml). The 
combined organic phase was dried by passing tlirough a hydrophobic frit and the solvent 
evaporated in vacuo to give a clear, colourless oil/solid. This cmde product was pmified 
by column cliromatogiaphy (10.6g Si02 , DCM: AcOEt 90:10), and the solvent evaporated 
imder high vacuum at 45°C to give the title compomid (87) + DIPEA as a clear, 
colomless oil/solid (0.099g). One spot by TLC, 0.25 [DCM:AcOEt 70:30]; Vmax 
(CH2CI2 fihn)/cm"^ 3253 (NH stretch of 2° amide), 2979 (CH3 asymmetric stietch), 2937 
(CH2 asynnnetiic and symmetric stretch), 2879 (CH3 syimnetric stietch), 1724 and 1682 
(C=0 stietch in ester), 1504 (NH bend), 1369 (CH3 syimnetric bend), 1251 and 1163 
(asymmetric C-C(=0)-0 stretch of ester); Ôh (500MHz, CDCI3): 9.66 (2H, bs, CHCON77, 
NHCOCO), 5.37 (IH, d, J8 .1 , NFfCH), 4.36 (2H, q, J7 .0 , OCFZ2CH3), 4.18 (IH, bs, 
NHCiT), 3.73 (2H, m, NCH [DIPEA]), 3.20 (2H, q, J7 .2 , NCH; [DIPEA]), 1.87 (IH, bs, 
NHCHCTT), 1.57 (IH, bs, C H C ^), 1.42 (24H, bs, t-butyl, N CH (C^)z [DIPEA], 
NCH2C/73 [DIPEA]), 1.37 (3H, t, /7 .0 , OCH2CF/3), 1.32 (IH, bs, CHCFfz'), 0.98 (3H, d, 
y 6.4, CHC%), 0.90 (3H, t, J7 .1 , CHCH2(% ); 6 c (125MHz, CDCI3): 169.79 (CO),
158.87 (CO), 156.19 (CO), 153.42 (CO), 80.57 (C(CH3)3), 63.67 (OCH2CH3), 57.81 
(NHCH), 55.94 (NCH [DIPEA]), 43.86 (NCH2 [DIPEA]), 37.19 (NHCHCH), 28.44 
(C(CH3)3), 24.87 (CHCH2), 18.69 (NCH(CH3)2 [DIPEA]), 15.52 (CHCH3), 14.07 
(OCH2CH3), 12.80 (NCH2CH3 [DIPEA]), 11.25 (CHCH2CH3); m/z (Cl) 475 (M" + 
DIPEA + H), 346 (M" + H), 290 (M"" -  t-butyl +2H), 246 (M" -  BOC + 2H), 130 (DIPEA 
+ H).
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Ethyl-5-[(5)-l-[(ter^-butyloxycarbonyl)amino]-3-(benzyIoxycarboiiyl)propyl]“l,3,4-
oxadiazole-2-carboxylate, (88)
N—N
(88)
81 (0.06g, 0.133nimol) and Burgess Reagent (0.063g, 0.266mniol) were refluxed in 
anliydrous THF (2ml) over the weekend. Reaction was incomplete so Burgess Reagent 
(0.063g, 0.266mmol) was added and the reaction refluxed for 18 hours. The solvent was 
evaporated in vacuo to give a yellow/brown oil. This was dissolved in DCM (5ml) and 
washed with water (5ml), the organic phase separated, then the product extracted from the 
aqueous phase with DCM (3 x 1ml). The combined organic phase was dried by passing 
tlnough a hydrophobic frit and the solvent evaporated in vacuo to give a clear, pale 
yellow oil (0.1 Ig). Tliis cmde product was pmified by colmnn chromatography (4.4g 
SiOz, first 110ml = DCMiAcOEt 90:10, second 60ml = DCMiAcOEt 85:15, third 34ml = 
DCM: AcOEt 80:20), and the solvent evaporated under high vacuum at 45°C to give the 
title compoimd (88) as a clear, colomiess oil (0.029g, 50.3%). One spot by TLC, Rf 0.3 
[DCM: AcOEt 90:10]; Vmax (CDCI3 film)/cm'^ 3353 (NH stretch of 2° amide) 2980 (CH3 
asynnnetiic stretch), 2937 (CH2 asynnnetric and symmetric stretch), 1746 and 1716 (C= 0  
stretch in ester), 1514 (NH bend), 1368 (CH3 symmetric bend), 1252 and 1166 
(asynnnetiic C-C(=0)-0 stietch of ester); Ôh (500MHz, CDCI3): 7.33-7.37 (5H, m, Ph),
5.26 (IH, bs, NTfCH), 5.15 (IH, bs, CH), 5.12 (2H, s, CTfzPh), 4.51 (2H, q, J7 .1 , 
C772CH3), 2.55 (2H, m, CH2CO), 2.36 (IH, m, CHC.%), 2.21 (IH, m, CHC% '), 1.45 
(3H, t, J7 .1 , CH2CJT3), 1.44 (9H, s, t-butyl); ôc (125MHz, CDCI3): 172.30 (CH2CO2), 
168.61 (CHC(0)N), 157.24 (NC(0 )C02 ), 155.12 (NHCO2), 154.31 (NC(0 )C02 ), 135.75, 
128.84, 128.61, 128.54 (Ph), 81.12 (C(CH3)3), 66.98 (CH2?h), 63.85 (CH2CH3), 47.22 
(CH), 30.23 (CH2CO2), 28.81 (CHCHz), 28.44 14.27 (CH2CH3); Found (Cl)
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434.1943 (M* + H), C21H28N3O7 requires 434.1922; m/z (CI) 434 (iVf + H). 378 (IVl" - 1- 
butyl + 2H).
Ethyl-5-[(tS)-l-[(^er^-butyloxycarboiiyl)amino]-5-(beiizyloxycarboiiyl)ammopentyl]" 
l,3,4-oxadiazole-2“Carboxylate, (89)
HN
N— N
(89)
75 (0.075g, 0.152imîiol) and Bui'gess Reagent (0.072g, 0.304nnnol) were refluxed in 
anhydrous THF (2.3ml) over the weekend. Reaction was incomplete so Burgess Reagent 
(0.072g, 0.304mmol) was added and the reaction refluxed for 18 hours. The solvent was 
evaporated in vacuo to give a yellow/brown oil. This was dissolved in DCM (5.2ml) and 
washed with water (5.2ml), the organic phase separated, then the product extracted from 
the aqueous phase with DCM (3 x 1ml). The combined organic phase was dried by 
passing tlirough a hydiophobic frit and the solvent evaporated in vacuo to give a clear 
yellow oil (0.149g). This crude product was purified by column chromatography (4.47g 
SiOi, DCMiAcOEt 70:30), and the solvent evaporated imder high vacuum at 45°C to give 
a clear, colomiess oil (0.042g). This crude product was pmified by column 
chi'omatography (4.4g SiOi, first 110ml -  DCMiAcOEt 85:15, second 162ml = 
DCMiAcOEt 80:20), and the solvent evaporated mider high vacuum at 45°C to give the 
title compound (89) as a clear, colourless oil (0.03Ig, 42.8%). One spot by TLC, 0.3 
[DCMiAcOEt 80:20]; v„,ax (CDCI3 film)/cm‘‘ 3333 (NH stretch of 2° amide) 2979 (CH3 
asymmetric stretch), 2936 (CH2 asymmetiic and symmetiic stretch), 1750 and 1705 (C=0
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stretch in ester), 1525 (NH bend), 1365 (CH3 symmetric bend), 1252 and 1156 
(asymmetric C-C(=0)-0 stretch of ester); Sh (500MHz, CDCI3): 7.30-7.38 (5H, m, Ph),
5.27 (IH, bs, NHCH), 5.09 (3H, bs, C%Ph, CH), 4.82 (IH, bs, NHCHj), 4.51 (2H, q, J
7.1, CH2CH3), 3.20 (2H, bs, NHC%), 1.98 (IH, bs, CHC%), 1.90 (IH, bs, CHCHj’),
1.55 (2H, m, CH2CH2NH), 1.43 (5H, m, CHCH2CH2, CH2CH3), 1.43 (9H, s, t-butyl);
5c (125MHz, CDCI3): 169.25 (CHC(0)N), 157.12 (CO), 156.78 (NHCO2CH2), 155.26 
(CO), 154.40 (NC(0)C02), 136.72, 128.74,128.35, 128.30 (Ph), 80.95 (C(CH3)3), 66.95 
(CH2Ph), 63.81 (CH2CH3), 47.54 (CH), 40.52 (CH2NH), 33.39 (CHCH2), 29.56 
(CH2CH2NH), 28.46 (C (Œ 3)3), 22.47 (CHCH2CH2), 14,26 (CH2CH3); Found (Cl) 
477.2347 (M" + H), C23H33N4O7 requires 477.2344; m/z (Cl) 477 (M+ + H), 421 (M+ -  
t-butyl + 2H), 377 (M^ -  BOC + 2H).
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Conclusions
A Study into the Effect of Triflic Anhydride Activation on a Secondary 
Amide, and its Subsequent Reaction with a Nucleophile
The reaction of the secondary ainide, piperidin-2-one (27), with a nucleophile in the 
presence of triflic anliydiide has been investigated in depth. It was shown that tiiflic 
anliydiide reacts with piperidin-2-one to fonn O-triflated derivatives, which rapidly 
reaiTange to the N-triflated imide (30) in the presence of a base (pyridine or a primary 
amine) (Scheme 84). Increasing reaction temperatme favoms the triflate group migration 
towards the N-triflated imide (30), but only when a base is present. Compound (30) could 
be isolated, however, it was not possible to isolate the 0-triflated derivatives. After 
addition of an amine base, the 0 -tiiflated derivatives could not be used in a synthetically 
useftil way under the conditions studied.
TfgO Base NTf
(30)
Scheme 84 Piperidin-2-one (27) reacts with tiiflic anhydride 
to form the 0 -triflated imidate (28), which rapidly rearranges 
to the N-triflated imide (30) when a base is present
When the N-triflated derivative (30) is reacted witli a suitable nucleophile, it results in the 
openmg of the lactam ring to fonn an acyclic compoimd, (an example of which is shown 
in Scheme 85). It has, therefore, not been possible to use this reaction to synthesise 
imidazole-based amide bond mimics as had been originally hoped. The process that does 
occur is, however, very interesting in itself, so has been further explored in tliis thesis.
The N-tiiflated imide (30) can be used as a highly reactive carbonyl derivative and has 
been reacted with a variety of nucleophiles to give an ester, a thio 1-ester and amides in 
good to excellent yields under extremely mild conditions (Scheme 85). A thorough search 
using SciFinder® has not shown any examples of this reaction in the literature.
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PyridineNH,
(30) -42°C
98.6%
Scheme 85 An example reaction of N-tiiflated valeolactam (30) with a 
nucleophile, (in tliis case the C-protected amino acid, /,-phenylalanine methyl ester
The reaction represents a formal transamidation (in some cases transpeptidation) and 
proceeds (to oui" laiowledge) under the mildest conditions Icnown for such a synthetic 
transfoimation, wliich should prove useful in many ai eas of medicinal chemistry and 
organic synthesis.
The novel compounds obtained using this reaction are fomially dipeptides of œ-amino 
acids and should be useful intermediates in organic synthesis and interesting derivatives 
in medicinal chemistry. Fuithermore, the chemistiy presented offers new prospects for the 
use of cyclic amides as protecting groups in organic chemistry, hi particular, the cyclic 
amides offer potential for cyclic stereocontrol in the stereoselective synthesis of other 
open chain amides after deprotection with tiiflic anliydiide.
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Synthesis of Oxadiazole-Based Peptldomimetics
A range of 1,3,4-oxadiazole based dipeptide minietics have been synthesised from various 
N-Boc-protected amino acids via a two-step process (Scheme 86). Tins route is more 
straightfoi*ward than the previously reported method and results in improved yields of 
oxadiazole product starting fr om various Boc-protected amino acids.^^
hi the first step, hydiazino ethyloxalate (54) is reacted with a Boc-aniino acid (50) to form 
a hydrazide product (52), using PyBOP® as the coupling reagent in the presence of 
DIPEA. This coupling reaction is generally efficient, but puiification problems have 
resulted in reduced yields in certain cases. Cyclisation of the diacylhydi azide (52) can be 
accomplished by dehydration using Bingess reagent in refluxing THF, to yield the 
oxadiazole product (53). This second step of the synthesis has produced products in 
moderate to good yield.
O R
H 
(50) O
PyBOP®
DIPEA
HgN'
O
OH
O
O (54)
DMF o o
(52)
THF
reflux
\  P
JN - S - N .
O
(Burgess reagent)
/ O R
(53)
.0
O'
Scheme 86 Synthesis of 1,3,4-oxadiazole derivatives starting from various 
Boc-protected amino acids, (50)
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The synthesis as a whole has produced oxadiazole based dipeptidomimetics in moderate 
overall yields, though so far only very limited optimisation of the synthesis has been 
perforaied. The reaction conditions have been shown to be compatible with a wide variety 
of fmictionalised side-chains. The enantiomerical purity of the chiral compoimds appear s 
to have been maintained during the synthesis according to the analytical results obtained 
from CD spectroscopy.
Hydrazino ethyloxalate (54) does not appear to be commercially available, but hatches 
can be easily synthesised in excellerrt yield (88%) by the acylation of ^ er^butyl carbazate 
with ethyl oxalyl chloride in the presence of triethylamirie. The Boc group can he de­
protected using TFA in DCM and purification with an Isolute® SCX-2 coliurm gives the 
free product (54), without the need for firrther purification.
1. NEta
2. Cl
:
(55)
O N O
DCM \  O (56)
20% TFA in 
DCM1. SCX-2 column 
in CHgCN
2 . 2MTEA O I
in CH,CN N
TFA - HgN" ' Y  I
(54) °
88.0% (62)
Scheme 87 Synthesis of hydrazino ethyloxalate (54) fi'om 
^g/T-hutyl carbazate and ethyl oxalyl chloride
These dipeptide minietics are envisaged to be used as building blocks in medicinal 
chemistry to produce various peptidomimetics using, for example, solid phase chemistry 
techniques. They could be used hr the targeting of specific protease enzymes of medicinal 
importarrce and subsequently lead to the development of new drug molecules.
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